Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References FTP Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) RatMine GViewer (Genome Viewer) Overgo Probe Designer ACP Haplotyper Genome Scanner
Aging & Age-Related Disease Cancer Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:liposaccharide
go back to main search page
Accession:CHEBI:35740 term browser browse the term
Synonyms:related_synonym: liposaccharides

show annotations for term's descendants           Sort by:
 
alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
increases chemical synthesis		 ISO Cyclosporine inhibits the reaction [ABCB1 protein results in increased chemical synthesis of globotriaosylceramide]; Ketoconazole inhibits the reaction [ABCB1 protein results in increased chemical synthesis of globotriaosylceramide] CTD PMID:14662772 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO Curcumin inhibits the reaction [IL1B protein promotes the reaction [Shiga Toxin binds to globotriaosylceramide]]; IL1B protein promotes the reaction [Shiga Toxin binds to globotriaosylceramide]; TNF protein promotes the reaction [IL1B protein promotes the reaction [Shiga Toxin binds to globotriaosylceramide]] CTD PMID:16819191 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Curcumin inhibits the reaction [TNF protein promotes the reaction [Shiga Toxin binds to globotriaosylceramide]]; TNF protein promotes the reaction [IL1B protein promotes the reaction [Shiga Toxin binds to globotriaosylceramide]]; TNF protein promotes the reaction [Shiga Toxin binds to globotriaosylceramide] CTD PMID:16819191 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 		JBrowse link
alpha-galactosylceramide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gata3 GATA binding protein 3 multiple interactions ISO [Ovalbumin co-treated with alpha-galactosylceramide] results in decreased expression of GATA3 mRNA CTD PMID:30803854 NCBI chr17:72,419,752...72,452,043
Ensembl chr17:72,429,618...72,450,681 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO [Floxacillin co-treated with alpha-galactosylceramide] results in increased expression of GPT protein CTD PMID:30993380 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931 		JBrowse link
G Ifng interferon gamma multiple interactions
increases secretion		 ISO [Alcohols co-treated with alpha-galactosylceramide] results in increased expression of IFNG protein; [Ovalbumin co-treated with alpha-galactosylceramide] results in increased secretion of IFNG protein
alpha-galactosylceramide results in increased secretion of IFNG protein		 CTD PMID:12482940, PMID:25499027, PMID:30803854 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419 		JBrowse link
G Il10 interleukin 10 multiple interactions ISO [Ovalbumin co-treated with alpha-galactosylceramide] results in decreased secretion of IL10 protein CTD PMID:30803854 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392 		JBrowse link
G Il13 interleukin 13 multiple interactions ISO [Ovalbumin co-treated with alpha-galactosylceramide] results in decreased secretion of IL13 protein CTD PMID:30803854 NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466 		JBrowse link
G Il17a interleukin 17A multiple interactions ISO [Ovalbumin co-treated with alpha-galactosylceramide] results in decreased secretion of IL17A protein CTD PMID:30803854 NCBI chr 9:26,841,299...26,844,786
Ensembl chr 9:26,841,299...26,844,786 		JBrowse link
G Il4 interleukin 4 increases secretion
multiple interactions		 ISO alpha-galactosylceramide results in increased secretion of IL4 protein
[Ovalbumin co-treated with alpha-galactosylceramide] results in decreased secretion of IL4 protein		 CTD PMID:12482940, PMID:30803854 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531 		JBrowse link
G Il5 interleukin 5 multiple interactions ISO [Ovalbumin co-treated with alpha-galactosylceramide] results in decreased secretion of IL5 protein CTD PMID:30803854 NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587 		JBrowse link
G Rorc RAR-related orphan receptor C multiple interactions ISO [Ovalbumin co-treated with alpha-galactosylceramide] results in decreased expression of RORC mRNA alternative form CTD PMID:30803854 NCBI chr 2:195,612,471...195,636,797
Ensembl chr 2:195,617,021...195,637,630 		JBrowse link
G Tbx21 T-box transcription factor 21 multiple interactions ISO [Ovalbumin co-treated with alpha-galactosylceramide] results in increased expression of TBX21 mRNA CTD PMID:30803854 NCBI chr10:85,032,799...85,049,331
Ensembl chr10:85,032,799...85,049,331 		JBrowse link
beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nos2 nitric oxide synthase 2 multiple interactions ISO ganglioside, GD1b analog inhibits the reaction [[lipopolysaccharide, E. coli O26-B6 results in increased activity of NOS2 protein] which results in increased secretion of Nitrites]; ganglioside, GD1b inhibits the reaction [[lipopolysaccharide, E. coli O26-B6 results in increased activity of NOS2 protein] which results in increased secretion of Nitrites] CTD PMID:31202640 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190 		JBrowse link
eritoran term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gpt glutamic--pyruvic transaminase multiple interactions ISO eritoran inhibits the reaction [Azathioprine results in increased expression of GPT protein]; eritoran inhibits the reaction [Diclofenac results in increased expression of GPT protein]; eritoran inhibits the reaction [Dicloxacillin results in increased expression of GPT protein]; eritoran inhibits the reaction [Halothane results in increased expression of GPT protein] CTD PMID:24184165, PMID:24747151 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931 		JBrowse link
ganglioside GM1 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cd14 CD14 molecule multiple interactions EXP CD14 protein affects the reaction [G(M1) Ganglioside results in increased secretion of Nitric Oxide] CTD PMID:16651628 NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression EXP G(M1) Ganglioside results in increased expression of CDKN1A protein CTD PMID:15654767 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B decreases expression EXP G(M1) Ganglioside results in decreased expression of CDKN1B protein CTD PMID:15654767 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964 		JBrowse link
G Npc1 NPC intracellular cholesterol transporter 1 affects localization ISO NPC1 affects the localization of G(M1) Ganglioside CTD PMID:12183525 NCBI chr18:3,616,878...3,662,656
Ensembl chr18:3,616,878...3,662,683 		JBrowse link
G Ntrk1 neurotrophic receptor tyrosine kinase 1 multiple interactions EXP G(M1) Ganglioside inhibits the reaction [Methylmercury Compounds results in decreased phosphorylation of NTRK1 protein]; G(M1) Ganglioside inhibits the reaction [staurosporine aglycone results in decreased phosphorylation of NTRK1 protein] CTD PMID:25545984 NCBI chr 2:187,143,568...187,160,373
Ensembl chr 2:187,143,568...187,160,373 		JBrowse link
G Pld1 phospholipase D1 multiple interactions EXP PLD1 protein affects the reaction [dinitrophenyl-bovine serum albumin affects the localization of G(M1) Ganglioside] CTD PMID:19794068 NCBI chr 2:113,651,967...113,849,403
Ensembl chr 2:113,652,348...113,849,403 		JBrowse link
G Pld2 phospholipase D2 multiple interactions EXP PLD2 protein affects the reaction [dinitrophenyl-bovine serum albumin affects the localization of G(M1) Ganglioside] CTD PMID:19794068 NCBI chr10:57,161,921...57,181,148
Ensembl chr10:57,163,174...57,179,730 		JBrowse link
G Slc18a2 solute carrier family 18 member A2 increases expression EXP G(M1) Ganglioside results in increased expression of SLC18A2 mRNA CTD PMID:14552908 NCBI chr 1:280,397,831...280,457,968
Ensembl chr 1:280,423,079...280,457,148 		JBrowse link
G Slc6a3 solute carrier family 6 member 3 increases expression EXP G(M1) Ganglioside results in increased expression of SLC6A3 mRNA CTD PMID:14552908 NCBI chr 1:32,323,011...32,363,983
Ensembl chr 1:32,321,580...32,363,983 		JBrowse link
G Th tyrosine hydroxylase increases activity EXP G(M1) Ganglioside results in increased activity of TH protein CTD PMID:14552908 NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287 		JBrowse link
G Tlr4 toll-like receptor 4 decreases expression EXP G(M1) Ganglioside results in decreased expression of TLR4 protein CTD PMID:16651628 NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052 		JBrowse link
lipid As term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ccl3 C-C motif chemokine ligand 3 increases expression
multiple interactions		 ISO Lipid A results in increased expression of CCL3 mRNA
anacetrapib inhibits the reaction [Lipid A results in increased expression of CCL3 mRNA]		 CTD PMID:20448206 NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066 		JBrowse link
G Ifng interferon gamma multiple interactions
increases expression		 ISO [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipid A] results in increased expression of IFNG mRNA; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipid A] results in increased expression of IFNG protein; [heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine co-treated with Lipid A] results in increased expression of IFNG mRNA; [heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine co-treated with Lipid A] results in increased expression of IFNG protein
Lipid A results in increased expression of IFNG mRNA; Lipid A results in increased expression of IFNG protein		 CTD PMID:16299289 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419 		JBrowse link
G Il12a interleukin 12A multiple interactions
increases expression		 ISO [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipid A] results in increased expression of [IL12A protein binds to IL12B protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipid A] results in increased expression of IL12A mRNA; [heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine co-treated with Lipid A] results in increased expression of [IL12A protein binds to IL12B protein]; [heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine co-treated with Lipid A] results in increased expression of IL12A mRNA; Lipid A results in increased expression of [IL12A protein binds to IL12B protein]
Lipid A results in increased expression of IL12A mRNA		 CTD PMID:16299289 NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318 		JBrowse link
G Il12b interleukin 12B multiple interactions
increases expression		 ISO [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipid A] results in increased expression of [IL12A protein binds to IL12B protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipid A] results in increased expression of IL12B mRNA; [heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine co-treated with Lipid A] results in increased expression of [IL12A protein binds to IL12B protein]; [heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine co-treated with Lipid A] results in increased expression of IL12B mRNA; Lipid A results in increased expression of [IL12A protein binds to IL12B protein]
Lipid A results in increased expression of IL12B mRNA		 CTD PMID:16299289 NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085 		JBrowse link
G Il15 interleukin 15 multiple interactions
increases expression		 ISO [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipid A] results in increased expression of IL15 mRNA; [heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine co-treated with Lipid A] results in increased expression of IL15 mRNA
Lipid A results in increased expression of IL15 mRNA		 CTD PMID:16299289 NCBI chr19:23,542,606...23,624,366
Ensembl chr19:23,542,889...23,554,594 		JBrowse link
G Il18 interleukin 18 increases expression ISO Lipid A results in increased expression of IL18 mRNA CTD PMID:16299289 NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299 		JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression		 ISO anacetrapib inhibits the reaction [Lipid A results in increased expression of IL6 mRNA] CTD PMID:20448206 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression		 ISO anacetrapib inhibits the reaction [Lipid A results in increased expression of TNF mRNA] CTD PMID:20448206 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 		JBrowse link
lipoarabinomannan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Csf2 colony stimulating factor 2 multiple interactions ISO CSF2 protein promotes the reaction [lipoarabinomannan results in increased secretion of CXCL8 protein] CTD PMID:12176910 NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070 		JBrowse link
G Cxcr2 C-X-C motif chemokine receptor 2 decreases expression ISO lipoarabinomannan results in decreased expression of CXCR2 protein CTD PMID:10950785 NCBI chr 9:81,427,275...81,435,065
Ensembl chr 9:81,427,730...81,434,102 		JBrowse link
G Il12b interleukin 12B multiple interactions ISO lipoarabinomannan inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B protein] CTD PMID:16263713 NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085 		JBrowse link
G Irak1 interleukin-1 receptor-associated kinase 1 multiple interactions ISO lipoarabinomannan inhibits the reaction [IRAK1 protein binds to TRAF6 protein] CTD PMID:16263713 NCBI chr  X:156,716,469...156,726,367
Ensembl chr  X:156,716,604...156,725,977 		JBrowse link
G Irak3 interleukin-1 receptor-associated kinase 3 increases expression
increases expression 		ISO lipoarabinomannan results in increased expression of IRAK3 protein
Lipoarabinomannan increases expression of Irak3 mRNA and protein in macrophages		 CTD PMID:16263713, PMID:16263713 RGD:36049804 NCBI chr 7:64,922,830...64,982,224
Ensembl chr 7:64,923,615...64,982,281 		JBrowse link
G Mmp9 matrix metallopeptidase 9 increases activity ISO lipoarabinomannan results in increased activity of MMP9 protein CTD PMID:11839551 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO lipoarabinomannan results in decreased localization of and results in decreased activity of NFKB1 protein CTD PMID:16263713 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689 		JBrowse link
G Nfkbia NFKB inhibitor alpha decreases phosphorylation ISO lipoarabinomannan results in decreased phosphorylation of NFKBIA protein CTD PMID:16263713 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457 		JBrowse link
G Rel REL proto-oncogene, NF-kB subunit multiple interactions ISO lipoarabinomannan results in decreased localization of and results in decreased activity of REL protein CTD PMID:16263713 NCBI chr14:108,490,794...108,517,582
Ensembl chr14:108,491,069...108,509,892 		JBrowse link
G Traf6 TNF receptor associated factor 6 multiple interactions ISO lipoarabinomannan inhibits the reaction [IRAK1 protein binds to TRAF6 protein] CTD PMID:16263713 NCBI chr 3:91,252,829...91,271,607
Ensembl chr 3:91,252,829...91,271,607 		JBrowse link
lipophosphoglycan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cd14 CD14 molecule multiple interactions ISO CD14 protein promotes the reaction [lipopeptidophosphoglycan results in increased activity of TLR2 protein]; CD14 protein promotes the reaction [lipopeptidophosphoglycan results in increased activity of TLR4 protein] CTD PMID:15910421 NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153 		JBrowse link
G Il10 interleukin 10 multiple interactions ISO [lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] which results in increased secretion of IL10 protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] which results in increased secretion of IL10 protein CTD PMID:15910421 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392 		JBrowse link
G Il12b interleukin 12B multiple interactions ISO [lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] which results in increased secretion of IL12B protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] which results in increased secretion of IL12B protein CTD PMID:15910421 NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO [lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] results in increased activity of [NFKB1 protein binds to RELA protein]; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] results in increased activity of [NFKB1 protein binds to RELA protein] CTD PMID:15910421 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO [lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] results in increased activity of [NFKB1 protein binds to RELA protein]; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] results in increased activity of [NFKB1 protein binds to RELA protein] CTD PMID:15910421 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249 		JBrowse link
G Tlr2 toll-like receptor 2 multiple interactions
increases response to substance		 ISO [lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] results in increased activity of [NFKB1 protein binds to RELA protein]; [lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] which results in increased secretion of CXCL8 protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] which results in increased secretion of IL10 protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] which results in increased secretion of IL12B protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] which results in increased secretion of TNF protein; CD14 protein promotes the reaction [lipopeptidophosphoglycan results in increased activity of TLR2 protein]; lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein
TLR2 protein results in increased susceptibility to lipopeptidophosphoglycan		 CTD PMID:15910421 NCBI chr 2:182,840,171...182,846,061
Ensembl chr 2:182,840,727...182,846,061 		JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions
increases response to substance		 ISO [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] results in increased activity of [NFKB1 protein binds to RELA protein]; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] which results in increased secretion of CXCL8 protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] which results in increased secretion of IL10 protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] which results in increased secretion of IL12B protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] which results in increased secretion of TNF protein; CD14 protein promotes the reaction [lipopeptidophosphoglycan results in increased activity of TLR4 protein]; lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein
TLR4 protein results in increased susceptibility to lipopeptidophosphoglycan		 CTD PMID:15910421 NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO [lipopeptidophosphoglycan binds to and results in increased activity of TLR2 protein] which results in increased secretion of TNF protein; [lipopeptidophosphoglycan binds to and results in increased activity of TLR4 protein] which results in increased secretion of TNF protein CTD PMID:15910421 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 		JBrowse link
lipopolysaccharide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2m alpha-2-macroglobulin increases expression ISO
EXP		 Lipopolysaccharides results in increased expression of A2M mRNA CTD PMID:11779202, PMID:27339419 NCBI chr 4:154,309,426...154,359,138
Ensembl chr 4:154,309,426...154,359,137 		JBrowse link
G Aars2 alanyl-tRNA synthetase 2, mitochondrial multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of AARS2 mRNA CTD PMID:31059760 NCBI chr 9:17,869,301...17,881,762
Ensembl chr 9:17,869,124...17,880,706 		JBrowse link
G Abca1 ATP binding cassette subfamily A member 1 multiple interactions
decreases expression		 ISO Lipopolysaccharides inhibits the reaction [TO-901317 results in increased expression of ABCA1 mRNA]
Lipopolysaccharides results in decreased expression of ABCA1 mRNA
Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in decreased expression of ABCA1 mRNA]		 CTD PMID:16847310, PMID:18192897, PMID:22240665 NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015 		JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 decreases expression
multiple interactions
affects expression		 ISO
EXP		 Lipopolysaccharides results in decreased expression of ABCB11 protein
Lipopolysaccharides results in decreased expression of ABCB11 mRNA
[Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of ABCB11 mRNA; Lipopolysaccharides affects the localization of and results in decreased expression of ABCB11 protein
Lipopolysaccharides results in decreased expression of ABCB11 mRNA; Lipopolysaccharides results in decreased expression of ABCB11 protein
Lipopolysaccharides affects the expression of ABCB11 protein		 CTD PMID:12706339, PMID:12795754, PMID:15205115, PMID:15205389, PMID:15312235, PMID:15313196, PMID:15778272, PMID:25331106, PMID:30633930 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
affects localization
decreases expression
affects expression
decreases activity		 ISO
EXP		 [Lipopolysaccharides co-treated with resveratrol] results in decreased expression of ABCB1 mRNA
Lipopolysaccharides affects the localization of ABCB1 protein
Lipopolysaccharides results in decreased expression of ABCB1 mRNA; Lipopolysaccharides results in decreased expression of ABCB1A mRNA
Lipopolysaccharides affects the expression of ABCB1A protein
Dexamethasone inhibits the reaction [Lipopolysaccharides results in decreased expression of ABCB1A mRNA]; GCG protein inhibits the reaction [Lipopolysaccharides affects the localization of ABCB1 protein]; GCG protein inhibits the reaction [Lipopolysaccharides results in decreased expression of ABCB1 mRNA]; GCG protein inhibits the reaction [Lipopolysaccharides results in decreased expression of and results in decreased activity of ABCB1 protein]; Lipopolysaccharides results in decreased expression of and results in decreased activity of ABCB1 protein
Lipopolysaccharides results in decreased activity of ABCB1A protein
Lipopolysaccharides affects the reaction [ABCB1A protein results in increased secretion of Doxorubicin]		 CTD PMID:14709616, PMID:15205389, PMID:15778272, PMID:23762418, PMID:26667767, PMID:28842383 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515 		JBrowse link
G Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B affects expression
increases expression
multiple interactions		 ISO
EXP		 Lipopolysaccharides affects the expression of ABCB1B mRNA; Lipopolysaccharides affects the expression of ABCB1B protein
Lipopolysaccharides results in increased expression of ABCB1B mRNA
Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of ABCB1B mRNA]; Lipopolysaccharides promotes the reaction [TNF protein results in increased expression of ABCB1B mRNA]
Lipopolysaccharides affects the reaction [ABCB1B protein results in increased secretion of Doxorubicin]		 CTD PMID:11779202, PMID:15205389, PMID:15778272, PMID:20300455 NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 affects expression
decreases expression		 ISO
EXP		 Lipopolysaccharides affects the expression of ABCB4 protein
Lipopolysaccharides results in decreased expression of ABCB4 mRNA
Lipopolysaccharides results in decreased expression of ABCB4 protein		 CTD PMID:12795754, PMID:15778272 NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions
increases expression		 ISO
EXP		 Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of ABCC1 mRNA]; Lipopolysaccharides results in increased expression of and results in increased activity of ABCC1 protein; Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of ABCC1 mRNA]; tocotrienol, delta inhibits the reaction [Lipopolysaccharides results in increased expression of ABCC1 mRNA] CTD PMID:15205389, PMID:19894120, PMID:22185406 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 decreases expression
affects localization
multiple interactions
decreases activity		 ISO
EXP		 Lipopolysaccharides results in decreased expression of ABCC2 protein
Lipopolysaccharides affects the localization of ABCC2 protein
Lipopolysaccharides results in decreased expression of ABCC2 mRNA
[Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of ABCC2 mRNA; GCG protein inhibits the reaction [Lipopolysaccharides affects the localization of ABCC2 protein]; GCG protein inhibits the reaction [Lipopolysaccharides results in decreased expression of ABCC2 mRNA]; GCG protein inhibits the reaction [Lipopolysaccharides results in decreased expression of and results in decreased activity of ABCC2 protein]; Lipopolysaccharides affects the localization of and results in decreased expression of ABCC2 protein; Lipopolysaccharides results in decreased expression of and results in decreased activity of ABCC2 protein
Lipopolysaccharides results in decreased activity of ABCC2 protein		 CTD PMID:12706339, PMID:14709616, PMID:15205115, PMID:15205389, PMID:15312239, PMID:15313196, PMID:25331106, PMID:28842383, PMID:30633930 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 decreases expression
multiple interactions
increases expression		 ISO
EXP		 Lipopolysaccharides results in decreased expression of ABCC3 mRNA
[Lipopolysaccharides co-treated with Isoniazid] results in increased expression of ABCC3 mRNA; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of ABCC3 mRNA]		 CTD PMID:15205389, PMID:15313196, PMID:25331106 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109 		JBrowse link
G Abcc6 ATP binding cassette subfamily C member 6 decreases expression EXP Lipopolysaccharides results in decreased expression of ABCC6 mRNA CTD PMID:15205389 NCBI chr 1:101,954,786...102,013,252
Ensembl chr 1:101,959,540...102,013,243 		JBrowse link
G Abcd2 ATP binding cassette subfamily D member 2 multiple interactions
decreases expression		 ISO Dexamethasone inhibits the reaction [Lipopolysaccharides results in decreased expression of ABCD2 mRNA]; Quercetin affects the reaction [Lipopolysaccharides results in decreased expression of ABCD2 mRNA] CTD PMID:22185406, PMID:25890327 NCBI chr 7:132,294,564...132,343,169
Ensembl chr 7:132,294,562...132,343,169 		JBrowse link
G Abcg1 ATP binding cassette subfamily G member 1 multiple interactions
increases expression
decreases expression		 ISO Lipopolysaccharides inhibits the reaction [rosiglitazone results in increased expression of ABCG1 mRNA]; Lipopolysaccharides inhibits the reaction [rosiglitazone results in increased expression of ABCG1 protein]; Lipopolysaccharides inhibits the reaction [TO-901317 results in increased expression of ABCG1 mRNA]
Lipopolysaccharides results in increased expression of ABCG1 mRNA
Lipopolysaccharides results in decreased expression of ABCG1 mRNA; Lipopolysaccharides results in decreased expression of ABCG1 protein		 CTD PMID:12057914, PMID:22240665 NCBI chr20:9,743,269...9,842,735
Ensembl chr20:9,743,269...9,840,489 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 affects expression
multiple interactions		 ISO Lipopolysaccharides affects the expression of ABCG2 mRNA
Plant Extracts affects the reaction [Lipopolysaccharides affects the expression of ABCG2 mRNA]		 CTD PMID:28070326 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621 		JBrowse link
G Abcg5 ATP binding cassette subfamily G member 5 decreases expression ISO Lipopolysaccharides results in decreased expression of ABCG5 mRNA CTD PMID:15312237 NCBI chr 6:7,935,771...7,961,207
Ensembl chr 6:7,935,771...7,961,207 		JBrowse link
G Abhd15 abhydrolase domain containing 15 decreases expression ISO Lipopolysaccharides results in decreased expression of ABHD15 mRNA CTD PMID:25890327 NCBI chr10:62,643,453...62,648,844
Ensembl chr10:62,643,453...62,648,844 		JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase increases expression ISO Lipopolysaccharides results in increased expression of ABL1 mRNA CTD PMID:12057914 NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388 		JBrowse link
G Abl2 ABL proto-oncogene 2, non-receptor tyrosine kinase multiple interactions
decreases expression		 ISO [Lipopolysaccharides co-treated with IL4] results in increased expression of ABL2 mRNA; Lipopolysaccharides affects the reaction [IL4 protein results in increased expression of ABL2 mRNA]
Lipopolysaccharides results in decreased expression of ABL2 mRNA		 CTD PMID:22024136 NCBI chr13:74,154,533...74,333,244
Ensembl chr13:74,154,835...74,333,244 		JBrowse link
G Acaa1b acetyl-Coenzyme A acyltransferase 1B decreases expression ISO Lipopolysaccharides results in decreased expression of ACAA1B mRNA CTD PMID:27339419 NCBI chr 8:127,836,235...127,845,296 JBrowse link
G Acaca acetyl-CoA carboxylase alpha increases phosphorylation
multiple interactions		 ISO Lipopolysaccharides results in increased phosphorylation of ACACA protein
resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of ACACA protein]		 CTD PMID:22025971 NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910 		JBrowse link
G Acadm acyl-CoA dehydrogenase medium chain decreases expression ISO Lipopolysaccharides results in decreased expression of ACADM mRNA CTD PMID:18940942 NCBI chr 2:260,124,418...260,148,589
Ensembl chr 2:260,124,418...260,148,589 		JBrowse link
G Ackr1 atypical chemokine receptor 1 affects response to substance ISO ACKR1 protein affects the susceptibility to Lipopolysaccharides CTD PMID:10757794 NCBI chr13:91,827,310...91,828,875 JBrowse link
G Ackr3 atypical chemokine receptor 3 increases expression
multiple interactions
affects expression		 ISO
EXP		 Lipopolysaccharides results in increased expression of ACKR3 mRNA
Plant Extracts affects the reaction [Lipopolysaccharides affects the expression of ACKR3 mRNA]
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ACKR3 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ACKR3 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ACKR3 mRNA]		 CTD PMID:16401727, PMID:16415329, PMID:22180778, PMID:28070326 NCBI chr 9:97,355,881...97,367,455
Ensembl chr 9:97,355,924...97,367,445 		JBrowse link
G Aco1 aconitase 1 multiple interactions
increases activity		 ISO [Lipopolysaccharides co-treated with IFNG protein] results in increased activity of ACO1 protein
Lipopolysaccharides results in increased activity of ACO1 protein		 CTD PMID:11054110 NCBI chr 5:56,425,076...56,481,218
Ensembl chr 5:56,425,024...56,481,218 		JBrowse link
G Acod1 aconitate decarboxylase 1 multiple interactions
increases expression		 ISO (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of ACOD1 mRNA]
Lipopolysaccharides results in increased expression of ACOD1 mRNA; Lipopolysaccharides results in increased expression of ACOD1 protein		 CTD PMID:25890327, PMID:26358042, PMID:26582142 NCBI chr15:93,612,968...93,622,322
Ensembl chr15:93,612,971...93,622,358 		JBrowse link
G Acot1 acyl-CoA thioesterase 1 decreases expression ISO Lipopolysaccharides results in decreased expression of ACOT1 mRNA CTD PMID:27339419 NCBI chr 6:107,485,088...107,493,082
Ensembl chr 6:107,485,249...107,493,798 		JBrowse link
G Acox1 acyl-CoA oxidase 1 decreases expression ISO Lipopolysaccharides results in decreased expression of ACOX1 mRNA CTD PMID:18940942 NCBI chr10:104,724,534...104,748,003
Ensembl chr10:104,722,958...104,748,050 		JBrowse link
G Acp5 acid phosphatase 5, tartrate resistant multiple interactions
increases expression		 ISO CSF1R affects the reaction [Lipopolysaccharides results in increased expression of ACP5 mRNA]; Thymol inhibits the reaction [Lipopolysaccharides results in increased expression of ACP5 mRNA]; Thymol inhibits the reaction [Lipopolysaccharides results in increased expression of ACP5 protein]
Lipopolysaccharides results in increased expression of ACP5 mRNA; Lipopolysaccharides results in increased expression of ACP5 protein		 CTD PMID:22067001, PMID:30048646 NCBI chr 8:23,142,733...23,149,067
Ensembl chr 8:23,142,734...23,148,396 		JBrowse link
G Acp6 acid phosphatase 6, lysophosphatidic multiple interactions ISO [Lipopolysaccharides co-treated with resveratrol] results in increased expression of ACP6 mRNA CTD PMID:26667767 NCBI chr 2:199,284,177...199,305,793
Ensembl chr 2:199,283,909...199,305,799 		JBrowse link
G Acsl3 acyl-CoA synthetase long-chain family member 3 multiple interactions ISO [Lipopolysaccharides co-treated with resveratrol] results in decreased expression of ACSL3 mRNA CTD PMID:26667767 NCBI chr 9:84,569,601...84,593,565
Ensembl chr 9:84,569,597...84,593,565 		JBrowse link
G Acsm3 acyl-CoA synthetase medium-chain family member 3 multiple interactions ISO [Lipopolysaccharides co-treated with resveratrol] results in increased expression of ACSM3 mRNA CTD PMID:26667767 NCBI chr 1:189,514,504...189,541,233
Ensembl chr 1:189,514,553...189,541,224 		JBrowse link
G Acss2 acyl-CoA synthetase short-chain family member 2 decreases expression ISO Lipopolysaccharides results in decreased expression of ACSS2 mRNA CTD PMID:27339419 NCBI chr 3:151,032,925...151,075,856
Ensembl chr 3:151,032,952...151,075,856 		JBrowse link
G Acta2 actin alpha 2, smooth muscle decreases expression
increases expression
multiple interactions		 EXP
ISO		 Lipopolysaccharides results in decreased expression of ACTA2 protein
Lipopolysaccharides results in increased expression of ACTA2 protein
2,5-dimethyl-4-benzoquinone inhibits the reaction [Lipopolysaccharides results in increased expression of ACTA2 protein]; 2-tert-butyl-4-quinone inhibits the reaction [Lipopolysaccharides results in increased expression of ACTA2 protein]; phenylbenzoquinone inhibits the reaction [Lipopolysaccharides results in increased expression of ACTA2 protein]; thymoquinone inhibits the reaction [Lipopolysaccharides results in increased expression of ACTA2 protein]		 CTD PMID:29775649, PMID:31935363 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394 		JBrowse link
G Actb actin, beta increases expression EXP Lipopolysaccharides results in increased expression of ACTB mRNA CTD PMID:11779202 NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841 		JBrowse link
G Actl6b actin-like 6B increases expression ISO Lipopolysaccharides results in increased expression of ACTL6B mRNA CTD PMID:22185406 NCBI chr12:22,194,595...22,211,107
Ensembl chr12:22,194,618...22,211,080 		JBrowse link
G Acvr1b activin A receptor type 1B multiple interactions ISO [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased methylation of ACVR1B gene CTD PMID:21212295 NCBI chr 7:142,817,174...142,858,365
Ensembl chr 7:142,817,157...142,860,572 		JBrowse link
G Adam17 ADAM metallopeptidase domain 17 multiple interactions
increases expression		 ISO TLR4 mutant form promotes the reaction [Lipopolysaccharides results in increased expression of ADAM17] CTD PMID:21874253 NCBI chr 6:43,400,525...43,448,280
Ensembl chr 6:43,400,528...43,448,280 		JBrowse link
G Adam8 ADAM metallopeptidase domain 8 decreases expression ISO Lipopolysaccharides results in decreased expression of ADAM8 mRNA CTD PMID:12057914 NCBI chr 1:212,317,510...212,332,895
Ensembl chr 1:212,317,848...212,330,349 		JBrowse link
G Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 multiple interactions
affects expression
increases expression		 EXP
ISO		 [Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ADAMTS1 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ADAMTS1 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ADAMTS1 mRNA]
Plant Extracts affects the reaction [Lipopolysaccharides affects the expression of ADAMTS1 mRNA]		 CTD PMID:16401727, PMID:16415329, PMID:28070326 NCBI chr11:25,342,119...25,350,938
Ensembl chr11:25,342,126...25,350,974 		JBrowse link
G Adamts13 ADAM metallopeptidase with thrombospondin type 1 motif, 13 decreases expression EXP Lipopolysaccharides results in decreased expression of ADAMTS13 mRNA; Lipopolysaccharides results in decreased expression of ADAMTS13 protein CTD PMID:21878173 NCBI chr 3:5,519,921...5,558,390
Ensembl chr 3:5,519,990...5,558,166 		JBrowse link
G Adamts17 ADAM metallopeptidase with thrombospondin type 1 motif, 17 multiple interactions ISO [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased methylation of ADAMTS17 gene CTD PMID:21212295 NCBI chr 1:127,802,872...128,126,764
Ensembl chr 1:127,802,978...128,124,171 		JBrowse link
G Adar adenosine deaminase, RNA-specific increases expression ISO Lipopolysaccharides results in increased expression of ADAR protein CTD PMID:30501627 NCBI chr 2:189,045,551...189,085,448
Ensembl chr 2:189,062,443...189,083,236 		JBrowse link
G Adcy5 adenylate cyclase 5 multiple interactions
increases expression		 ISO [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased expression of ADCY5 mRNA
Lipopolysaccharides results in increased expression of ADCY5 mRNA		 CTD PMID:21212295 NCBI chr11:68,695,839...68,842,452
Ensembl chr11:68,695,839...68,842,320 		JBrowse link
G Adgre1 adhesion G protein-coupled receptor E1 increases expression
multiple interactions		 ISO Lipopolysaccharides results in increased expression of ADGRE1 mRNA
3,3'-diindolylmethane inhibits the reaction [Lipopolysaccharides results in increased expression of ADGRE1 mRNA]		 CTD PMID:24162184, PMID:27339419 NCBI chr 9:9,431,888...9,585,883
Ensembl chr 9:9,431,860...9,585,865 		JBrowse link
G Adgre5 adhesion G protein-coupled receptor E5 increases expression ISO Lipopolysaccharides results in increased expression of ADGRE5 mRNA CTD PMID:25890327 NCBI chr19:24,854,981...24,875,712
Ensembl chr19:24,855,299...24,875,137 		JBrowse link
G Adgrf2 adhesion G protein-coupled receptor F2 multiple interactions ISO [Lipopolysaccharides co-treated with resveratrol] results in decreased expression of ADGRF2 mRNA CTD PMID:26667767 NCBI chr 9:20,898,943...20,948,284
Ensembl chr 9:20,917,673...20,950,386 		JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 decreases expression ISO Lipopolysaccharides results in decreased expression of ADGRG1 mRNA CTD PMID:18192897 NCBI chr19:10,423,534...10,460,674
Ensembl chr19:10,423,501...10,460,674 		JBrowse link
G Adh7 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide increases expression ISO Lipopolysaccharides results in increased expression of ADH7 mRNA CTD PMID:27339419 NCBI chr 2:243,500,540...243,516,865
Ensembl chr 2:243,502,073...243,516,532 		JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing decreases response to substance
multiple interactions
increases secretion
increases expression		 ISO
EXP		 ADIPOQ results in decreased susceptibility to Lipopolysaccharides
ADIPOQ inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
ADIPOQ protein inhibits the reaction [Ethanol promotes the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; ADIPOQ protein inhibits the reaction [Ethanol promotes the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]]; ADIPOQ protein inhibits the reaction [Ethanol promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; IL10 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Ethanol promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]]; zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]
ADIPOQ gene mutant form promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; ADIPOQ protein inhibits the reaction [[Lipopolysaccharides results in increased activity of TLR4 protein] which results in increased expression of CXCL10 mRNA]; ADIPOQ protein inhibits the reaction [[Lipopolysaccharides results in increased activity of TLR4 protein] which results in increased expression of IFNB1 mRNA]; ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG mRNA]; ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of HMOX1 protein]; ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of STAT1 protein]; ADIPOR1 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; ADIPOR1 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]]; ADIPOR2 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; ADIPOR2 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]]; HMOX1 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; HMOX1 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of ADIPOQ mRNA]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of ADIPOQ protein]; zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]]		 CTD PMID:17641834, PMID:20052772, PMID:20861358, PMID:22156343 NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488 		JBrowse link
G Adipor1 adiponectin receptor 1 multiple interactions ISO ADIPOR1 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; ADIPOR1 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]] CTD PMID:20861358 NCBI chr13:51,240,470...51,260,233
Ensembl chr13:51,240,911...51,260,228 		JBrowse link
G Adipor2 adiponectin receptor 2 multiple interactions
decreases expression 		ISO
EXP		 ADIPOR2 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; ADIPOR2 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]]
lipopolysaccharide decreases expression of adipor2 mRNA in obese rat liver		 CTD PMID:20861358, PMID:23838384 RGD:8695926 NCBI chr 4:151,412,135...151,480,108
Ensembl chr 4:151,414,684...151,428,894 		JBrowse link
G Adm adrenomedullin decreases expression
increases expression
multiple interactions		 ISO
EXP		 Lipopolysaccharides results in decreased expression of ADM mRNA
Lipopolysaccharides results in increased expression of ADM protein
ADM protein inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; ADM protein inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]
[Ionomycin co-treated with Lipopolysaccharides] results in decreased expression of ADM protein		 CTD PMID:14766677, PMID:20682585, PMID:21803157 NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259 		JBrowse link
G Adora2a adenosine A2a receptor multiple interactions
increases expression		 ISO Adenosine promotes the reaction [Lipopolysaccharides results in increased expression of ADORA2A mRNA]
Lipopolysaccharides results in increased expression of ADORA2A mRNA; Lipopolysaccharides results in increased expression of ADORA2A protein		 CTD PMID:16387843, PMID:20067761 NCBI chr20:14,265,251...14,282,873
Ensembl chr20:14,265,252...14,282,873 		JBrowse link
G Adora2b adenosine A2B receptor decreases expression
increases expression
multiple interactions		 ISO Lipopolysaccharides results in decreased expression of ADORA2B mRNA
Lipopolysaccharides results in increased expression of ADORA2B mRNA
[Lipopolysaccharides co-treated with Melatonin] results in decreased expression of ADORA2B mRNA; Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of ADORA2B mRNA]		 CTD PMID:20067761, PMID:21461237, PMID:25890327 NCBI chr10:48,569,563...48,586,366
Ensembl chr10:48,569,555...48,586,365 		JBrowse link
G Adora3 adenosine A3 receptor decreases expression
increases expression		 ISO Lipopolysaccharides results in decreased expression of ADORA3 mRNA
Lipopolysaccharides results in increased expression of ADORA3 mRNA		 CTD PMID:10975854, PMID:12057914, PMID:20067761 NCBI chr 2:208,336,909...208,379,217
Ensembl chr 2:208,373,154...208,376,803 		JBrowse link
G Adrb2 adrenoceptor beta 2 multiple interactions
decreases response to substance
increases expression		 ISO
EXP		 ADRB2 protein promotes the reaction [Terbutaline promotes the reaction [Lipopolysaccharides results in increased expression of CXCL8 protein]]
ADRB2 protein results in decreased susceptibility to Lipopolysaccharides
ADRB2 protein affects the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; ADRB2 protein promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; ADRB2 protein promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; ADRB2 protein promotes the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased activity of MAPK1 protein]]; ADRB2 protein promotes the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased activity of MAPK3 protein]]; ADRB2 protein promotes the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; ADRB2 protein promotes the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ADRB2 protein promotes the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; ADRB2 protein promotes the reaction [Terbutaline promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]
Lipopolysaccharides results in increased expression of ADRB2 mRNA		 CTD PMID:9258252, PMID:10469353, PMID:10525314, PMID:10857765, PMID:11096136, PMID:12057914, PMID:15021963 NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834 		JBrowse link
G Aff2 AF4/FMR2 family, member 2 decreases expression ISO Lipopolysaccharides results in decreased expression of AFF2 mRNA CTD PMID:12057914 NCBI chr  X:153,539,951...154,051,022
Ensembl chr  X:153,539,668...154,051,181 		JBrowse link
G Afp alpha-fetoprotein increases expression ISO Lipopolysaccharides results in increased expression of AFP mRNA CTD PMID:27339419 NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923 		JBrowse link
G Ager advanced glycosylation end product-specific receptor increases expression
multiple interactions
affects expression		 ISO
EXP		 Lipopolysaccharides results in increased expression of AGER mRNA; Lipopolysaccharides results in increased expression of AGER protein
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Curcumin inhibits the reaction [Lipopolysaccharides results in increased expression of AGER protein]]; Curcumin inhibits the reaction [Lipopolysaccharides results in increased expression of AGER protein]
Lipopolysaccharides affects the expression of AGER mRNA
[Eicosapentaenoic Acid co-treated with procyanidin B3 co-treated with Lipopolysaccharides] results in increased expression of AGER mRNA
lycopene inhibits the reaction [Lipopolysaccharides results in increased expression of AGER protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of AGER protein]		 CTD PMID:17038636, PMID:22169119, PMID:22429818, PMID:24747151, PMID:29480285 NCBI chr20:4,363,152...4,366,079
Ensembl chr20:4,363,152...4,366,079 		JBrowse link
G Agpat2 1-acylglycerol-3-phosphate O-acyltransferase 2 decreases expression ISO Lipopolysaccharides results in decreased expression of AGPAT2 mRNA CTD PMID:16847310 NCBI chr 3:4,044,741...4,055,384
Ensembl chr 3:4,044,542...4,055,806 		JBrowse link
G Agt angiotensinogen multiple interactions
decreases expression
increases expression		 EXP
ISO		 AGT protein promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; candesartan inhibits the reaction [AGT protein promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]
AGT protein modified form promotes the reaction [FXN gene mutant form promotes the reaction [Lipopolysaccharides results in increased expression of AIF1 protein]]; AGT protein modified form promotes the reaction [FXN gene mutant form promotes the reaction [Lipopolysaccharides results in increased expression of GFAP protein]]
Lipopolysaccharides results in decreased expression of AGT protein
Lipopolysaccharides results in increased expression of AGT mRNA		 CTD PMID:10525314, PMID:12575980, PMID:19118600, PMID:26954031 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433 		JBrowse link
G Agtr1a angiotensin II receptor, type 1a multiple interactions
decreases expression		 EXP Edaravone inhibits the reaction [Lipopolysaccharides results in decreased expression of AGTR1A mRNA] CTD PMID:19118600 NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077 		JBrowse link
G Agtr2 angiotensin II receptor, type 2 multiple interactions
increases expression		 EXP AGTR2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; AGTR2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; AGTR2 protein promotes the reaction [Lipopolysaccharides results in increased expression of TGFB1 mRNA]; Edaravone inhibits the reaction [Lipopolysaccharides results in increased expression of AGTR2 mRNA] CTD PMID:19118600 NCBI chr  X:119,389,480...119,393,845
Ensembl chr  X:119,390,013...119,393,842 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
increases response to substance
increases expression		 ISO
EXP		 [Lipopolysaccharides co-treated with resveratrol] results in decreased expression of AHR mRNA; AHR protein affects the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Lipopolysaccharides results in increased expression of IL12A mRNA]]; AHR protein affects the reaction [Tetrachlorodibenzodioxin promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; prolinedithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased expression of AHR mRNA]; RELA mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of AHR mRNA]
AHR gene mutant form results in increased susceptibility to Lipopolysaccharides
Lipopolysaccharides results in increased expression of AHR mRNA; Lipopolysaccharides results in increased expression of AHR protein
AHR gene mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of CYP1A1 mRNA]; AHR mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of CYP1A1 mRNA]; AHR promotes the reaction [[Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of CCL20 protein]; AHR promotes the reaction [[Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA]; AHR protein affects the reaction [[Dust co-treated with Lipopolysaccharides] results in increased expression of CYP1A1 mRNA]; AHR protein affects the reaction [[Dust co-treated with Lipopolysaccharides] results in increased expression of IL22 mRNA]; AHR protein affects the reaction [[Dust co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; AHR protein affects the reaction [[Dust co-treated with Lipopolysaccharides] results in increased secretion of IL17A protein]; AHR protein affects the reaction [[Dust co-treated with Lipopolysaccharides] results in increased secretion of IL22 protein]; AHR protein affects the reaction [[Particulate Matter co-treated with Lipopolysaccharides] results in increased expression of AHRR mRNA]; AHR protein affects the reaction [[Particulate Matter co-treated with Lipopolysaccharides] results in increased expression of CYP1A1 mRNA]; AHR protein affects the reaction [[Particulate Matter co-treated with Lipopolysaccharides] results in increased expression of IL17A mRNA]; AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in decreased expression of BCL2 mRNA]; AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in decreased expression of STAT5A mRNA]; AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]; AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased expression of IL6 mRNA]; AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased expression of SERPINB2 mRNA]; AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased expression of STAT2 mRNA]; AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein]; AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased secretion of CXCL1 protein]; AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased secretion of IFNG protein]; AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased secretion of IL10 protein]; AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]; AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased secretion of IL6 protein]; AHR protein affects the reaction [[Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased expression of CYP1A1 mRNA]; AHR protein affects the reaction [[Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased expression of IL22 mRNA]; AHR protein affects the reaction [[Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; AHR protein affects the susceptibility to [[Lipopolysaccharides co-treated with indole-3-carbinol] results in increased secretion of IL10 protein]; CASP1 protein affects the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in decreased expression of BCL2 mRNA]]; CASP1 protein affects the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]]; CASP1 protein affects the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased expression of IL6 mRNA]]; CASP1 protein affects the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased expression of SERPINB2 mRNA]]; CASP1 protein affects the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased expression of STAT2 mRNA]]; IL10 protein inhibits the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein]]; IL10 protein inhibits the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased secretion of CXCL1 protein]]; IL10 protein inhibits the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased secretion of IFNG protein]]; IL10 protein inhibits the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; IL10 protein inhibits the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased secretion of IL6 protein]]; IL10 protein promotes the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased secretion of IL10 protein]]; Lipopolysaccharides promotes the reaction [AHR protein binds to CCL20 promoter]; Lipopolysaccharides promotes the reaction [AHR protein binds to CYP1A1 promoter]; Lipopolysaccharides promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to IGH enhancer]]; RELA mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of AHR mRNA]		 CTD PMID:9547351, PMID:21948866, PMID:22273745, PMID:24302727, PMID:26259605, PMID:26377645, PMID:26667767, PMID:27590929, PMID:27783115, PMID:29689377 NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464 		JBrowse link
G Ahrr aryl-hydrocarbon receptor repressor multiple interactions ISO [Particulate Matter co-treated with Lipopolysaccharides] results in increased expression of AHRR mRNA; AHR protein affects the reaction [[Particulate Matter co-treated with Lipopolysaccharides] results in increased expression of AHRR mRNA] CTD PMID:29689377 NCBI chr 1:31,603,297...31,698,329
Ensembl chr 1:31,603,297...31,698,329 		JBrowse link
G Aicda activation-induced cytidine deaminase decreases expression ISO Lipopolysaccharides results in decreased expression of AICDA mRNA CTD PMID:25890327 NCBI chr 4:155,359,909...155,371,104
Ensembl chr 4:155,359,921...155,369,671 		JBrowse link
G Aif1 allograft inflammatory factor 1 multiple interactions
increases expression		 ISO
EXP		 3,3'-diindolylmethane inhibits the reaction [Lipopolysaccharides results in increased expression of AIF1 protein]; AGT protein modified form promotes the reaction [FXN gene mutant form promotes the reaction [Lipopolysaccharides results in increased expression of AIF1 protein]]; FXN gene mutant form promotes the reaction [Lipopolysaccharides results in increased expression of AIF1 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Lipopolysaccharides results in increased expression of AIF1 protein]
Lipopolysaccharides results in increased expression of AIF1; Lipopolysaccharides results in increased expression of AIF1 mRNA; Lipopolysaccharides results in increased expression of AIF1 protein		 CTD PMID:21245015, PMID:24162184, PMID:25447322, PMID:26954031, PMID:27339419 NCBI chr20:5,161,350...5,167,176
Ensembl chr20:5,161,333...5,166,448 		JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions
increases expression		 EXP Honghua extract, Carthamus tinctorius inhibits the reaction [Lipopolysaccharides results in increased expression of AIFM1 protein] CTD PMID:31486215 NCBI chr  X:135,304,063...135,343,062
Ensembl chr  X:135,304,066...135,343,087 		JBrowse link
G Aim2 absent in melanoma 2 multiple interactions
affects expression		 ISO AIM2 protein promotes the reaction [[Lipopolysaccharides co-treated with Poly dA-dT] results in increased secretion of IL1B protein]
Lipopolysaccharides affects the expression of AIM2 mRNA
Plant Extracts affects the reaction [Lipopolysaccharides affects the expression of AIM2 mRNA]		 CTD PMID:24158569, PMID:28070326 NCBI chr13:91,919,834...91,963,080
Ensembl chr13:91,954,138...91,962,588 		JBrowse link
G Ajuba ajuba LIM protein increases expression ISO Lipopolysaccharides results in increased expression of AJUBA mRNA CTD PMID:12057914 NCBI chr15:33,208,210...33,218,456
Ensembl chr15:33,208,216...33,218,456 		JBrowse link
G Akap12 A-kinase anchoring protein 12 increases expression ISO Lipopolysaccharides results in increased expression of AKAP12 mRNA CTD PMID:27339419 NCBI chr 1:40,816,130...40,906,582
Ensembl chr 1:40,816,107...40,906,581 		JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B multiple interactions ISO [sorbinil results in decreased activity of AKR1B1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Reactive Oxygen Species]; [sorbinil results in decreased activity of AKR1B1 protein] inhibits the reaction [Lipopolysaccharides results in increased secretion of Dinoprostone]; [sorbinil results in decreased activity of AKR1B1 protein] which results in decreased susceptibility to Lipopolysaccharides
Lipopolysaccharides inhibits the reaction [Sodium Chloride results in increased expression of AKR1B3 mRNA]		 CTD PMID:21334316, PMID:23867654 NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases phosphorylation
increases phosphorylation
increases expression
increases activity		 ISO
EXP		 4-phenylbutyric acid inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]; Amino Acids, Peptides, and Proteins inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]
Honghua extract, Carthamus tinctorius inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]; Lipopolysaccharides results in increased phosphorylation of and results in increased activity of AKT1 protein; Organoselenium Compounds inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of AKT1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]; triptolide inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; wuzi yanzong analog inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]
Lipopolysaccharides results in increased expression of AKT1 mRNA
Lipopolysaccharides results in increased activity of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cobaltiprotoporphyrin promotes the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of AKT1 protein]; 3,4-dihydroxybenzohydroxamic acid inhibits the reaction [Lipopolysaccharides results in increased expression of AKT1 mRNA]; [Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased phosphorylation of AKT1 protein; [Lipopolysaccharides co-treated with TLR4] results in increased phosphorylation of AKT1 protein; AG 1879 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; Caffeine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; cinnamic aldehyde inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; cobaltiprotoporphyrin promotes the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; Fluorouracil inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; hydroquinone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of AKT1 protein]; Lipopolysaccharides results in decreased phosphorylation of and results in decreased activity of AKT1 protein; Lipopolysaccharides results in increased phosphorylation of and results in increased activity of AKT1 protein; Luteolin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; Melatonin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; phlorofucofuroeckol A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; Quercetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with TLR4] results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; shogaol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased phosphorylation of AKT1 protein]; timosaponin BIII inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; Wortmannin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of AKT1 protein]		 CTD PMID:16724238, PMID:17131360, PMID:17172471, PMID:17322126, PMID:17464197, PMID:18047562, PMID:18538761, PMID:18683823, PMID:18720166, PMID:20467561, PMID:21078380, PMID:21125213, PMID:21212295, PMID:21717513, PMID:21893401, PMID:21963823, PMID:22003094, PMID:22102721, PMID:22118570, PMID:22225513, PMID:22974838, PMID:23735482, PMID:25171655, PMID:25843059, PMID:26497626, PMID:28245985, PMID:30322157, PMID:31486215, PMID:31499194 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258 		JBrowse link
G Alas1 5'-aminolevulinate synthase 1 increases expression ISO Lipopolysaccharides results in increased expression of ALAS1 mRNA CTD PMID:27339419 NCBI chr 8:114,927,704...114,941,038
Ensembl chr 8:114,927,722...114,940,177 		JBrowse link
G Alb albumin multiple interactions
decreases expression		 ISO
EXP		 ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]
Lipopolysaccharides results in decreased expression of ALB mRNA
[ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein; Lipopolysaccharides inhibits the reaction [HNF1A protein binds to ALB promoter]; Lipopolysaccharides inhibits the reaction [USP3 protein binds to ALB promoter]		 CTD PMID:14561216, PMID:17963606, PMID:19376148 NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863 		JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 multiple interactions ISO Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of ALDH1A1 protein] CTD PMID:21948866 NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330 		JBrowse link
G Aldh1a2 aldehyde dehydrogenase 1 family, member A2 multiple interactions ISO Lipopolysaccharides affects the susceptibility to [indole-3-carbinol results in decreased expression of ALDH1A2 mRNA] CTD PMID:21948866 NCBI chr 8:77,640,234...77,719,488
Ensembl chr 8:77,640,222...77,719,489 		JBrowse link
G Aldh9a1 aldehyde dehydrogenase 9 family, member A1 multiple interactions ISO [Lipopolysaccharides co-treated with resveratrol] results in increased expression of ALDH9A1 mRNA CTD PMID:26667767 NCBI chr13:85,580,828...85,597,497
Ensembl chr13:85,580,828...85,597,493 		JBrowse link
G Aldoa aldolase, fructose-bisphosphate A multiple interactions EXP [Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ALDOA mRNA CTD PMID:16415329 NCBI chr 1:198,228,387...198,233,988
Ensembl chr 1:198,228,387...198,233,588 		JBrowse link
G Alox15 arachidonate 15-lipoxygenase multiple interactions ISO [TLR4 gene mutant form co-treated with Lipopolysaccharides] results in increased expression of ALOX15 mRNA CTD PMID:23000425 NCBI chr10:56,953,692...56,962,145
Ensembl chr10:56,953,691...56,962,161 		JBrowse link
G Alox5 arachidonate 5-lipoxygenase increases expression
multiple interactions		 ISO Lipopolysaccharides results in increased expression of ALOX5 mRNA
Lipopolysaccharides results in increased expression of ALOX5 mRNA; Lipopolysaccharides results in increased expression of ALOX5 protein
EPHX2 gene mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of ALOX5 protein]; EPHX2 gene mutant form promotes the reaction [MK-886 inhibits the reaction [Lipopolysaccharides results in increased expression of ALOX5 protein]]; MK-886 inhibits the reaction [Lipopolysaccharides results in increased expression of ALOX5 protein]
glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of ALOX5 mRNA]; Lipopolysaccharides results in increased phosphorylation of and results in increased activity of ALOX5 protein		 CTD PMID:10779545, PMID:19896470, PMID:20453108, PMID:21877189 NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303 		JBrowse link
G Alox5ap arachidonate 5-lipoxygenase activating protein multiple interactions
decreases expression		 ISO clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of ALOX5AP mRNA]
Lipopolysaccharides results in decreased expression of ALOX5AP mRNA		 CTD PMID:19172522, PMID:21461237 NCBI chr12:6,854,930...6,879,112
Ensembl chr12:6,854,920...6,879,154 		JBrowse link
G Als2 alsin Rho guanine nucleotide exchange factor ALS2 increases expression
multiple interactions		 ISO Lipopolysaccharides results in increased expression of ALS2 mRNA
methyldithiocarbamate affects the reaction [Lipopolysaccharides results in increased expression of ALS2 mRNA]		 CTD PMID:19339665 NCBI chr 9:65,961,361...66,034,396
Ensembl chr 9:65,961,346...66,033,871 		JBrowse link
G Ambra1 autophagy and beclin 1 regulator 1 increases expression EXP Lipopolysaccharides results in increased expression of AMBRA1 mRNA; Lipopolysaccharides results in increased expression of AMBRA1 protein CTD PMID:30084861 NCBI chr 3:80,634,470...80,830,068
Ensembl chr 3:80,634,470...80,830,068 		JBrowse link
G Amotl2 angiomotin like 2 increases expression
multiple interactions		 EXP Lipopolysaccharides results in increased expression of AMOTL2 mRNA
Ranitidine inhibits the reaction [Lipopolysaccharides results in increased expression of AMOTL2 mRNA]		 CTD PMID:16415329 NCBI chr 8:111,210,261...111,226,217
Ensembl chr 8:111,209,908...111,226,226 		JBrowse link
G Ampd3 adenosine monophosphate deaminase 3 increases expression ISO Lipopolysaccharides results in increased expression of AMPD3 mRNA CTD PMID:25890327 NCBI chr 1:175,585,301...175,630,479
Ensembl chr 1:175,586,097...175,630,467 		JBrowse link
G Amy1a amylase, alpha 1A decreases expression ISO Lipopolysaccharides results in decreased expression of AMY1 mRNA CTD PMID:27339419 NCBI chr 2:216,428,709...216,443,518
Ensembl chr 2:216,428,709...216,443,518 		JBrowse link
G Anapc7 anaphase promoting complex subunit 7 increases methylation ISO Lipopolysaccharides results in increased methylation of ANAPC7 gene CTD PMID:21212295 NCBI chr12:39,613,898...39,641,999
Ensembl chr12:39,614,733...39,641,285 		JBrowse link
G Angptl4 angiopoietin-like 4 decreases expression
multiple interactions
increases expression		 ISO Lipopolysaccharides results in decreased expression of ANGPTL4 mRNA
genipin inhibits the reaction [Lipopolysaccharides results in increased expression of ANGPTL4 mRNA]		 CTD PMID:22687549, PMID:26582142 NCBI chr 7:18,627,814...18,634,043
Ensembl chr 7:18,627,808...18,634,079 		JBrowse link
G Ankrd1 ankyrin repeat domain 1 multiple interactions ISO [Lipopolysaccharides co-treated with resveratrol] results in decreased expression of ANKRD1 mRNA CTD PMID:26667767 NCBI chr 1:254,726,985...254,745,673
Ensembl chr 1:254,726,969...254,735,548 		JBrowse link
G Ankrd22 ankyrin repeat domain 22 increases expression ISO Lipopolysaccharides results in increased expression of ANKRD22 mRNA CTD PMID:18192897 NCBI chr 1:252,430,750...252,461,346
Ensembl chr 1:252,429,677...252,461,461 		JBrowse link
G Anos1 anosmin 1 increases expression ISO Lipopolysaccharides results in increased expression of WFDC17 mRNA CTD PMID:27339419 Ensembl chr10:70,999,780...71,000,627 JBrowse link
G Anxa1 annexin A1 multiple interactions
decreases response to substance		 ISO
EXP		 ANXA1 protein inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]; ANXA1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; ANXA1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]; ANXA1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; ANXA1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; ANXA1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; ANXA1 protein inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; ANXA1 protein inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; ANXA1 protein inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
ANXA1 protein results in decreased susceptibility to Lipopolysaccharides
ANXA1 protein affects the reaction [Lipopolysaccharides affects the secretion of IL6 protein]; ANXA1 protein affects the reaction [Lipopolysaccharides affects the secretion of TNF protein]; ANXA1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; ANXA1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]		 CTD PMID:16633358, PMID:16835395, PMID:21777521 NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012 		JBrowse link
G Anxa2 annexin A2 increases expression ISO Lipopolysaccharides results in increased expression of ANXA2 mRNA CTD PMID:27339419 NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594 		JBrowse link
G Anxa4 annexin A4 decreases methylation
multiple interactions		 ISO Lipopolysaccharides results in decreased methylation of ANXA4 gene
[Lipopolysaccharides co-treated with resveratrol] results in decreased expression of ANXA4 mRNA		 CTD PMID:21212295, PMID:26667767 NCBI chr 4:118,538,775...118,595,591
Ensembl chr 4:118,538,777...118,595,580 		JBrowse link
G Anxa5 annexin A5 multiple interactions
increases expression
decreases expression		 ISO E804 bisindole inhibits the reaction [Lipopolysaccharides results in increased expression of ANXA5 mRNA]; Lipopolysaccharides inhibits the reaction [E804 bisindole results in increased expression of ANXA5 mRNA]
Lipopolysaccharides results in decreased expression of ANXA5 mRNA		 CTD PMID:22777745, PMID:23107598 NCBI chr 2:123,162,477...123,194,730
Ensembl chr 2:123,162,461...123,193,130 		JBrowse link
G Aoah acyloxyacyl hydrolase multiple interactions
increases expression		 ISO (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of AOAH mRNA] CTD PMID:25890327 NCBI chr17:45,872,414...46,115,026
Ensembl chr17:45,872,414...46,115,004 		JBrowse link
G Ap1b1 adaptor related protein complex 1 subunit beta 1 multiple interactions ISO [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased methylation of AP1B1 gene CTD PMID:21212295 NCBI chr14:85,230,652...85,281,806
Ensembl chr14:85,230,648...85,281,803 		JBrowse link
G Ap2a1 adaptor related protein complex 2 subunit alpha 1 decreases methylation
multiple interactions		 ISO Lipopolysaccharides results in decreased methylation of AP2A1 gene
[Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased methylation of AP2A1 gene		 CTD PMID:21212295 NCBI chr 1:100,896,582...100,926,443
Ensembl chr 1:100,896,947...100,926,335 		JBrowse link
G Apba3 amyloid beta precursor protein binding family A member 3 multiple interactions
affects response to substance		 ISO APBA3 affects the reaction [Lipopolysaccharides results in increased expression of TNF protein]
APBA3 affects the susceptibility to Lipopolysaccharides		 CTD PMID:21778228 NCBI chr 7:11,314,468...11,319,540
Ensembl chr 7:11,314,424...11,319,516 		JBrowse link
G Apbb1 amyloid beta precursor protein binding family B member 1 increases expression ISO Lipopolysaccharides results in increased expression of APBB1 mRNA CTD PMID:15919760 NCBI chr 1:170,387,625...170,411,263
Ensembl chr 1:170,387,609...170,404,056 		JBrowse link
G Apcs amyloid P component, serum affects response to substance
increases expression		 ISO APCS protein affects the susceptibility to Lipopolysaccharides
Lipopolysaccharides results in increased expression of APCS mRNA
Lipopolysaccharides results in increased expression of APCS protein		 CTD PMID:9205823, PMID:17321000, PMID:21731756, PMID:27339419 NCBI chr13:91,426,621...91,427,417
Ensembl chr13:91,426,479...91,427,575 		JBrowse link
G Aplp1 amyloid beta precursor like protein 1 increases expression ISO Lipopolysaccharides results in increased expression of APLP1 mRNA CTD PMID:15919760 NCBI chr 1:88,897,525...88,908,750
Ensembl chr 1:88,897,532...88,908,750 		JBrowse link
G Apoa1 apolipoprotein A1 multiple interactions
decreases expression		 ISO APOA1 protein inhibits the reaction [Lipopolysaccharides results in increased activity of RELA protein]; APOA1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of MYD88 mRNA]
Lipopolysaccharides results in decreased expression of APOA1 protein
APOA1 protein inhibits the reaction [Lipopolysaccharides results in decreased abundance of Cholesterol, HDL]; APOA1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of MYD88 mRNA]; APOA1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TICAM1 mRNA]; APOA1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA]		 CTD PMID:20972769, PMID:21474830 NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875 		JBrowse link
G Apoa4 apolipoprotein A4 increases expression ISO Lipopolysaccharides results in increased expression of APOA4 mRNA CTD PMID:27339419 NCBI chr 8:50,536,983...50,539,371
Ensembl chr 8:50,537,009...50,539,376 		JBrowse link
G Apoe apolipoprotein E decreases expression ISO Lipopolysaccharides results in decreased expression of APOE mRNA CTD PMID:16847310 NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057 		JBrowse link
G Apom apolipoprotein M decreases expression ISO Lipopolysaccharides results in decreased expression of APOM mRNA; Lipopolysaccharides results in decreased expression of APOM protein CTD PMID:18054359 NCBI chr20:5,120,473...5,123,073
Ensembl chr20:5,120,474...5,123,073 		JBrowse link
G App amyloid beta precursor protein increases expression
multiple interactions		 ISO
EXP		 Lipopolysaccharides results in increased expression of APP mRNA
[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of APP mRNA; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of APP protein; Ditiocarb inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of APP mRNA]; Ditiocarb inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of APP protein]; pimagedine inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of APP mRNA]; pimagedine inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of APP protein]
APP protein modified form inhibits the reaction [Lipopolysaccharides results in increased activity of CEBPD protein]; APP protein modified form inhibits the reaction [Lipopolysaccharides results in increased expression of CEBPD protein]; APP protein modified form promotes the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]; Vitamin E inhibits the reaction [APP protein modified form promotes the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]]		 CTD PMID:15223066, PMID:15919760, PMID:18405661, PMID:28242320 NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858 		JBrowse link
G Appl1 adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 multiple interactions ISO APPL1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; APPL1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; APPL1 protein promotes the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; APPL1 protein promotes the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; APPL1 protein promotes the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; APPL1 protein promotes the reaction [Lipopolysaccharides results in increased phosphorylation of IKBKE protein]; APPL1 protein promotes the reaction [Lipopolysaccharides results in increased phosphorylation of IRF3 protein]; APPL1 protein promotes the reaction [Lipopolysaccharides results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; Chloroquine inhibits the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; DNM2 protein promotes the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; Lipopolysaccharides inhibits the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; Lipopolysaccharides promotes the reaction [APPL1 protein binds to IKBKE protein]; Lipopolysaccharides promotes the reaction [APPL1 protein binds to NAP1 protein]; Lipopolysaccharides promotes the reaction [APPL1 protein binds to TANK protein]; Lipopolysaccharides promotes the reaction [APPL1 protein binds to TBK1 protein modified form]; Lipopolysaccharides promotes the reaction [APPL1 protein binds to TBK1 protein]; Lipopolysaccharides promotes the reaction [APPL1 protein binds to TRAF3 protein]; Lipopolysaccharides results in increased ubiquitination of and results in increased degradation of APPL1 protein; N'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide inhibits the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; U 0126 inhibits the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein] CTD PMID:25780039 NCBI chr16:2,560,103...2,602,035
Ensembl chr16:2,563,520...2,602,103 		JBrowse link
G Aqp1 aquaporin 1 multiple interactions
increases expression		 ISO 3,5-bis(2-fluorobenzylidene)piperidin-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of AQP1 mRNA]; 3,5-bis(2-fluorobenzylidene)piperidin-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of AQP1 protein]
Lipopolysaccharides results in increased expression of AQP1 mRNA; Lipopolysaccharides results in increased expression of AQP1 protein		 CTD PMID:24028651, PMID:27339419 NCBI chr 4:85,551,503...85,563,683
Ensembl chr 4:85,551,502...85,569,360 		JBrowse link
G Aqp3 aquaporin 3 (Gill blood group) increases expression ISO Lipopolysaccharides results in increased expression of AQP3 mRNA CTD PMID:21362464 NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245 		JBrowse link
G Aqp4 aquaporin 4 multiple interactions
affects response to substance		 ISO [AQP4 protein affects the susceptibility to Lipopolysaccharides] which affects the abundance of Reactive Oxygen Species; [AQP4 protein affects the susceptibility to Lipopolysaccharides] which affects the expression of CYP2E1 mRNA; allyl sulfide inhibits the reaction [AQP4 protein affects the susceptibility to Lipopolysaccharides] CTD PMID:20615459 NCBI chr18:6,766,009...6,782,757
Ensembl chr18:6,765,945...6,782,996 		JBrowse link
G Aqp8 aquaporin 8 decreases expression ISO Lipopolysaccharides results in decreased expression of AQP8 mRNA CTD PMID:27339419 NCBI chr 1:193,424,818...193,430,665
Ensembl chr 1:193,424,812...193,430,676 		JBrowse link
G Ar androgen receptor multiple interactions
decreases expression		 ISO Cryptoxanthins inhibits the reaction [Lipopolysaccharides results in decreased expression of AR mRNA] CTD PMID:12057914, PMID:26686910 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026 		JBrowse link
G Arap2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 multiple interactions
increases expression		 ISO coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of ARAP2 mRNA] CTD PMID:21370964 NCBI chr14:48,726,033...48,922,809
Ensembl chr14:48,726,045...48,922,983 		JBrowse link
G Areg amphiregulin multiple interactions
affects expression		 ISO [Lipopolysaccharides co-treated with resveratrol] results in decreased expression of AREG mRNA; Plant Extracts affects the reaction [Lipopolysaccharides affects the expression of AREG mRNA] CTD PMID:26667767, PMID:28070326 NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179 		JBrowse link
G Arg1 arginase 1 increases expression
decreases expression
multiple interactions		 ISO
EXP		 Lipopolysaccharides results in increased expression of ARG1 mRNA
Lipopolysaccharides results in decreased expression of ARG1 mRNA
Lipopolysaccharides results in increased expression of ARG1 mRNA; Lipopolysaccharides results in increased expression of ARG1 protein
Aminoimidazole Carboxamide analog promotes the reaction [Lipopolysaccharides results in increased expression of ARG1 protein]; dorsomorphin promotes the reaction [Lipopolysaccharides results in increased expression of ARG1 protein]
[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of ARG1 mRNA; [Lipopolysaccharides co-treated with IL4 protein] results in increased expression of ARG1 mRNA; cypermethrin promotes the reaction [Lipopolysaccharides results in increased expression of ARG1 mRNA]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of ARG1 mRNA]; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate inhibits the reaction [Lipopolysaccharides results in increased expression of ARG1 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of ARG1 mRNA]; Progesterone inhibits the reaction [[Lipopolysaccharides co-treated with IL4 protein] results in increased expression of ARG1 mRNA]; Progesterone inhibits the reaction [Lipopolysaccharides results in increased expression of ARG1 mRNA]		 CTD PMID:19853624, PMID:21977998, PMID:26748080, PMID:26918785, PMID:28693884, PMID:29191728, PMID:29471534 NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863 		JBrowse link
G Arhgap19 Rho GTPase activating protein 19 decreases expression ISO Lipopolysaccharides results in decreased expression of ARHGAP19 mRNA CTD PMID:26582142 NCBI chr 1:261,015,083...261,051,515
Ensembl chr 1:261,015,123...261,051,498 		JBrowse link
G Arhgap31 Rho GTPase activating protein 31 multiple interactions ISO clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of ARHGAP31 mRNA] CTD PMID:19172522 NCBI chr11:64,600,968...64,714,114
Ensembl chr11:64,601,029...64,714,252 		JBrowse link
G Arhgdib Rho GDP dissociation inhibitor beta increases expression ISO Lipopolysaccharides results in increased expression of ARHGDIB mRNA CTD PMID:27339419 NCBI chr 4:170,913,920...170,932,789
Ensembl chr 4:170,913,923...170,932,618 		JBrowse link
G Arhgef11 Rho guanine nucleotide exchange factor 11 multiple interactions EXP [Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ARHGEF11 mRNA CTD PMID:16415329 NCBI chr 2:186,979,850...187,102,523
Ensembl chr 2:186,980,793...187,101,768 		JBrowse link
G Arhgef2 Rho/Rac guanine nucleotide exchange factor 2 multiple interactions
increases expression		 ISO ARHGEF2 mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]; ARHGEF2 mutant form inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; ARHGEF2 mutant form inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK14 protein]; ARHGEF2 mutant form inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; ARHGEF2 mutant form inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]; Lipopolysaccharides promotes the reaction [TLR4 protein binds to ARHGEF2 protein]; TLR4 mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of ARHGEF2 protein] CTD PMID:22226621 NCBI chr 2:187,964,100...188,022,847
Ensembl chr 2:187,977,008...188,021,377 		JBrowse link
G Arl10 ADP-ribosylation factor like GTPase 10 multiple interactions ISO [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased methylation of ARL10 gene CTD PMID:21212295 NCBI chr17:10,567,064...10,575,518
Ensembl chr17:10,568,959...10,575,203 		JBrowse link
G Arl11 ADP-ribosylation factor like GTPase 11 decreases expression ISO Lipopolysaccharides results in decreased expression of ARL11 mRNA CTD PMID:25890327 NCBI chr15:41,639,985...41,645,685
Ensembl chr15:41,643,541...41,645,685 		JBrowse link
G Arl16 ADP-ribosylation factor like GTPase 16 multiple interactions ISO [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased methylation of ARL16 gene CTD PMID:21212295 NCBI chr10:109,636,770...109,639,018
Ensembl chr10:109,636,896...109,639,054 		JBrowse link
G Arl4a ADP-ribosylation factor like GTPase 4A decreases expression ISO Lipopolysaccharides results in decreased expression of ARL4A mRNA CTD PMID:27339419 NCBI chr 6:59,945,926...59,950,586
Ensembl chr 6:59,948,577...59,950,586 		JBrowse link
G Arl4d ADP-ribosylation factor like GTPase 4D decreases expression ISO Lipopolysaccharides results in decreased expression of ARL4D mRNA CTD PMID:27339419 NCBI chr10:89,577,556...89,580,368
Ensembl chr10:89,578,212...89,580,368 		JBrowse link
G Armcx2 armadillo repeat containing, X-linked 2 increases expression ISO Lipopolysaccharides results in increased expression of ARMCX2 mRNA CTD PMID:27339419 NCBI chr  X:105,617,383...105,622,209
Ensembl chr  X:105,617,385...105,622,156 		JBrowse link
G Arrb1 arrestin, beta 1 increases expression ISO Lipopolysaccharides results in increased expression of ARRB1 mRNA CTD PMID:27339419 NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139 		JBrowse link
G Arrdc3 arrestin domain containing 3 decreases expression ISO Lipopolysaccharides results in decreased expression of ARRDC3 mRNA CTD PMID:26582142 NCBI chr 2:8,732,907...8,745,445
Ensembl chr 2:8,732,932...8,743,069 		JBrowse link
G Arvcf ARVCF, delta catenin family member multiple interactions ISO [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased methylation of ARVCF gene CTD PMID:21212295 NCBI chr11:86,736,125...86,793,795
Ensembl chr11:86,736,142...86,793,791 		JBrowse link
G Asb10 ankyrin repeat and SOCS box-containing 10 decreases expression ISO Lipopolysaccharides results in decreased expression of ASB10 mRNA CTD PMID:25890327 NCBI chr 4:7,158,293...7,167,505
Ensembl chr 4:7,158,448...7,167,509 		JBrowse link
G Asl argininosuccinate lyase increases expression EXP Lipopolysaccharides results in increased expression of ASL mRNA CTD PMID:11779202 NCBI chr12:30,160,922...30,178,348
Ensembl chr12:30,165,694...30,178,341 		JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) increases expression ISO Lipopolysaccharides results in increased expression of ASNS mRNA CTD PMID:27339419 NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163 		JBrowse link
G Atf2 activating transcription factor 2 multiple interactions
increases phosphorylation		 ISO
EXP		 [Drugs, Chinese Herbal co-treated with niuhuang] inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of ATF2 protein]; Lipopolysaccharides results in increased phosphorylation of and results in increased activity of ATF2 protein
baicalin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of ATF2 protein]		 CTD PMID:23106696, PMID:23256447, PMID:24312512 NCBI chr 3:60,721,137...60,795,951
Ensembl chr 3:60,721,135...60,795,951 		JBrowse link
G Atf3 activating transcription factor 3 multiple interactions
increases expression		 EXP
ISO		 [Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ATF3 mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of ATF3 mRNA] CTD PMID:16401727, PMID:16415329, PMID:27783115 NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632 		JBrowse link
G Atf4 activating transcription factor 4 increases expression
multiple interactions		 ISO
EXP		 Lipopolysaccharides results in increased expression of ATF4 protein
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein		 CTD PMID:19675143, PMID:28844859 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772 		JBrowse link
G Atf6 activating transcription factor 6 increases cleavage
increases expression
multiple interactions		 ISO Lipopolysaccharides results in increased cleavage of ATF6 protein
Lipopolysaccharides results in increased expression of ATF6 protein
4-phenylbutyric acid inhibits the reaction [Lipopolysaccharides results in increased expression of ATF6 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of ATF6 protein]		 CTD PMID:19675143, PMID:28245985, PMID:30918470 NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443 		JBrowse link
G Atg12 autophagy related 12 increases expression EXP Lipopolysaccharides results in increased expression of ATG12 mRNA; Lipopolysaccharides results in increased expression of ATG12 protein CTD PMID:30084861 NCBI chr18:40,721,799...40,732,143
Ensembl chr18:40,721,800...40,732,126 		JBrowse link
G Atg5 autophagy related 5 increases cleavage
multiple interactions		 EXP Lipopolysaccharides results in increased cleavage of ATG5 protein
Sialic Acids inhibits the reaction [Lipopolysaccharides results in increased cleavage of ATG5 protein]		 CTD PMID:24973090 NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140 		JBrowse link
G Atg7 autophagy related 7 multiple interactions ISO [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased methylation of ATG7 gene CTD PMID:21212295 NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124 		JBrowse link
G Atox1 antioxidant 1 copper chaperone increases expression ISO Lipopolysaccharides results in increased expression of ATOX1 mRNA CTD PMID:22369063 NCBI chr10:40,790,850...40,805,886
Ensembl chr10:40,790,845...40,805,941 		JBrowse link
G Atp11a ATPase phospholipid transporting 11A increases expression ISO Lipopolysaccharides results in increased expression of ATP11A mRNA CTD PMID:27339419 NCBI chr16:81,990,340...82,100,222
Ensembl chr16:81,990,340...82,100,222 		JBrowse link
G Atp1b1 ATPase Na+/K+ transporting subunit beta 1 multiple interactions
decreases expression		 EXP [Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ATP1B1 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of ATP1B1 mRNA]; Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of ATP1B1 mRNA] CTD PMID:16401727, PMID:16415329 NCBI chr13:82,737,161...82,757,681
Ensembl chr13:82,737,159...82,758,004 		JBrowse link
G Atp2a2 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 increases expression
multiple interactions		 ISO Lipopolysaccharides results in increased expression of ATP2A2 mRNA
Dexamethasone promotes the reaction [Lipopolysaccharides results in increased expression of ATP2A2 mRNA]; tocotrienol, delta promotes the reaction [Lipopolysaccharides results in increased expression of ATP2A2 mRNA]		 CTD PMID:22185406 NCBI chr12:39,553,903...39,603,326
Ensembl chr12:39,553,903...39,603,326 		JBrowse link
G Atp2b2 ATPase plasma membrane Ca2+ transporting 2 decreases expression ISO Lipopolysaccharides results in decreased expression of ATP2B2 mRNA CTD PMID:12057914 NCBI chr 4:145,704,779...145,948,997
Ensembl chr 4:145,703,046...146,016,325 		JBrowse link
G Atp5f1b ATP synthase F1 subunit beta decreases expression
multiple interactions		 ISO Lipopolysaccharides results in decreased expression of ATP5B mRNA
[Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of ATP5B mRNA		 CTD PMID:31059760 NCBI chr 7:2,504,708...2,511,748
Ensembl chr 7:2,504,695...2,511,749 		JBrowse link
G Atp5f1c ATP synthase F1 subunit gamma multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of ATP5C1 mRNA CTD PMID:31059760 NCBI chr17:72,209,321...72,231,562
Ensembl chr17:72,209,373...72,394,271 		JBrowse link
G Atp5f1d ATP synthase F1 subunit delta multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of ATP5D mRNA CTD PMID:31059760 NCBI chr 7:12,426,807...12,432,120
Ensembl chr 7:12,426,809...12,432,130 		JBrowse link
G Atp5f1e ATP synthase F1 subunit epsilon multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of ATP5E mRNA CTD PMID:31059760 NCBI chr 3:172,563,105...172,566,007
Ensembl chr 3:172,563,105...172,566,010 		JBrowse link
G Atp5if1 ATP synthase inhibitory factor subunit 1 decreases expression
multiple interactions		 ISO Lipopolysaccharides results in decreased expression of ATPIF1 mRNA
[Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of ATPIF1 mRNA		 CTD PMID:31059760 NCBI chr 5:150,719,570...150,723,287
Ensembl chr 5:150,719,569...150,723,321 		JBrowse link
G Atp5mc1 ATP synthase membrane subunit c locus 1 multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of ATP5G1 mRNA CTD PMID:31059760 NCBI chr10:83,895,941...83,898,640
Ensembl chr10:83,895,947...83,898,527 		JBrowse link
G Atp5mc2 ATP synthase membrane subunit c locus 2 multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of ATP5G2 mRNA CTD PMID:31059760 NCBI chr 7:144,264,207...144,272,578
Ensembl chr 7:144,264,199...144,272,578 		JBrowse link
G Atp5mc3 ATP synthase membrane subunit c locus 3 multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of ATP5G3 mRNA CTD PMID:31059760 NCBI chr 3:60,811,218...60,813,903
Ensembl chr 3:60,811,210...60,813,869 		JBrowse link
G Atp5mf ATP synthase membrane subunit f multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of ATP5J2 mRNA CTD PMID:31059760 NCBI chr12:11,191,799...11,198,369
Ensembl chr12:11,191,812...11,198,369 		JBrowse link
G Atp5mg ATP synthase membrane subunit g multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of ATP5L mRNA CTD PMID:31059760 NCBI chr 8:49,220,441...49,227,273
Ensembl chr 8:49,220,443...49,227,273 		JBrowse link
G Atp5pb ATP synthase peripheral stalk-membrane subunit b multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of ATP5F1 mRNA CTD PMID:31059760 NCBI chr 2:208,566,385...208,577,147
Ensembl chr 2:208,566,385...208,577,146 		JBrowse link
G Atp5pf ATP synthase peripheral stalk subunit F6 multiple interactions
decreases expression		 ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of ATP5J mRNA
Lipopolysaccharides results in decreased expression of ATP5J mRNA		 CTD PMID:31059760 NCBI chr11:24,286,806...24,294,419
Ensembl chr11:24,286,787...24,294,179 		JBrowse link
G Atp6v1h ATPase H+ transporting V1 subunit H decreases expression ISO Lipopolysaccharides results in decreased expression of ATP6V1H mRNA CTD PMID:22185406 NCBI chr 5:14,262,352...14,367,898
Ensembl chr 5:14,262,349...14,367,898 		JBrowse link
G Atp7a ATPase copper transporting alpha increases expression ISO Lipopolysaccharides results in increased expression of ATP7A mRNA CTD PMID:22369063 NCBI chr  X:77,076,085...77,193,644
Ensembl chr  X:77,076,106...77,193,644 		JBrowse link
G Avp arginine vasopressin affects expression ISO Lipopolysaccharides affects the expression of AVP mRNA CTD PMID:15667454 NCBI chr 3:123,117,482...123,119,460
Ensembl chr 3:123,117,492...123,119,460 		JBrowse link
G B3galt1 Beta-1,3-galactosyltransferase 1 increases expression ISO Lipopolysaccharides results in increased expression of B3GALT1 mRNA CTD PMID:27339419 NCBI chr 3:53,699,409...54,269,612
Ensembl chr 3:54,253,949...54,267,292 		JBrowse link
G B3gnt8 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 decreases expression ISO Lipopolysaccharides results in decreased expression of B3GNT8 mRNA CTD PMID:26582142 NCBI chr 1:82,419,264...82,422,852
Ensembl chr 1:82,419,947...82,422,846 		JBrowse link
G B4galt1 beta-1,4-galactosyltransferase 1 increases expression ISO Lipopolysaccharides results in increased expression of B4GALT1 mRNA CTD PMID:19540263 NCBI chr 5:57,121,768...57,168,610
Ensembl chr 5:57,121,769...57,168,610 		JBrowse link
G Baat bile acid CoA:amino acid N-acyltransferase decreases expression ISO Lipopolysaccharides results in decreased expression of BAAT mRNA CTD PMID:27339419 NCBI chr 5:64,768,397...64,777,368
Ensembl chr 5:64,768,401...64,777,368 		JBrowse link
G Bace1 beta-secretase 1 multiple interactions ISO [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of BACE1 mRNA; Ditiocarb inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of BACE1 mRNA]; pimagedine inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of BACE1 mRNA] CTD PMID:28242320 NCBI chr 8:50,140,092...50,162,388
Ensembl chr 8:50,139,997...50,162,361 		JBrowse link
G Bach2 BTB domain and CNC homolog 2 multiple interactions
increases expression		 ISO [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] promotes the reaction [BACH2 protein binds to PRDM1 intron]
Lipopolysaccharides results in increased expression of BACH2 mRNA		 CTD PMID:21296099 NCBI chr 5:47,458,891...47,807,176
Ensembl chr 5:47,546,014...47,807,166 		JBrowse link
G Bad BCL2-associated agonist of cell death increases expression
multiple interactions		 EXP Lipopolysaccharides results in increased expression of BAD protein
Diosmin inhibits the reaction [Lipopolysaccharides results in increased expression of BAD protein]; Honghua extract, Carthamus tinctorius inhibits the reaction [Lipopolysaccharides results in increased expression of and results in decreased phosphorylation of BAD protein]; Lipopolysaccharides results in decreased expression of and results in increased phosphorylation of BAD protein; Tigecycline inhibits the reaction [Lipopolysaccharides results in increased expression of BAD protein]		 CTD PMID:21477647, PMID:23200736, PMID:31486215 NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453 		JBrowse link
G Bag3 BAG cochaperone 3 multiple interactions
increases expression		 ISO 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Lipopolysaccharides results in increased expression of BAG3 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Lipopolysaccharides results in increased expression of BAG3 protein]; Dactinomycin inhibits the reaction [Lipopolysaccharides results in increased expression of BAG3 mRNA]; Lipopolysaccharides promotes the reaction [SP1 protein binds to BAG3 promoter]; MAPK8 gene mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of BAG3 protein]; NFKBIA gene mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of BAG3 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of BAG3 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of BAG3 protein]
Lipopolysaccharides results in increased expression of BAG3 mRNA; Lipopolysaccharides results in increased expression of BAG3 protein		 CTD PMID:22020323 NCBI chr 1:199,941,258...199,965,191
Ensembl chr 1:199,941,161...199,965,191 		JBrowse link
G Bambi BMP and activin membrane-bound inhibitor decreases expression ISO Lipopolysaccharides results in decreased expression of BAMBI mRNA CTD PMID:30097701 NCBI chr17:56,905,419...56,909,675
Ensembl chr17:56,905,112...56,909,992 		JBrowse link
G Bank1 B-cell scaffold protein with ankyrin repeats 1 increases methylation
multiple interactions		 ISO Lipopolysaccharides results in increased methylation of BANK1 gene
[Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased expression of BANK1 mRNA		 CTD PMID:21212295 NCBI chr 2:241,273,763...241,545,527
Ensembl chr 2:241,273,763...241,545,250 		JBrowse link
G Basp1 brain abundant, membrane attached signal protein 1 increases expression ISO Lipopolysaccharides results in increased expression of BASP1 mRNA CTD PMID:27339419 NCBI chr 2:77,586,424...77,632,626
Ensembl chr 2:77,586,424...77,632,628 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
affects expression
multiple interactions		 ISO
EXP		 Lipopolysaccharides results in increased expression of BAX protein
Lipopolysaccharides affects the expression of BAX protein
Lipopolysaccharides affects the expression of BAX mRNA
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX mRNA; Apigenin inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]; Honghua extract, Carthamus tinctorius inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]; Sialic Acids inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]
Lipopolysaccharides results in increased expression of BAX mRNA; Lipopolysaccharides results in increased expression of BAX protein
2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]; 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of BAX protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form]; Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]; Cyclosporine inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of BAX protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]; EPO protein inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein]; Lipopolysaccharides inhibits the reaction [E804 bisindole results in increased expression of BAX mRNA]; Scutellaria baicalensis extract inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]; sesamol affects the reaction [Lipopolysaccharides affects the expression of BAX protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form]; Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of BAX protein]; zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]
adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; alpha-Tocopherol affects the reaction [Lipopolysaccharides results in increased expression of BAX protein]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]; cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]; KR-31612 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]; N''-cyano-N-(6-amino-3,4-dihydro-3-hydroxy-2-methyl-2-dimethoxymethyl-2H-benzopyran-4-yl)-N'-benzylguanidine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]		 CTD PMID:10205001, PMID:11805214, PMID:16822680, PMID:20558151, PMID:20850421, PMID:21127968, PMID:21299906, PMID:21401295, PMID:23063943, PMID:23107598, PMID:24561306, PMID:24973090, PMID:25557508, PMID:27339419, PMID:27523796, PMID:30261164, PMID:30776389, PMID:31486215, PMID:32687258 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207 		JBrowse link
G Bbs2 Bardet-Biedl syndrome 2 multiple interactions ISO [Lipopolysaccharides co-treated with resveratrol] results in increased expression of BBS2 mRNA CTD PMID:26667767 NCBI chr19:11,385,921...11,421,523
Ensembl chr19:11,386,024...11,421,498 		JBrowse link
G Bcas2 BCAS2, pre-mRNA processing factor multiple interactions
increases expression		 ISO genipin inhibits the reaction [Lipopolysaccharides results in increased expression of BCAS2 mRNA] CTD PMID:22687549 NCBI chr 2:205,662,633...205,670,514
Ensembl chr 2:205,662,588...205,670,511 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
affects expression
increases expression
decreases expression		 ISO
EXP		 (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2 mRNA]; [Dehydroascorbic Acid co-treated with Lipopolysaccharides] results in increased expression of BCL2 protein; adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; alpha-Tocopherol affects the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; cilostazol inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; KR-31612 affects the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; N''-cyano-N-(6-amino-3,4-dihydro-3-hydroxy-2-methyl-2-dimethoxymethyl-2H-benzopyran-4-yl)-N'-benzylguanidine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]
Lipopolysaccharides affects the expression of BCL2 protein
Lipopolysaccharides results in increased expression of BCL2 protein
[Diosmin co-treated with Lipopolysaccharides] results in increased expression of BCL2 protein; Apigenin inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; Bezafibrate inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2 protein]; Honghua extract, Carthamus tinctorius inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; Sialic Acids inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; tetramethylpyrazine inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2 protein]; Tigecycline inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]
Lipopolysaccharides affects the expression of BCL2 mRNA
2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form; [Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of BCL2 protein; [Silicon Dioxide co-treated with Lipopolysaccharides] results in decreased expression of BCL2 mRNA; [TNFAIP3 gene mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased expression of BCL2 mRNA; AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in decreased expression of BCL2 mRNA]; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]; Carticaine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; CASP1 protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in decreased expression of BCL2 mRNA]; CASP1 protein affects the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in decreased expression of BCL2 mRNA]]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein]; MYD88 protein affects the reaction [[TNFAIP3 gene mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased expression of BCL2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; sesamol affects the reaction [Lipopolysaccharides affects the expression of BCL2 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]; Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of BCL2 protein]; zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]
Lipopolysaccharides results in increased expression of BCL2 mRNA; Lipopolysaccharides results in increased expression of BCL2 protein		 CTD PMID:10205001, PMID:11805214, PMID:12704018, PMID:16822680, PMID:20166893, PMID:20558151, PMID:20850421, PMID:21127968, PMID:21299906, PMID:21477647, PMID:21504754, PMID:21586279, PMID:22273745, PMID:23063943, PMID:23170834, PMID:23200736, PMID:24453940, PMID:24973090, PMID:25557508, PMID:25725100, PMID:27523796, PMID:30084861, PMID:30261164, PMID:30776389, PMID:31486215, PMID:32687258 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374 		JBrowse link
G Bcl2a1 BCL2-related protein A1 increases expression ISO Lipopolysaccharides results in increased expression of BCL2A1 mRNA
Lipopolysaccharides results in increased expression of BCL2A1B mRNA		 CTD PMID:15860229, PMID:21540303, PMID:25890327 NCBI chr 8:96,551,424...96,559,527
Ensembl chr 8:96,551,245...96,559,483 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
decreases expression
increases expression		 ISO
EXP		 (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein]
MIR16 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2L1 protein]
Lipopolysaccharides results in increased expression of BCL2L1 mRNA; Lipopolysaccharides results in increased expression of BCL2L1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein]; [Lipopolysaccharides co-treated with EPO protein] results in increased expression of BCL2L1 protein; [TNFAIP3 gene mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased expression of BCL2L1 mRNA; [TNFAIP3 gene mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased expression of BCL2L1 protein; E804 bisindole inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 mRNA]; Lipopolysaccharides promotes the reaction [E804 bisindole results in decreased expression of BCL2L1 mRNA]; MYD88 protein affects the reaction [[TNFAIP3 gene mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased expression of BCL2L1 mRNA]; MYD88 protein affects the reaction [[TNFAIP3 gene mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased expression of BCL2L1 protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein]		 CTD PMID:18789402, PMID:23107598, PMID:24453940, PMID:24561306, PMID:25725100, PMID:31777165 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810 		JBrowse link
G Bcl3 BCL3, transcription coactivator increases expression
multiple interactions		 ISO Lipopolysaccharides results in increased expression of BCL3 mRNA
(+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of BCL3 mRNA]		 CTD PMID:25725100, PMID:25890327 NCBI chr 1:80,730,758...80,745,273
Ensembl chr 1:80,730,499...80,744,831 		JBrowse link
G Bcl6 BCL6, transcription repressor multiple interactions
decreases expression
affects expression		 ISO (+)-JQ1 compound inhibits the reaction [[Lipopolysaccharides co-treated with IL4 protein] results in increased expression of BCL6 protein]; [Lipopolysaccharides co-treated with IL4 protein] results in increased expression of BCL6 protein; [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased expression of BCL6 protein
Lipopolysaccharides results in decreased expression of BCL6 mRNA
Lipopolysaccharides affects the expression of BCL6 protein		 CTD PMID:19675145, PMID:20348231, PMID:25656449, PMID:25725100 NCBI chr11:80,255,790...80,279,075
Ensembl chr11:80,255,790...80,279,075 		JBrowse link
G Bcor BCL6 co-repressor decreases expression
increases methylation		 ISO Lipopolysaccharides results in decreased expression of BCOR mRNA
Lipopolysaccharides results in increased methylation of BCOR gene		 CTD PMID:21212295 NCBI chr  X:11,570,155...11,692,022
Ensembl chr  X:11,648,989...11,691,099 		JBrowse link
G Bdkrb1 bradykinin receptor B1 affects response to substance
multiple interactions
affects expression
increases expression		 ISO
EXP		 BDKRB1 protein affects the susceptibility to Lipopolysaccharides
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Lipopolysaccharides results in increased expression of BDKRB1 protein]
Lipopolysaccharides affects the expression of BDKRB1 protein
Lipopolysaccharides results in increased expression of BDKRB1 mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of BDKRB1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Lipopolysaccharides results in increased expression of BDKRB1 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Lipopolysaccharides results in increased expression of BDKRB1 mRNA]		 CTD PMID:20096676, PMID:29775649 NCBI chr 6:129,437,423...129,441,553
Ensembl chr 6:129,438,158...129,440,574 		JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions
increases expression		 EXP Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of BDNF mRNA] CTD PMID:18047562 NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210 		JBrowse link
G Becn1 beclin 1 increases expression
multiple interactions		 EXP Lipopolysaccharides results in increased expression of BECN1 protein
Sialic Acids inhibits the reaction [Lipopolysaccharides results in increased expression of BECN1 protein]		 CTD PMID:24973090 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297 		JBrowse link
G Bhlhe40 basic helix-loop-helix family, member e40 multiple interactions
increases expression		 EXP Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of BHLHE40 mRNA] CTD PMID:16415329 NCBI chr 4:140,703,619...140,709,319
Ensembl chr 4:140,703,619...140,709,319 		JBrowse link
G Bhlhe41 basic helix-loop-helix family, member e41 decreases expression ISO Lipopolysaccharides results in decreased expression of BHLHE41 mRNA CTD PMID:25890327 NCBI chr 4:180,230,742...180,235,138
Ensembl chr 4:180,232,382...180,234,804 		JBrowse link
G Bid BH3 interacting domain death agonist increases expression
multiple interactions		 ISO
EXP		 Lipopolysaccharides results in increased expression of BID protein modified form
Lipopolysaccharides results in increased expression of BID protein; Lipopolysaccharides results in increased expression of BID protein alternative form
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BID mRNA; Honghua extract, Carthamus tinctorius inhibits the reaction [Lipopolysaccharides results in increased expression of BID protein alternative form]; Honghua extract, Carthamus tinctorius inhibits the reaction [Lipopolysaccharides results in increased expression of BID protein]
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of BID protein modified form]		 CTD PMID:19675143, PMID:21401295, PMID:23170834, PMID:31486215 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203 		JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 increases expression
multiple interactions		 ISO Lipopolysaccharides results in increased expression of BIRC3 mRNA; Lipopolysaccharides results in increased expression of BIRC3 protein
genipin inhibits the reaction [Lipopolysaccharides results in increased expression of BIRC3 mRNA]		 CTD PMID:15454145, PMID:22687549 NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598 		JBrowse link
G Blnk B-cell linker multiple interactions ISO [Lipopolysaccharides co-treated with resveratrol] results in decreased expression of BLNK mRNA CTD PMID:26667767 NCBI chr 1:260,187,023...260,254,490
Ensembl chr 1:260,186,967...260,254,600 		JBrowse link
G Blvrb biliverdin reductase B increases expression ISO Lipopolysaccharides results in increased expression of BLVRB mRNA CTD PMID:21356202 NCBI chr 1:84,256,063...84,273,726
Ensembl chr 1:84,256,159...84,274,075 		JBrowse link
G Bmf Bcl2 modifying factor decreases expression ISO Lipopolysaccharides results in decreased expression of BMF mRNA CTD PMID:25890327, PMID:26582142 NCBI chr 3:110,303,515...110,324,125
Ensembl chr 3:110,306,067...110,324,084 		JBrowse link
G Bmp2 bone morphogenetic protein 2 decreases expression
multiple interactions		 EXP
ISO		 Lipopolysaccharides results in decreased expression of BMP2 mRNA
Ranitidine inhibits the reaction [Lipopolysaccharides results in decreased expression of BMP2 mRNA]
Triclosan promotes the reaction [Lipopolysaccharides results in increased expression of BMP2 mRNA]		 CTD PMID:16415329, PMID:20507366 NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318 		JBrowse link
G Bmp2k BMP-2 inducible kinase multiple interactions ISO [Lipopolysaccharides co-treated with resveratrol] results in decreased expression of BMP2K mRNA CTD PMID:26667767 NCBI chr14:14,126,086...14,226,823
Ensembl chr14:14,129,725...14,192,048 		JBrowse link
G Bmp6 bone morphogenetic protein 6 multiple interactions
decreases expression		 ISO Triclosan promotes the reaction [Lipopolysaccharides results in increased expression of BMP6 mRNA]
Lipopolysaccharides results in decreased expression of BMP6 mRNA
BMP6 gene mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of HAMP mRNA]		 CTD PMID:12057914, PMID:19252488, PMID:20507366 NCBI chr17:26,955,142...27,112,820
Ensembl chr17:26,955,142...27,112,820 		JBrowse link
G Bnip3 BCL2 interacting protein 3 multiple interactions
increases expression		 ISO
EXP		 HIF1A protein promotes the reaction [Lipopolysaccharides results in increased expression of BNIP3 mRNA]; Propofol inhibits the reaction [Lipopolysaccharides results in increased expression of BNIP3 mRNA]; Propofol inhibits the reaction [Lipopolysaccharides results in increased expression of BNIP3 protein]
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of BNIP3 mRNA
Lipopolysaccharides results in increased expression of BNIP3 mRNA; Lipopolysaccharides results in increased expression of BNIP3 protein		 CTD PMID:16401727, PMID:16415329, PMID:21307008 NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282 		JBrowse link
G Bnip3l BCL2 interacting protein 3 like increases expression EXP Lipopolysaccharides results in increased expression of BNIP3L mRNA; Lipopolysaccharides results in increased expression of BNIP3L protein CTD PMID:30084861 NCBI chr15:43,643,897...43,667,123
Ensembl chr15:43,643,897...43,667,029 		JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase multiple interactions
increases phosphorylation		 ISO Ketamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of BRAF protein] CTD PMID:19540866 NCBI chr 4:67,389,331...67,520,549
Ensembl chr 4:67,396,192...67,520,356 		JBrowse link
G Brd4 bromodomain containing 4 multiple interactions ISO GSK1210151A inhibits the reaction [[Lipopolysaccharides results in increased acetylation of RELA protein] which binds to BRD4 protein] CTD PMID:25778533 NCBI chr 7:14,222,101...14,303,055
Ensembl chr 7:14,222,101...14,303,055 		JBrowse link
G Bst2 bone marrow stromal cell antigen 2 multiple interactions
increases expression		 ISO genipin inhibits the reaction [Lipopolysaccharides results in increased expression of BST2 mRNA] CTD PMID:22687549 NCBI chr16:19,938,781...19,942,353
Ensembl chr16:19,938,784...19,942,353 		JBrowse link
G Btbd11 BTB domain containing 11 multiple interactions ISO [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased methylation of BTBD11 gene CTD PMID:21212295 NCBI chr 7:24,041,194...24,314,418
Ensembl chr 7:24,043,126...24,313,885 		JBrowse link
G Btbd19 BTB domain containing 19 increases expression ISO Lipopolysaccharides results in increased expression of BTBD19 mRNA CTD PMID:18192897 NCBI chr 5:135,988,549...135,994,985
Ensembl chr 5:135,987,573...135,994,848 		JBrowse link
G Btg1 BTG anti-proliferation factor 1 decreases expression ISO Lipopolysaccharides results in decreased expression of BTG1 mRNA CTD PMID:27339419 NCBI chr 7:37,812,831...37,815,088
Ensembl chr 7:37,812,831...37,815,088 		JBrowse link
G Btg2 BTG anti-proliferation factor 2 increases expression
decreases expression
multiple interactions		 ISO
EXP		 Lipopolysaccharides results in increased expression of BTG2 mRNA
Lipopolysaccharides results in decreased expression of BTG2 mRNA
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of BTG2 mRNA; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of BTG2 mRNA]		 CTD PMID:12057914, PMID:16401727, PMID:16415329, PMID:27339419 NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982 		JBrowse link
G Bzw1 basic leucine zipper and W2 domains 1 multiple interactions ISO [Lipopolysaccharides co-treated with resveratrol] results in decreased expression of BZW1 mRNA CTD PMID:26667767 NCBI chr 9:65,279,675...65,293,471
Ensembl chr 9:65,279,675...65,291,651 		JBrowse link
G C1qa complement C1q A chain increases expression ISO Lipopolysaccharides results in increased expression of C1QA mRNA CTD PMID:27339419 NCBI chr 5:155,261,254...155,264,101
Ensembl chr 5:155,261,250...155,264,143 		JBrowse link
G C1qb complement C1q B chain increases expression ISO Lipopolysaccharides results in increased expression of C1QB mRNA CTD PMID:27339419 NCBI chr 5:155,246,444...155,251,995
Ensembl chr 5:155,246,447...155,252,003 		JBrowse link
G C1qc complement C1q C chain increases expression ISO Lipopolysaccharides results in increased expression of C1QC mRNA CTD PMID:27339419 NCBI chr 5:155,255,013...155,258,631
Ensembl chr 5:155,255,005...155,258,392 		JBrowse link
G C1ql3 complement C1q like 3 increases expression ISO Lipopolysaccharides results in increased expression of C1QL3 mRNA CTD PMID:15919760 NCBI chr17:80,314,186...80,320,681
Ensembl chr17:80,314,186...80,320,681 		JBrowse link
G C1qtnf4 C1q and TNF related 4 increases expression ISO Lipopolysaccharides results in increased expression of C1QTNF4 mRNA CTD PMID:15919760 NCBI chr 3:79,713,580...79,718,018
Ensembl chr 3:79,713,567...79,718,025 		JBrowse link
G C3 complement C3 multiple interactions
increases expression		 ISO (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of C3 mRNA]; 3,4-dihydroxybenzohydroxamic acid inhibits the reaction [Lipopolysaccharides results in increased expression of C3 mRNA]; CFP gene mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of C3 protein]; Estradiol inhibits the reaction [Lipopolysaccharides results in increased expression of C3 mRNA]
Lipopolysaccharides results in increased expression of C3 mRNA; Lipopolysaccharides results in increased expression of C3 protein		 CTD PMID:16977382, PMID:17916747, PMID:25843059, PMID:25890327 NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167 		JBrowse link
G C3ar1 complement C3a receptor 1 increases expression ISO Lipopolysaccharides results in increased expression of C3AR1 mRNA CTD PMID:12604170 NCBI chr 4:155,681,767...155,691,240
Ensembl chr 4:155,684,029...155,690,869 		JBrowse link
G C4b complement C4B (Chido blood group) multiple interactions ISO clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of C4B mRNA] CTD PMID:19172522 NCBI chr20:4,302,344...4,316,752
Ensembl chr20:4,302,344...4,316,715 		JBrowse link
G C5ar2 complement component 5a receptor 2 decreases expression ISO Lipopolysaccharides results in decreased expression of C5AR2 mRNA CTD PMID:25890327 NCBI chr 1:78,165,155...78,183,426
Ensembl chr 1:78,166,810...78,180,216 		JBrowse link
G Ca3 carbonic anhydrase 3 decreases expression
increases secretion		 ISO Lipopolysaccharides results in decreased expression of CAR3 mRNA
Lipopolysaccharides results in increased secretion of CAR3 protein		 CTD PMID:24038040, PMID:27339419 NCBI chr 2:88,126,519...88,136,063
Ensembl chr 2:88,126,667...88,135,410 		JBrowse link
G Cabin1 calcineurin binding protein 1 multiple interactions ISO clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CABIN1 mRNA] CTD PMID:19172522 NCBI chr20:13,836,032...13,963,003
Ensembl chr20:13,836,030...13,963,003 		JBrowse link
G Cacna2d3 calcium voltage-gated channel auxiliary subunit alpha2delta 3 decreases expression ISO Lipopolysaccharides results in decreased expression of CACNA2D3 mRNA CTD PMID:18192897 NCBI chr16:4,871,348...5,795,825
Ensembl chr16:4,871,650...5,795,825 		JBrowse link
G Cadps2 calcium dependent secretion activator 2 multiple interactions ISO [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased methylation of CADPS2 gene CTD PMID:21212295 NCBI chr 4:50,326,447...50,861,161
Ensembl chr 4:50,326,442...50,860,756 		JBrowse link
G Calca calcitonin-related polypeptide alpha multiple interactions
increases expression		 ISO
EXP		 2-aminoethoxydiphenyl borate inhibits the reaction [Lipopolysaccharides results in increased expression of CALCA mRNA]; [Ionomycin co-treated with Lipopolysaccharides] results in increased expression of CALCA protein; Calcium promotes the reaction [Lipopolysaccharides results in increased expression of CALCA mRNA]; Ionomycin promotes the reaction [Lipopolysaccharides results in increased expression of CALCA mRNA]; Thapsigargin promotes the reaction [Lipopolysaccharides results in increased expression of CALCA mRNA]; Verapamil inhibits the reaction [[Ionomycin co-treated with Lipopolysaccharides] results in increased expression of CALCA protein]; Verapamil inhibits the reaction [Lipopolysaccharides results in increased expression of CALCA mRNA]
CALCA protein inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; CALCA protein inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; CALCA protein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; CALCA protein inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; CALCA protein inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; calcitonin gene-related peptide (8-37) inhibits the reaction [CALCA protein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; calcitonin gene-related peptide (8-37) inhibits the reaction [CALCA protein inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; calcitonin gene-related peptide (8-37) inhibits the reaction [CALCA protein inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]
Lipopolysaccharides results in increased expression of CALCA protein
CALCA protein promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; resiniferatoxin inhibits the reaction [Lipopolysaccharides results in increased expression of CALCA protein]		 CTD PMID:17291600, PMID:20682585, PMID:21803157 NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911 		JBrowse link
G Calcr calcitonin receptor multiple interactions ISO [Lipopolysaccharides co-treated with CSF1 protein] results in increased expression of CALCR protein CTD PMID:21127049 NCBI chr 4:28,627,439...28,702,559
Ensembl chr 4:28,627,442...28,702,559 		JBrowse link
G Calhm6 calcium homeostasis modulator family member 6 multiple interactions
increases expression		 ISO genipin inhibits the reaction [Lipopolysaccharides results in increased expression of CALHM6 mRNA] CTD PMID:22687549, PMID:27339419 NCBI chr20:27,681,138...27,683,580
Ensembl chr20:27,681,036...27,682,861 		JBrowse link
G Camkk2 calcium/calmodulin-dependent protein kinase kinase 2 multiple interactions ISO clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CAMKK2 mRNA] CTD PMID:19172522 NCBI chr12:39,253,409...39,302,601
Ensembl chr12:39,253,409...39,302,601 		JBrowse link
G Cant1 calcium activated nucleotidase 1 multiple interactions ISO CANT1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] CTD PMID:24849676 NCBI chr10:107,432,500...107,445,634
Ensembl chr10:107,432,506...107,445,522 		JBrowse link
G Capg capping actin protein, gelsolin like increases expression ISO Lipopolysaccharides results in increased expression of CAPG mRNA CTD PMID:27339419 NCBI chr 4:100,395,693...100,419,447
Ensembl chr 4:100,407,658...100,419,446 		JBrowse link
G Capn1 calpain 1 increases expression
affects expression		 ISO
EXP		 Lipopolysaccharides results in increased expression of CAPN1 protein
Lipopolysaccharides affects the expression of CAPN1 mRNA		 CTD PMID:19675143, PMID:21127968 NCBI chr 1:221,346,081...221,370,965
Ensembl chr 1:221,346,066...221,370,322 		JBrowse link
G Capn2 calpain 2 increases expression ISO Lipopolysaccharides results in increased expression of CAPN2 protein CTD PMID:19675143 NCBI chr13:100,878,649...100,928,811
Ensembl chr13:100,878,650...100,928,811 		JBrowse link
G Card10 caspase recruitment domain family, member 10 multiple interactions ISO CARD10 protein affects the reaction [Lipopolysaccharides results in increased localization of RELA protein] CTD PMID:24863965 NCBI chr 7:119,998,639...120,028,632
Ensembl chr 7:119,999,472...120,027,026 		JBrowse link
G Cars2 cysteinyl-tRNA synthetase 2, mitochondrial multiple interactions
decreases expression		 ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of CARS2 mRNA
Lipopolysaccharides results in decreased expression of CARS2 mRNA		 CTD PMID:31059760 NCBI chr16:83,288,613...83,325,706
Ensembl chr16:83,288,664...83,325,699 		JBrowse link
G Cartpt CART prepropeptide affects localization
increases expression		 EXP Lipopolysaccharides affects the localization of CARTPT protein
Lipopolysaccharides results in increased expression of CARTPT protein		 CTD PMID:12559087 NCBI chr 2:30,125,249...30,127,408
Ensembl chr 2:30,125,249...30,127,269 		JBrowse link
G Casp1 caspase 1 multiple interactions
increases phosphorylation
increases expression
increases secretion
increases cleavage
decreases degradation
increases activity
decreases expression		 ISO
EXP		 1-(2-((1-(4-amino-3-chlorophenyl)methanoyl)amino)-3,3-dimethylbutanoyl)pyrrolidine-2-carboxylic acid inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; 2,5-dimethyl-4-benzoquinone inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein]; 2-tert-butyl-4-quinone inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein]; 3-methyladenine promotes the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; [Acrolein co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein; [Cadmium Chloride co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; [Calcitriol co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides co-treated with Nanotubes, Carbon] affects the expression of CASP1 mRNA; [Calcitriol co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] affects the expression of and affects the activity of CASP1 protein; [Ethanol co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA; [IL13 protein co-treated with IL4 protein co-treated with Nanotubes, Carbon] inhibits the reaction [[Calcitriol co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] affects the expression of CASP1 protein]; [IL13 protein co-treated with IL4 protein] inhibits the reaction [[Calcitriol co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] affects the expression of CASP1 protein]; [IL4 protein co-treated with IL13 protein] inhibits the reaction [Nanotubes, Carbon promotes the reaction [[Calcitriol co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides co-treated with Nanotubes, Carbon] affects the expression of CASP1 mRNA]]; [Irinotecan co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Silicon Dioxide] results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of CASP1 protein; acanthoic acid inhibits the reaction [[Ethanol co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA]; Acetylcysteine inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with Alum Compounds] results in increased cleavage of and results in increased secretion of IL1B protein]; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with Silicon Dioxide] results in increased cleavage of and results in increased secretion of IL1B protein]; Coal Tar promotes the reaction [Lipopolysaccharides results in increased expression of CASP1 protein]; fraxinellone inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; IL13 protein inhibits the reaction [[Calcitriol co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] affects the expression of CASP1 protein]; IL4 protein inhibits the reaction [Nanotubes, Carbon promotes the reaction [[Calcitriol co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides co-treated with Nanotubes, Carbon] affects the expression of CASP1 mRNA]]; JAK1 protein affects the reaction [[Calcitriol co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] affects the expression of and affects the activity of CASP1 protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; Leflunomide inhibits the reaction [[IL13 protein co-treated with IL4 protein] inhibits the reaction [[Calcitriol co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] affects the expression of and affects the activity of CASP1 protein]]; Lipopolysaccharides promotes the reaction [Coal Tar results in increased expression of CASP1 protein modified form]; MitoTEMPO inhibits the reaction [[Cadmium Chloride co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; Nanotubes, Carbon promotes the reaction [[Calcitriol co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides co-treated with Nanotubes, Carbon] affects the expression of CASP1 mRNA]; NLRP3 protein affects the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; NLRP3 protein promotes the reaction [[Cadmium Chloride co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; phenylbenzoquinone inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein]; Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; thymoquinone inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein]; tyrosyl-valyl-alanyl-aspartic acid fluoromethyl ketone analog inhibits the reaction [[Cadmium Chloride co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]
Lipopolysaccharides results in increased phosphorylation of CASP1 protein
Lipopolysaccharides results in increased expression of CASP1 mRNA; Lipopolysaccharides results in increased expression of CASP1 protein
Lipopolysaccharides results in increased secretion of CASP1 protein modified form
Lipopolysaccharides results in increased cleavage of CASP1 protein
3-methyladenine promotes the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of CASP1 protein modified form]; [Arsenic Trioxide co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; [Zearalenone co-treated with Lipopolysaccharides] results in increased expression of CASP1 protein; [Zearalenone co-treated with Lipopolysaccharides] results in increased expression of CASP1 protein modified form; butaprost inhibits the reaction [Lipopolysaccharides results in decreased degradation of CASP1 protein]; Lenalidomide inhibits the reaction [[Arsenic Trioxide co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; MCC-950 inhibits the reaction [[Arsenic Trioxide co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; MCC-950 inhibits the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of CASP1 protein modified form]; NLRP3 protein promotes the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of CASP1 protein modified form]; Sialic Acids inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein]; Sirolimus inhibits the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of CASP1 protein modified form]; Taurine inhibits the reaction [[Arsenic Trioxide co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]
1-dodecylsulfonyl-5N,6O-oxomethylidenenojirimycin inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP1 protein]; [Irinotecan co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [PML protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with aluminum sulfate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Silicon Dioxide] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Silicon Dioxide] results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Uric Acid] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of CASP1 protein; Acetylcysteine inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP1 protein]; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; CA 074 methyl ester inhibits the reaction [[Lipopolysaccharides co-treated with Silicon Dioxide] results in increased activity of CASP1 protein]; Carticaine inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein]; CASP1 protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in decreased expression of BCL2 mRNA]; CASP1 protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]; CASP1 protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased expression of STAT2 mRNA]; CASP1 protein affects the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in decreased expression of BCL2 mRNA]]; CASP1 protein affects the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]]; CASP1 protein affects the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased expression of IL6 mRNA]]; CASP1 protein affects the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased expression of SERPINB2 mRNA]]; CASP1 protein affects the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased expression of STAT2 mRNA]]; CASP1 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; CASP1 protein promotes the reaction [[Lipopolysaccharides co-treated with nickel chloride] results in increased secretion of IL1B protein]; CASP1 protein promotes the reaction [[Lipopolysaccharides co-treated with Poly dA-dT] results in increased secretion of IL1B protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP1 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein]; Dexmedetomidine inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP1 protein]; E804 bisindole inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 mRNA]; leptomycin B inhibits the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased activity of CASP1 protein]; Lipopolysaccharides inhibits the reaction [E804 bisindole results in increased expression of CASP1 mRNA]; maytenonic acid inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP1 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Silicon Dioxide] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of CASP1 protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Silicon Dioxide] results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of CASP1 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Lipopolysaccharides results in increased activity of CASP1 protein]
Lipopolysaccharides results in decreased expression of CASP1 mRNA		 CTD PMID:10975854, PMID:12057914, PMID:12878042, PMID:18604214, PMID:19130485, PMID:22147977, PMID:22273745, PMID:23107598, PMID:23430110, PMID:24149798, PMID:24158569, PMID:24973090, PMID:25448682, PMID:25715797, PMID:26086368, PMID:26091108, PMID:26431797, PMID:26586371, PMID:26809137, PMID:27689324, PMID:27751938, PMID:28484691, PMID:28814068, PMID:28964808, PMID:29191728, PMID:30102002, PMID:30205151, PMID:30660605, PMID:30698909, PMID:30842373, PMID:31586597, PMID:31935363, PMID:32453893, PMID:32687258 NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631 		JBrowse link
G Casp12 caspase 12 multiple interactions
increases expression		 ISO 4-phenylbutyric acid inhibits the reaction [Lipopolysaccharides results in increased expression of CASP12 protein] CTD PMID:28245985 NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160 		JBrowse link
G Casp2 caspase 2 decreases expression ISO Lipopolysaccharides results in decreased expression of CASP2 mRNA CTD PMID:12057914 NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
increases activity
increases expression		 ISO
EXP		 2,5-dimethyl-4-benzoquinone inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein]; 2-tert-butyl-4-quinone inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein]; [NOS2 protein results in increased abundance of Nitric Oxide] inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal inhibits the reaction [Lipopolysaccharides results in increased ubiquitination of and results in increased degradation of and results in decreased activity of CASP3 protein]; Dithiothreitol inhibits the reaction [[NOS2 protein results in increased abundance of Nitric Oxide] inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]]; Lipopolysaccharides results in increased ubiquitination of and results in increased degradation of and results in decreased activity of CASP3 protein; MIR152 mRNA affects the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]; phenylbenzoquinone inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein]; Quercetin inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]; Resveratrol inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]; thymoquinone inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein]
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 mRNA; Apigenin inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]; Diosmin inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; HBEGF protein inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; Honghua extract, Carthamus tinctorius inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]; IGF1R protein affects the reaction [Honghua extract, Carthamus tinctorius inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]]; Lipopolysaccharides results in increased activity of and results in increased cleavage of CASP3 protein; Lipopolysaccharides results in increased expression of and results in increased activity of CASP3 protein; MIR16 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; pifithrin inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]; Protein Kinase Inhibitors inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein]; Quercetin inhibits the reaction [17-(dimethylaminoethylamino)-17-demethoxygeldanamycin inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]]; Quercetin inhibits the reaction [Lipopolysaccharides results in increased activity of and results in increased cleavage of CASP3 protein]; Tigecycline inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; TNF protein affects the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; tyrphostin AG 1024 inhibits the reaction [Honghua extract, Carthamus tinctorius inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]]
Lipopolysaccharides results in increased expression of CASP3 protein modified form
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]; [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; [CCR5 gene mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased cleavage of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form; [Lipopolysaccharides co-treated with IFNG protein] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Scutellaria baicalensis extract] results in increased cleavage of and results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Simvastatin] results in increased activity of CASP3 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; [triptolide co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [[triptolide co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form]; Biliverdine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; Cyclosporine inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased activity of CASP3 protein]; EPO protein inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]; Methylene Chloride inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein modified form]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; sesamol inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased activity of CASP3 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]]		 CTD PMID:9755104, PMID:10205001, PMID:12665479, PMID:12878042, PMID:14512878, PMID:15454145, PMID:15486963, PMID:16325779, PMID:16567187, PMID:17602819, PMID:17929310, PMID:19675143, PMID:20558151, PMID:20850421, PMID:21146893, PMID:21299906, PMID:21401295, PMID:21477647, PMID:21844306, PMID:22685622, PMID:23102375, PMID:23170834, PMID:23200736, PMID:24561306, PMID:24803807, PMID:25557508, PMID:25738436, PMID:26055553, PMID:27224288, PMID:28070109, PMID:30261164, PMID:30633930, PMID:30776389, PMID:31486215, PMID:31777165, PMID:31935363, PMID:32453893, PMID:32583487 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204 		JBrowse link
G Casp4 caspase 4 multiple interactions
increases expression		 ISO [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein]
Lipopolysaccharides results in increased expression of CASP4 mRNA		 CTD PMID:24149798, PMID:25890327 NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652 		JBrowse link
G Casp6 caspase 6 increases activity ISO Lipopolysaccharides results in increased activity of CASP6 protein CTD PMID:20848084 NCBI chr 2:235,341,326...235,353,715
Ensembl chr 2:235,341,365...235,353,967
Ensembl chr 2:235,341,365...235,353,967 		JBrowse link
G Casp7 caspase 7 increases expression
multiple interactions		 ISO Lipopolysaccharides results in increased expression of CASP7 protein
[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein]		 CTD PMID:21146893, PMID:21844306 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774 		JBrowse link
G Casp8 caspase 8 increases expression
increases cleavage
multiple interactions
increases activity		 ISO
EXP		 Lipopolysaccharides results in increased expression of CASP8 protein
Lipopolysaccharides results in increased cleavage of CASP8 protein
Honghua extract, Carthamus tinctorius inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP8 protein]; IGF1R protein affects the reaction [Honghua extract, Carthamus tinctorius inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP8 protein]]
Lipopolysaccharides results in increased activity of CASP8 protein
Lipopolysaccharides results in increased expression of CASP8 mRNA
15,16-dihydrotanshinone I inhibits the reaction [[Lipopolysaccharides co-treated with benzyloxycarbonyl-valyl-alanyl-aspartic acid] results in decreased expression of CASP8 protein]; 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP8 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form; [Lipopolysaccharides co-treated with benzyloxycarbonyl-valyl-alanyl-aspartic acid] results in decreased expression of CASP8 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form; [triptolide co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; E804 bisindole inhibits the reaction [Lipopolysaccharides results in increased expression of CASP8 mRNA]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form]; Lipopolysaccharides inhibits the reaction [E804 bisindole results in increased expression of CASP8 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP8 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein]		 CTD PMID:20558151, PMID:20850421, PMID:21146893, PMID:21844306, PMID:23107598, PMID:23170834, PMID:29496522, PMID:30633930, PMID:30776389, PMID:31486215 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106 		JBrowse link
G Casp9 caspase 9 increases activity
increases expression
increases cleavage
multiple interactions		 ISO
EXP		 Lipopolysaccharides results in increased activity of CASP9 protein
Lipopolysaccharides results in increased expression of CASP9 protein
Lipopolysaccharides results in increased cleavage of CASP9 protein
Apigenin inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]; Honghua extract, Carthamus tinctorius inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]; IGF1R protein affects the reaction [Honghua extract, Carthamus tinctorius inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]]; MIR16 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]; tyrphostin AG 1024 inhibits the reaction [Honghua extract, Carthamus tinctorius inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]]
[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP9 protein]; sesamol inhibits the reaction [Lipopolysaccharides results in increased activity of CASP9 protein]; zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased activity of CASP9 protein]]
Acetylcysteine inhibits the reaction [Lipopolysaccharides results in increased activity of CASP9 protein]		 CTD PMID:20558151, PMID:20848084, PMID:21844306, PMID:23170834, PMID:25557508, PMID:30084861, PMID:30261164, PMID:31486215, PMID:31777165 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778 		JBrowse link
G Cast calpastatin affects expression EXP Lipopolysaccharides affects the expression of CAST mRNA CTD PMID:21127968 NCBI chr 2:1,452,111...1,561,669
Ensembl chr 2:1,452,116...1,561,464 		JBrowse link
G Cat catalase multiple interactions
decreases expression
affects expression
decreases activity
increases expression
increases activity		 ISO
EXP		 [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of CAT mRNA; [Dehydroascorbic Acid co-treated with Lipopolysaccharides] results in increased expression of CAT protein; [Lipopolysaccharides co-treated with CAT protein] results in increased stability of PTGS2 protein; Plant Extracts affects the reaction [Lipopolysaccharides affects the expression of CAT mRNA]
Lipopolysaccharides results in decreased expression of CAT mRNA
Lipopolysaccharides results in decreased activity of CAT protein
Lipopolysaccharides results in increased expression of CAT protein
[Lipopolysaccharides co-treated with Tobacco Smoke Pollution] results in decreased activity of CAT protein; CAT protein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; CAT protein inhibits the reaction [Lipopolysaccharides results in increased expression of SOD2 mRNA]; Curcumin inhibits the reaction [[Lipopolysaccharides co-treated with Tobacco Smoke Pollution] results in decreased activity of CAT protein]; Streptozocin inhibits the reaction [Lipopolysaccharides results in increased expression of CAT protein]; Thioctic Acid inhibits the reaction [Lipopolysaccharides results in decreased activity of CAT protein]
Lipopolysaccharides results in increased expression of CAT mRNA
Lipopolysaccharides results in increased activity of CAT protein
3,4-dihydroxybenzohydroxamic acid promotes the reaction [Lipopolysaccharides results in increased expression of CAT mRNA]; 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein]; [Eicosapentaenoic Acid co-treated with Lipopolysaccharides] results in increased expression of CAT mRNA; [Eicosapentaenoic Acid co-treated with procyanidin B3 co-treated with Lipopolysaccharides] results in increased expression of CAT mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein; [Lipopolysaccharides co-treated with Methylene Chloride] results in increased activity of CAT protein; Caffeine inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; CAT protein inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; Clozapine inhibits the reaction [Lipopolysaccharides inhibits the reaction [Corticosterone results in increased activity of CAT protein]]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in decreased activity of CAT protein]; Lipopolysaccharides inhibits the reaction [Corticosterone results in increased activity of CAT protein]; methyldithiocarbamate promotes the reaction [Lipopolysaccharides results in increased expression of CAT mRNA]; Oligopeptides inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Plant Extracts inhibits the reaction [Lipopolysaccharides results in decreased activity of CAT protein]; Resveratrol inhibits the reaction [Lipopolysaccharides results in increased activity of CAT protein]; Rutin inhibits the reaction [Lipopolysaccharides results in decreased activity of CAT protein]; Saponins inhibits the reaction [Lipopolysaccharides results in decreased activity of CAT protein]; Sulpiride promotes the reaction [Lipopolysaccharides inhibits the reaction [Corticosterone results in increased activity of CAT protein]]; Zinc Oxide promotes the reaction [Lipopolysaccharides results in decreased activity of CAT protein]		 CTD PMID:9522273, PMID:10899936, PMID:11344824, PMID:11350798, PMID:14730115, PMID:15563889, PMID:15612528, PMID:19153979, PMID:19339665, PMID:19699728, PMID:20166893, PMID:22154906, PMID:22169119, PMID:23921197, PMID:25843059, PMID:26363199, PMID:28070326, PMID:28137607, PMID:28951138, PMID:29743444, PMID:30236599, PMID:31059760, PMID:31804693, PMID:32453893 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058 		JBrowse link
G Cav1 caveolin 1 multiple interactions
increases expression
affects expression		 ISO
EXP		 CAV1 mutant form promotes the reaction [Lipopolysaccharides results in increased expression of NOX1 mRNA]; CAV1 mutant form promotes the reaction [Lipopolysaccharides results in increased expression of NOX2 mRNA]; CAV1 mutant form promotes the reaction [Lipopolysaccharides results in increased expression of NOX4 mRNA]; Lipopolysaccharides results in increased phosphorylation of and affects the localization of CAV1 protein
Lipopolysaccharides results in increased expression of CAV1 protein modified form
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CAV1 protein]; AG 1879 inhibits the reaction [Lipopolysaccharides results in increased expression of CAV1 protein modified form]; AG 1879 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CAV1 protein]; Lipopolysaccharides results in increased phosphorylation of and affects the localization of CAV1 protein; methyl-beta-cyclodextrin inhibits the reaction [Lipopolysaccharides results in increased expression of CAV1 protein modified form]; Quercetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CAV1 protein]; saracatinib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CAV1 protein]
Lipopolysaccharides affects the expression of CAV1 mRNA; Lipopolysaccharides affects the expression of CAV1 protein
CAV1 gene mutant form promotes the reaction [Lipopolysaccharides results in increased expression of NOX2 mRNA]; CAV1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of NOX2 mRNA]		 CTD PMID:10948129, PMID:24835767, PMID:26357463 NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200 		JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO CBR1 protein modified form inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; CBR1 protein modified form inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; CBR1 protein modified form inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; CBR1 protein modified form inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; CBR1 protein modified form inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; CBR1 protein modified form inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; CBR1 protein modified form inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; CBR1 protein modified form inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; CBR1 protein modified form inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein]; CBR1 protein modified form inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK9 protein]; CBR1 protein modified form inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein] CTD PMID:25818598 NCBI chr11:33,813,041...33,815,418
Ensembl chr11:33,845,463...33,847,793 		JBrowse link
G Cbx8 chromobox 8 decreases expression ISO Lipopolysaccharides results in decreased expression of CBX8 mRNA CTD PMID:25890327 NCBI chr10:108,148,073...108,150,511
Ensembl chr10:108,148,073...108,150,511 		JBrowse link
G Ccdc137 coiled-coil domain containing 137 multiple interactions ISO [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased methylation of CCDC137 gene CTD PMID:21212295 NCBI chr10:109,630,099...109,636,480
Ensembl chr10:109,630,099...109,636,480 		JBrowse link
G Ccl1 C-C motif chemokine ligand 1 increases expression
multiple interactions		 ISO Lipopolysaccharides results in increased expression of CCL1 mRNA
6-formylindolo(3,2-b)carbazole promotes the reaction [Lipopolysaccharides results in increased expression of CCL1 mRNA]; indole-3-carbinol promotes the reaction [Lipopolysaccharides results in increased expression of CCL1 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Lipopolysaccharides results in increased expression of CCL1 mRNA]		 CTD PMID:27783115 NCBI chr10:69,534,976...69,537,836
Ensembl chr10:69,534,933...69,537,882 		JBrowse link
G Ccl11 C-C motif chemokine ligand 11 multiple interactions
increases expression		 ISO coagulin-L inhibits the reaction [Lipopolysaccharides results in increased expression of CCL11 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL11 protein]; fexofenadine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL11 mRNA]; fexofenadine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL11 protein]
Lipopolysaccharides results in increased expression of CCL11 mRNA; Lipopolysaccharides results in increased expression of CCL11 protein
Lipopolysaccharides results in increased expression of and results in increased secretion of CCL11 protein; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL11 protein]		 CTD PMID:10027076, PMID:15460210, PMID:26918785, PMID:27568862 NCBI chr10:69,434,965...69,439,566
Ensembl chr10:69,434,941...69,439,575 		JBrowse link
G Ccl12 chemokine (C-C motif) ligand 12 multiple interactions
increases secretion
increases expression		 ISO (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CCL12 mRNA]; resveratrol inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL12 protein] CTD PMID:15665042, PMID:22118570, PMID:25890327, PMID:26582142 NCBI chr10:69,476,866...69,478,416
Ensembl chr10:69,476,775...69,478,462 		JBrowse link
G Ccl19 C-C motif chemokine ligand 19 increases expression ISO Lipopolysaccharides results in increased expression of CCL19 mRNA CTD PMID:15665042 NCBI chr 5:58,181,025...58,182,969
Ensembl chr 5:58,181,026...58,183,017 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions
decreases secretion
increases secretion
increases expression
affects secretion		 ISO
EXP		 1,3-dimethylthiourea inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Eicosapentaenoic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]]; 3,4,5,3',4'-pentachlorobiphenyl promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CCL2 mRNA]; [Cadmium Chloride co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA; [Lipopolysaccharides co-treated with HMGB1 protein] results in increased expression of CCL2 protein; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CCL2 mRNA; [Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of CCL2 mRNA; [Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased secretion of CCL2 protein; [Zinc Sulfate co-treated with Disulfiram] inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; Acetylcysteine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; ANXA1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Aspirin inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]]; Capsaicin promotes the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; coagulin-L inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; dienogest inhibits the reaction [[Lipopolysaccharides co-treated with HMGB1 protein] results in increased expression of CCL2 protein]; Dihydrotestosterone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Dimethyl Sulfoxide inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Dimethyl Sulfoxide inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]]]; Dinoprostone promotes the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]]; Dinoprostone promotes the reaction [roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]]; Disulfiram inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Docosahexaenoic Acids inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Docosahexaenoic Acids inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Eicosapentaenoic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Eicosapentaenoic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; fluridone inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; Gentamicins inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Gentamicins promotes the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; hesperetin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]]; Lidocaine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Lidocaine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Lipopolysaccharides promotes the reaction [Histamine results in increased expression of CCL2 protein]; Lipopolysaccharides results in increased expression of and results in increased secretion of CCL2 protein; Naloxone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; phenethyl isothiocyanate inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Phloretin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Progesterone inhibits the reaction [[Lipopolysaccharides co-treated with HMGB1 protein] results in increased expression of CCL2 protein]; Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; Silymarin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; SMIM20 protein modified form inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; SMIM20 protein modified form inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Zinc inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL2 protein]; Ziram inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]
Lipopolysaccharides results in decreased secretion of CCL2 protein
Lipopolysaccharides results in increased expression of CCL2; Lipopolysaccharides results in increased expression of CCL2 mRNA; Lipopolysaccharides results in increased expression of CCL2 protein
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; [2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; [2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; [2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl] inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; [2,4,5,2',5'-pentachlorobiphenyl co-treated with PCB 180] inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; [Lipopolysaccharides co-treated with Fructose co-treated with Copper deficiency] results in increased expression of CCL2 protein; ADM protein inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; alpha-Tocopherol inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Amiloride inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; CALCA protein inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; deferiprone inhibits the reaction [[Lipopolysaccharides co-treated with Fructose co-treated with Copper deficiency] results in increased expression of CCL2 protein]; Deferoxamine inhibits the reaction [[Lipopolysaccharides co-treated with Fructose co-treated with Copper deficiency] results in increased expression of CCL2 protein]; Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Sodium deficiency inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; tin protoporphyrin IX inhibits the reaction [Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]]; Titanium promotes the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Titanium promotes the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]
(+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; 2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; 2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; 3,4-dihydroxybenzohydroxamic acid inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; [2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180 co-treated with 2,4,5,2',5'-pentachlorobiphenyl] inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; [2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180 co-treated with 2,4,5,2',5'-pentachlorobiphenyl] inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; [2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; [2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; [2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl] inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; [2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl] inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; [2,4,5,2',5'-pentachlorobiphenyl co-treated with PCB 180] inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; [2,4,5,2',5'-pentachlorobiphenyl co-treated with PCB 180] inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of and results in increased secretion of CCL2 protein; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CCL2 mRNA; [procyanidin B3 co-treated with Eicosapentaenoic Acid] inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; [Shiga Toxin 2 co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA; [Silicon Dioxide co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein; AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein]; AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; bisphenol A promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of and results in increased secretion of CCL2 protein]; bisphenol A promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CCL2 mRNA]; caffeic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; CAP18 lipopolysaccharide-binding protein inhibits the reaction [[Shiga Toxin 2 co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; Carbenoxolone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; coagulin-L inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; CP 105696 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; crocetin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Curcumin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; DCB-SLE1 inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL2 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Diethylhexyl Phthalate promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CCL2 mRNA]; dimemorfan inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Dipyridamole inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; dorsomorphin inhibits the reaction [AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]]; Estradiol inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of and results in increased secretion of CCL2 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Fenofibrate inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Fenofibrate inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; fidarestat inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; fidarestat inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Gallic Acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; Gentamicins promotes the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Gentamicins promotes the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; IFNB1 protein affects the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; IL10 protein inhibits the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein]; IL10 protein inhibits the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein]]; IL6 protein affects the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; kaempferol inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; Latex promotes the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; LCN2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Lipopolysaccharides promotes the reaction [RELA protein binds to CCL2 promoter]; Lipopolysaccharides results in increased expression of and results in increased secretion of CCL2 protein; Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL2 protein]; Niclosamide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; NR1H4 gene mutant form promotes the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; PARP1 gene mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Particulate Matter inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Particulate Matter inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; phenethyl isothiocyanate inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; pirinixic acid inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; pitavastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Plant Extracts inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; PPARA affects the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; procyanidin B3 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; protocatechuic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Quercetin inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; resolvin D2 inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Resveratrol inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; sodium arsenite promotes the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; t-butyloxycarbonyl-methionyl-leucyl-phenylalanine inhibits the reaction [resolvin D1 inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]]; terameprocol inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to CCL2 promoter]]; terameprocol inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; terameprocol inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Titanium promotes the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Titanium promotes the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; triptolide promotes the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein]; Vehicle Emissions inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Vehicle Emissions inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Wortmannin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; ZFP36 mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Zinc Oxide promotes the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]
Lipopolysaccharides affects the secretion of CCL2 protein		 CTD PMID:9973430, PMID:10027076, PMID:10223745, PMID:11336536, PMID:11340305, PMID:12818967, PMID:12963494, PMID:14570645, PMID:15196211, PMID:15593098, PMID:15698426, PMID:15721863, PMID:15788441, PMID:15804595, PMID:15824212, PMID:15968640, PMID:16303184, PMID:16306350, PMID:16317058, PMID:16443229, PMID:16765938, PMID:17076685, PMID:17084265, PMID:17438151, PMID:17442725, PMID:17529908, PMID:17618502, PMID:17699551, PMID:18292240, PMID:18323514, PMID:18390722, PMID:18500357, PMID:18706406, PMID:18938192, PMID:19020770, PMID:19133137, PMID:19136613, PMID:19279313, PMID:19293636, PMID:19880577, PMID:20423518, PMID:20682337, PMID:20699433, PMID:20712904, PMID:20851137, PMID:20940016, PMID:21035309, PMID:21138578, PMID:21146893, PMID:21147091, PMID:21262334, PMID:21371465, PMID:21504754, PMID:21677146, PMID:21724996, PMID:21731756, PMID:21777521, PMID:21803157, PMID:21878375, PMID:21913898, PMID:21925167, PMID:22014880, PMID:22081859, PMID:22093924, PMID:22118570, PMID:22124178, PMID:22135065, PMID:22169119, PMID:22210036, PMID:22225513, PMID:22253906, PMID:22273745, PMID:22869926, PMID:22939914, PMID:23170834, PMID:23724058, PMID:23958496, PMID:24211328, PMID:24333275, PMID:24465016, PMID:24561310, PMID:24584901, PMID:24707119, PMID:25171655, PMID:25446332, PMID:25472953, PMID:25813056, PMID:25843059, PMID:25890327, PMID:26111115, PMID:26141388, PMID:26582142, PMID:26809137, PMID:26918785, PMID:27339419, PMID:27523796, PMID:27568862, PMID:28065790, PMID:28500084, PMID:28693884, PMID:29718165, PMID:30244119, PMID:30633930, PMID:30635848, PMID:30768972, PMID:31306686, PMID:31804693, PMID:32017913, PMID:32712770 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870 		JBrowse link
G Ccl20 C-C motif chemokine ligand 20 multiple interactions
increases expression		 ISO HNRNPD protein inhibits the reaction [Lipopolysaccharides results in increased expression of CCL20 mRNA]
[Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA; AHR promotes the reaction [[Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of CCL20 protein]; AHR promotes the reaction [[Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA]; Lipopolysaccharides inhibits the reaction [HDAC1 protein binds to CCL20 promoter]; Lipopolysaccharides promotes the reaction [AHR protein binds to CCL20 promoter]		 CTD PMID:15860229, PMID:18192897, PMID:19428942, PMID:21135123, PMID:21356202, PMID:21540303, PMID:26259605 NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001 		JBrowse link
G Ccl21 C-C motif chemokine ligand 21 multiple interactions ISO [usnic acid co-treated with Lipopolysaccharides] results in increased expression of CCL21 mRNA CTD PMID:22777745 NCBI chr 5:58,197,678...58,198,782
Ensembl chr 5:58,197,680...58,198,782 		JBrowse link
G Ccl22 C-C motif chemokine ligand 22 multiple interactions
increases expression		 ISO Lipopolysaccharides promotes the reaction [Shiga Toxin 2 results in increased secretion of CCL22 protein]
Lipopolysaccharides results in increased expression of CCL22 mRNA
(+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CCL22 mRNA]		 CTD PMID:15665042, PMID:16366002, PMID:26582142 NCBI chr19:10,674,189...10,681,145
Ensembl chr19:10,674,189...10,681,145 		JBrowse link
G Ccl26 C-C motif chemokine ligand 26 decreases expression ISO Lipopolysaccharides results in decreased expression of CCL26 mRNA CTD PMID:19428942 NCBI chr12:24,157,182...24,161,870
Ensembl chr12:24,158,766...24,161,869 		JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases expression
increases secretion
multiple interactions
decreases expression		 ISO
EXP		 Lipopolysaccharides results in increased expression of CCL3 mRNA; Lipopolysaccharides results in increased expression of CCL3 protein
Lipopolysaccharides results in increased secretion of CCL3 protein
Lipopolysaccharides results in increased expression of CCL3; Lipopolysaccharides results in increased expression of CCL3 mRNA; Lipopolysaccharides results in increased expression of CCL3 protein
ADM protein inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; CALCA protein inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; cannabigerol inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; VCE-003 inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]
Lipopolysaccharides results in decreased expression of CCL3 mRNA
2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; 3,4,5,3',4'-pentachlorobiphenyl promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CCL3 mRNA]; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CCL3 mRNA; Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]; coagulin-L inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]; Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]]]; Dinoprostone promotes the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]]; Dinoprostone promotes the reaction [roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]]; Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]; honokiol inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]; Ibuprofen inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]; Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]]; Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]
3,4-dihydroxybenzohydroxamic acid inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; 5-aminoisoquinolinone inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; [3-methylquercetin co-treated with Lipopolysaccharides] affects the expression of CCL3 mRNA; [Quercetin co-treated with Lipopolysaccharides] affects the expression of CCL3 mRNA; [Shiga Toxin 2 co-treated with Lipopolysaccharides] results in increased expression of CCL3 mRNA; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; CAP18 lipopolysaccharide-binding protein inhibits the reaction [[Shiga Toxin 2 co-treated with Lipopolysaccharides] results in increased expression of CCL3 mRNA]; coagulin-L inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]; Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; DUSP1 gene mutant form inhibits the reaction [Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]]; Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; Epinephrine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; IL6 protein affects the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Lipopolysaccharides results in increased expression of and results in increased secretion of CCL3 protein; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL3 protein]; methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Niclosamide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; PARP1 protein affects the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]; PARP1 protein affects the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Propranolol inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]]; Propranolol promotes the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]; Rolipram inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; Rolipram inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; terameprocol affects the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]		 CTD PMID:9863660, PMID:10027076, PMID:10223745, PMID:10975854, PMID:11818323, PMID:12818968, PMID:15263833, PMID:15289356, PMID:15804595, PMID:16880258, PMID:17529908, PMID:18390722, PMID:19133137, PMID:19211157, PMID:19339665, PMID:20579867, PMID:21147091, PMID:21284090, PMID:21352583, PMID:21356202, PMID:21362633, PMID:21731756, PMID:21803157, PMID:21913898, PMID:22210036, PMID:22777745, PMID:22939914, PMID:22971837, PMID:24056979, PMID:24561310, PMID:24707119, PMID:25843059, PMID:25890327, PMID:26582142, PMID:26918785, PMID:27339419, PMID:27568862, PMID:27984176, PMID:28065790, PMID:30768972 NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066 		JBrowse link
G Ccl4 C-C motif chemokine ligand 4 multiple interactions
increases expression
increases secretion
decreases expression		 ISO 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL4 protein]; 3,4,5,3',4'-pentachlorobiphenyl promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CCL4 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Lipopolysaccharides results in increased expression of CCL4 mRNA]; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CCL4 mRNA; [Lipopolysaccharides co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CCL4 mRNA; [usnic acid co-treated with Lipopolysaccharides] results in increased expression of CCL4 mRNA; coagulin-L inhibits the reaction [Lipopolysaccharides results in increased expression of CCL4 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL4 protein]; Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL4 protein]]]; Dinoprostone promotes the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL4 protein]]; Dinoprostone promotes the reaction [roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL4 protein]]; Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL4 protein]]; Particulate Matter inhibits the reaction [Lipopolysaccharides results in increased expression of CCL4 mRNA]; Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL4 protein]; roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL4 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL4 mRNA]; Vehicle Emissions inhibits the reaction [Lipopolysaccharides results in increased expression of CCL4 mRNA]
(+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CCL4 mRNA]; E804 bisindole inhibits the reaction [Lipopolysaccharides results in increased expression of CCL4 mRNA]; Lipopolysaccharides inhibits the reaction [E804 bisindole results in increased expression of CCL4 mRNA]; Lipopolysaccharides results in increased expression of and results in increased secretion of CCL4 protein; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL4 protein]
Lipopolysaccharides results in increased expression of CCL4 mRNA; Lipopolysaccharides results in increased expression of CCL4 protein
Lipopolysaccharides results in decreased expression of CCL4 mRNA		 CTD PMID:9122163, PMID:10027076, PMID:10975854, PMID:12057914, PMID:14966191, PMID:15289356, PMID:15788441, PMID:17529908, PMID:18390722, PMID:19020770, PMID:19211157, PMID:21352583, PMID:21913898, PMID:22777745, PMID:23107598, PMID:24707119, PMID:25890327, PMID:26111115, PMID:26582142, PMID:26918785, PMID:27568862, PMID:27783115, PMID:30768972 NCBI chr10:70,870,926...70,886,357
Ensembl chr10:70,884,531...70,886,355 		JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions
increases expression
increases secretion		 ISO
EXP		 1,25-dihydroxyvitamin D inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL5 protein]; [Homocysteine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein; [Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of CCL5 mRNA; coagulin-L inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]; Dimethyl Sulfoxide inhibits the reaction [[Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased secretion of CCL5 protein]; fexofenadine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; fexofenadine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]; hesperetin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]; Lipopolysaccharides promotes the reaction [Shiga Toxin 2 results in increased secretion of CCL5 protein]; Phloretin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]; resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]; Silymarin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]
Lipopolysaccharides inhibits the reaction [Rutin results in decreased expression of CCL5 mRNA]
Lipopolysaccharides results in increased expression of CCL5 mRNA; Lipopolysaccharides results in increased expression of CCL5 protein
(+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; 4-hydroxy-2-nonenal inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; 4-hydroxy-2-nonenal inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CCL5 mRNA; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CCL5 protein; [procyanidin B3 co-treated with Eicosapentaenoic Acid] inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; [Shiga Toxin 2 co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; APPL1 protein promotes the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; CAP18 lipopolysaccharide-binding protein inhibits the reaction [[Shiga Toxin 2 co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; IL6 protein affects the reaction [Lipopolysaccharides results in increased secretion of CCL5 protein]; Lipopolysaccharides inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; Lipopolysaccharides promotes the reaction [RELA protein binds to CCL5 promoter]; Lipopolysaccharides results in increased expression of and results in increased secretion of CCL5 protein; mangiferin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CCL5 protein]; Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL5 protein]; Niclosamide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL5 protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; terameprocol inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to CCL5 promoter]]; trametinib promotes the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein]; Wortmannin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]		 CTD PMID:15135318, PMID:15289356, PMID:15460210, PMID:15804595, PMID:16225753, PMID:16366002, PMID:16367934, PMID:18390722, PMID:18684396, PMID:19133137, PMID:19428942, PMID:19627980, PMID:21138578, PMID:21146893, PMID:21147091, PMID:21731756, PMID:21878375, PMID:21979172, PMID:22169119, PMID:22225513, PMID:23958496, PMID:24561310, PMID:24707119, PMID:25780039, PMID:25890327, PMID:26582142, PMID:26918785, PMID:27339419, PMID:27568862, PMID:28065790, PMID:28693884, PMID:29730267 NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315 		JBrowse link
G Ccl6 chemokine (C-C motif) ligand 6 increases expression ISO Lipopolysaccharides results in increased expression of CCL6 mRNA CTD PMID:27339419 NCBI chr10:70,798,118...70,802,750
Ensembl chr10:70,797,124...70,802,782 		JBrowse link
G Ccl7 C-C motif chemokine ligand 7 multiple interactions
increases expression		 ISO [nickel chloride co-treated with Lipopolysaccharides] results in increased secretion of CCL7 protein
Lipopolysaccharides results in increased expression of CCL7 mRNA
(+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CCL7 mRNA]; [procyanidin B3 co-treated with Eicosapentaenoic Acid] inhibits the reaction [Lipopolysaccharides results in increased expression of CCL7 mRNA]; cypermethrin promotes the reaction [Lipopolysaccharides results in increased expression of CCL7 mRNA]		 CTD PMID:18437699, PMID:22169119, PMID:25890327, PMID:26582142, PMID:27339419, PMID:29471534 NCBI chr10:69,423,083...69,424,933
Ensembl chr10:69,423,086...69,424,979 		JBrowse link
G Ccn1 cellular communication network factor 1 decreases expression
multiple interactions
affects expression		 ISO Lipopolysaccharides results in decreased expression of CCN1 mRNA
Plant Extracts affects the reaction [Lipopolysaccharides affects the expression of CCN1 mRNA]		 CTD PMID:27339419, PMID:28070326 NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312 		JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions
increases expression		 ISO
EXP		 Lipopolysaccharides inhibits the reaction [Curcumin results in decreased expression of CCN2 mRNA]
Lipopolysaccharides results in increased expression of CCN2 mRNA; Lipopolysaccharides results in increased expression of CCN2 protein
[[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] which results in decreased expression of CCN2 protein; [Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of CCN2 protein; aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of CCN2 protein]		 CTD PMID:17965732, PMID:24412304 NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773 		JBrowse link
G Ccna1 cyclin A1 decreases expression ISO Lipopolysaccharides results in decreased expression of CCNA1 mRNA CTD PMID:12057914 NCBI chr 2:144,456,689...144,503,570
Ensembl chr 2:144,458,153...144,467,912 		JBrowse link
G Ccna2 cyclin A2 multiple interactions
affects expression		 ISO Plant Extracts affects the reaction [Lipopolysaccharides affects the expression of CCNA2 mRNA] CTD PMID:28070326 NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214 		JBrowse link
G Ccnb1 cyclin B1 increases expression ISO Lipopolysaccharides results in increased expression of CCNB1 mRNA CTD PMID:10975854 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221 		JBrowse link
G Ccnb2 cyclin B2 decreases expression ISO Lipopolysaccharides results in decreased expression of CCNB2 mRNA CTD PMID:12057914 NCBI chr 8:76,847,972...76,861,165 JBrowse link
G Ccnc cyclin C multiple interactions ISO Lipopolysaccharides promotes the reaction [E804 bisindole results in decreased expression of CCNC mRNA]
[usnic acid co-treated with Lipopolysaccharides] results in decreased expression of CCNC mRNA		 CTD PMID:22777745, PMID:23107598 NCBI chr 5:35,865,598...35,883,732
Ensembl chr 5:35,865,605...35,883,706 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression
decreases expression		 ISO Lipopolysaccharides inhibits the reaction [E804 bisindole results in decreased expression of CCND1 mRNA]
Lipopolysaccharides results in increased expression of CCND1 mRNA
Lipopolysaccharides results in decreased expression of CCND1 mRNA		 CTD PMID:22135065, PMID:23107598 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325 		JBrowse link
G Ccnd2 cyclin D2 increases expression
multiple interactions		 ISO Lipopolysaccharides results in increased expression of CCND2 mRNA
Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of CCND2 mRNA]; tocotrienol, delta inhibits the reaction [Lipopolysaccharides results in increased expression of CCND2 mRNA]		 CTD PMID:22185406 NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207 		JBrowse link
G Ccne2 cyclin E2 decreases expression ISO Lipopolysaccharides results in decreased expression of CCNE2 mRNA CTD PMID:12057914 NCBI chr 5:24,434,077...24,446,406
Ensembl chr 5:24,434,872...24,446,406 		JBrowse link
G Ccng1 cyclin G1 multiple interactions ISO Lipopolysaccharides inhibits the reaction [E804 bisindole results in increased expression of CCNG1 mRNA] CTD PMID:23107598 NCBI chr10:25,903,925...25,910,298
Ensembl chr10:25,903,911...25,910,325 		JBrowse link
G Ccnl1 cyclin L1 increases expression
multiple interactions		 EXP Lipopolysaccharides results in increased expression of CCNL1 mRNA
Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CCNL1 mRNA]		 CTD PMID:16415329 NCBI chr 2:157,747,295...157,759,838
Ensembl chr 2:157,747,542...157,759,838 		JBrowse link
G Ccnl2 cyclin L2 multiple interactions
affects expression		 ISO Plant Extracts affects the reaction [Lipopolysaccharides affects the expression of CCNL2 mRNA] CTD PMID:28070326 NCBI chr 5:173,256,301...173,268,279
Ensembl chr 5:173,256,637...173,276,169 		JBrowse link
G Ccnt1 cyclin T1 decreases expression ISO Lipopolysaccharides results in decreased expression of CCNT1 mRNA CTD PMID:12057914 NCBI chr 7:140,215,052...140,245,958
Ensembl chr 7:140,219,551...140,245,723 		JBrowse link
G Ccr1 C-C motif chemokine receptor 1 decreases expression
increases expression		 ISO Lipopolysaccharides results in decreased expression of CCR1 mRNA
Lipopolysaccharides results in increased expression of CCR1 protein		 CTD PMID:26111115 NCBI chr 8:132,996,646...133,002,201
Ensembl chr 8:132,996,649...133,002,201 		JBrowse link
G Ccr3 C-C motif chemokine receptor 3 decreases expression ISO Lipopolysaccharides results in decreased expression of CCR3 mRNA CTD PMID:23999131 NCBI chr 8:133,026,539...133,040,999
Ensembl chr 8:133,029,625...133,040,997 		JBrowse link
G Ccr5 C-C motif chemokine receptor 5 multiple interactions
increases response to substance
increases expression		 ISO methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate promotes the reaction [Lipopolysaccharides results in increased expression of CCR5 mRNA]
CCR5 gene mutant form results in increased susceptibility to Lipopolysaccharides
[CCR5 gene mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased cleavage of CASP3 protein; [CCR5 gene mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased expression of ICAM1 protein; CCR5 gene mutant form promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; CCR5 gene mutant form promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; CCR5 gene mutant form promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]		 CTD PMID:26055553, PMID:26918785 NCBI chr 8:133,192,398...133,215,599
Ensembl chr 8:133,197,032...133,215,614 		JBrowse link
G Ccr6 C-C motif chemokine receptor 6 decreases expression ISO Lipopolysaccharides results in decreased expression of CCR6 protein CTD PMID:15924226 NCBI chr 1:53,063,380...53,087,519
Ensembl chr 1:53,065,025...53,087,474 		JBrowse link
G Ccr7 C-C motif chemokine receptor 7 increases expression
multiple interactions		 ISO Lipopolysaccharides results in increased expression of CCR7 mRNA
genipin inhibits the reaction [Lipopolysaccharides results in increased expression of CCR7 mRNA]
[Lipopolysaccharides co-treated with 6-formylindolo(3,2-b)carbazole] results in decreased expression of CCR7 protein; [Lipopolysaccharides co-treated with indole-3-carbinol] results in decreased expression of CCR7 protein; [Lipopolysaccharides co-treated with Tetrachlorodibenzodioxin] affects the expression of CCR7 protein; HNRNPD protein inhibits the reaction [Lipopolysaccharides results in increased expression of CCR7 mRNA]		 CTD PMID:21135123, PMID:22687549, PMID:27783115 NCBI chr10:87,057,335...87,067,444
Ensembl chr10:87,057,136...87,067,456 		JBrowse link
G Ccrl2 C-C motif chemokine receptor like 2 multiple interactions
increases expression		 ISO genipin inhibits the reaction [Lipopolysaccharides results in increased expression of CCRL2 mRNA] CTD PMID:22687549, PMID:26582142 NCBI chr 8:119,324,298...119,326,954
Ensembl chr 8:119,324,613...119,326,938 		JBrowse link
G Ccs copper chaperone for superoxide dismutase increases expression ISO Lipopolysaccharides results in increased expression of CCS mRNA CTD PMID:22369063 NCBI chr 1:220,075,251...220,096,319
Ensembl chr 1:220,075,247...220,096,404 		JBrowse link
G Cd109 CD109 molecule multiple interactions
increases expression		 ISO Estradiol promotes the reaction [Lipopolysaccharides results in increased expression of CD109 mRNA] CTD PMID:16977382 NCBI chr 8:85,951,420...86,065,411
Ensembl chr 8:85,951,191...86,065,409 		JBrowse link
G Cd14 CD14 molecule decreases expression
increases expression
affects binding
multiple interactions
increases localization
increases response to substance
affects response to substance		 ISO
EXP		 Lipopolysaccharides results in decreased expression of CD14 protein
Lipopolysaccharides results in increased expression of CD14 mRNA; Lipopolysaccharides results in increased expression of CD14 protein
Lipopolysaccharides binds to CD14 protein
CD14 protein affects the reaction [Lipopolysaccharides results in increased secretion of Nitric Oxide]; CD14 protein promotes the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of NOS2 protein]; CD14 protein promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Tretinoin promotes the reaction [Lipopolysaccharides results in increased expression of CD14 mRNA]
Lipopolysaccharides results in increased localization of CD14 protein
Lipopolysaccharides results in decreased expression of CD14 mRNA
CD14 protein results in increased susceptibility to Lipopolysaccharides
CD14 protein affects the susceptibility to Lipopolysaccharides
2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 mRNA]; 2,4,5,2',5'-pentachlorobiphenyl inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 mRNA]; [2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180 co-treated with 2,4,5,2',5'-pentachlorobiphenyl] inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 mRNA]; [2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 mRNA]; [2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl] inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 mRNA]; [2,4,5,2',5'-pentachlorobiphenyl co-treated with PCB 180] inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 mRNA]; [Aflatoxin B1 co-treated with aflatoxin B2] inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 protein]; [CD14 protein results in increased susceptibility to Lipopolysaccharides] which affects the susceptibility to Ethanol; [Lipopolysaccharides co-treated with CD14 protein] results in increased phosphorylation of RELA protein; [Lipopolysaccharides co-treated with CD14 protein] results in increased secretion of IL6 protein; CD14 protein affects the reaction [Lipopolysaccharides results in increased expression of IL12A mRNA]; CD14 protein affects the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA]; CD14 protein affects the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; CD14 protein affects the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; CD14 protein affects the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; CD14 protein affects the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein]; genipin inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 mRNA]; glutamyl-(2-(((3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl)oxy)carbonyl)-3-((2-(1H-indol-3-yl)ethyl)amino)-3-oxopropyl)-cysteinyl-glycine sodium salt inhibits the reaction [Lipopolysaccharides results in increased localization of CD14 protein]; Lipopolysaccharides promotes the reaction [LPAR1 protein binds to CD14 protein]; methyl-beta-cyclodextrin inhibits the reaction [Lipopolysaccharides promotes the reaction [LPAR1 protein binds to CD14 protein]]; PCB 180 inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 mRNA]
2,5-dimethyl-4-benzoquinone inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 protein]; 2-tert-butyl-4-quinone inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 protein]; [alfacalcidol co-treated with Lipopolysaccharides] results in increased expression of CD14 protein; [LY96 protein results in increased expression of CD14 mRNA] which results in increased susceptibility to Lipopolysaccharides; [Resveratrol co-treated with Lipopolysaccharides] results in increased expression of CD14 protein; BAY 11-7085 inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 protein]; CD14 protein affects the reaction [Glucose promotes the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]]; Curcumin inhibits the reaction [Glucose promotes the reaction [Lipopolysaccharides results in increased expression of CD14 protein]]; Curcumin inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 protein]; Glucose promotes the reaction [Lipopolysaccharides results in increased expression of CD14 protein]; phenylbenzoquinone inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 protein]; thymoquinone inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 protein]		 CTD PMID:10223745, PMID:10975854, PMID:11123339, PMID:11343695, PMID:11581577, PMID:12057914, PMID:12133974, PMID:12176910, PMID:15135313, PMID:15946915, PMID:16309824, PMID:16651628, PMID:18180316, PMID:18390722, PMID:18710323, PMID:19136613, PMID:20700758, PMID:21266194, PMID:21276822, PMID:21821728, PMID:21846543, PMID:22445859, PMID:22687549, PMID:23182953, PMID:26141388, PMID:27339419, PMID:28411859, PMID:31935363 NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153 		JBrowse link
G Cd160 CD160 molecule decreases expression ISO Lipopolysaccharides results in decreased expression of CD160 mRNA CTD PMID:18192897 NCBI chr 2:198,933,681...198,965,380
Ensembl chr 2:198,935,133...198,942,732 		JBrowse link
G Cd163 CD163 molecule increases expression
multiple interactions		 ISO Lipopolysaccharides results in increased expression of CD163 mRNA; Lipopolysaccharides results in increased expression of CD163 protein
[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CD163 mRNA; bisphenol A inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CD163 mRNA]; mono-(2-ethylhexyl)phthalate inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CD163 mRNA]
methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate inhibits the reaction [Lipopolysaccharides results in increased expression of CD163 mRNA]; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate inhibits the reaction [Lipopolysaccharides results in increased expression of CD163 protein]		 CTD PMID:26918785, PMID:29718165 NCBI chr 4:156,752,063...156,785,467
Ensembl chr 4:156,752,082...156,785,467 		JBrowse link
G Cd177 CD177 molecule increases expression ISO Lipopolysaccharides results in increased expression of CD177 mRNA CTD PMID:18192897 NCBI chr 1:82,964,683...82,987,306
Ensembl chr 1:82,964,683...82,987,253 		JBrowse link
G Cd200r1 CD200 receptor 1 decreases expression ISO Lipopolysaccharides results in decreased expression of CD200R1 mRNA CTD PMID:25890327 NCBI chr11:60,848,161...60,882,470
Ensembl chr11:60,848,131...60,882,379 		JBrowse link
G Cd207 CD207 molecule decreases expression ISO Lipopolysaccharides results in decreased expression of CD207 mRNA CTD PMID:30942577 NCBI chr 4:115,333,124...115,355,034
Ensembl chr 4:115,348,491...115,354,795 		JBrowse link
G Cd274 CD274 molecule increases expression ISO Lipopolysaccharides results in increased expression of CD274 mRNA CTD PMID:18192897, PMID:25890327, PMID:27339419 NCBI chr 1:247,519,890...247,539,659
Ensembl chr 1:247,519,939...247,537,943 		JBrowse link
G Cd300lb CD300 molecule-like family member b decreases expression ISO Lipopolysaccharides results in decreased expression of CD300LB mRNA CTD PMID:25890327, PMID:26582142 NCBI chr10:103,471,082...103,481,071
Ensembl chr10:103,467,725...103,481,153 		JBrowse link
G Cd36 CD36 molecule multiple interactions
increases expression
decreases expression		 ISO [bisphenol A affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of CD36 mRNA; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CD36 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of CD36 mRNA; [SMYD2 mRNA affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of CD36 mRNA; bisphenol A inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CD36 mRNA]; Decitabine inhibits the reaction [[bisphenol A affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of CD36 mRNA]; Diethylhexyl Phthalate inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CD36 mRNA]; Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of CD36 mRNA]; mono-(2-ethylhexyl)phthalate inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CD36 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of CD36 mRNA]; trichostatin A inhibits the reaction [[bisphenol A affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of CD36 mRNA] CTD PMID:21689150, PMID:21873422, PMID:27339419, PMID:29718165 NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749 		JBrowse link
G Cd38 CD38 molecule increases expression ISO Lipopolysaccharides results in increased expression of CD38 mRNA CTD PMID:27339419 NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672 		JBrowse link
G Cd40 CD40 molecule multiple interactions
increases expression
affects expression
decreases expression		 ISO
EXP		 [Acetaminophen co-treated with Lipopolysaccharides] results in increased expression of CD40 mRNA; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipopolysaccharides] results in increased expression of CD40 protein; [heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine co-treated with Lipopolysaccharides] results in increased expression of CD40 protein; Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]]; Dihydrotestosterone inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]; Eicosapentaenoic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]; Fatty Acids, Unsaturated inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]; phenethyl isothiocyanate inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]
Lipopolysaccharides results in increased expression of CD40 protein
Lipopolysaccharides affects the expression of CD40 protein
Lipopolysaccharides results in increased expression of CD40 mRNA; Lipopolysaccharides results in increased expression of CD40 protein
3,4-dihydroxybenzohydroxamic acid inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]; 4-cresol sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 protein]; [Lipopolysaccharides co-treated with CSF2 protein] results in increased expression of CD40 protein; [Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of CD40 protein; [Lipopolysaccharides co-treated with indole-3-carbinol] results in decreased expression of CD40 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of CD40 protein; daidzein inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]; Estradiol promotes the reaction [Lipopolysaccharides results in increased expression of CD40 protein]; genipin inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 protein]; indole-3-carbinol inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 protein]; methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]; Niclosamide inhibits the reaction [Lipopolysaccharides affects the expression of CD40 protein]; phenethyl isothiocyanate inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]; Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]; Raloxifene Hydrochloride inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 protein]; tocotrienol, delta inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]
Lipopolysaccharides results in decreased expression of CD40 protein		 CTD PMID:10975854, PMID:11884429, PMID:12057914, PMID:15246609, PMID:15618177, PMID:15684433, PMID:16081843, PMID:16299289, PMID:16317058, PMID:17512567, PMID:18390722, PMID:20423518, PMID:21742781, PMID:21945492, PMID:21948866, PMID:22185406, PMID:22687549, PMID:22916010, PMID:23376802, PMID:23724058, PMID:24056979, PMID:24561310, PMID:25843059, PMID:25890327, PMID:26784855, PMID:28811679, PMID:31059760, PMID:31777165 NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704 		JBrowse link
G Cd40lg CD40 ligand increases expression
multiple interactions		 ISO Lipopolysaccharides results in increased expression of CD40LG mRNA; Lipopolysaccharides results in increased expression of CD40LG protein
Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CD40LG protein]		 CTD PMID:10975854, PMID:30537341 NCBI chr  X:159,703,703...159,714,886
Ensembl chr  X:159,703,578...159,716,562 		JBrowse link
G Cd44 CD44 molecule (Indian blood group) increases expression ISO Lipopolysaccharides results in increased expression of CD44 mRNA CTD PMID:27339419 NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658 		JBrowse link
G Cd48 Cd48 molecule increases expression ISO Lipopolysaccharides results in increased expression of CD48 mRNA CTD PMID:27339419 NCBI chr13:90,116,601...90,140,371
Ensembl chr13:90,116,843...90,140,371 		JBrowse link
G Cd5 Cd5 molecule decreases expression ISO Lipopolysaccharides results in decreased expression of CD5 mRNA CTD PMID:21540303 NCBI chr 1:226,770,912...226,791,861
Ensembl chr 1:226,770,744...226,791,879 		JBrowse link
G Cd52 CD52 molecule increases expression ISO Lipopolysaccharides results in increased expression of CD52 mRNA CTD PMID:27339419 NCBI chr 5:152,322,910...152,324,469
Ensembl chr 5:152,322,916...152,324,469 		JBrowse link
G Cd55 CD55 molecule (Cromer blood group) decreases expression
multiple interactions
increases expression		 ISO Lipopolysaccharides results in decreased expression of CD55 mRNA
methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in decreased expression of CD55 mRNA]
Lipopolysaccharides results in increased expression of CD55 mRNA		 CTD PMID:24056979, PMID:27339419 NCBI chr13:47,125,156...47,153,557
Ensembl chr13:47,126,741...47,154,292 		JBrowse link
G Cd5l Cd5 molecule-like increases expression ISO Lipopolysaccharides results in increased expression of CD5L mRNA CTD PMID:27339419 NCBI chr 2:186,685,104...186,696,117
Ensembl chr 2:186,685,104...186,696,117 		JBrowse link
G Cd68 Cd68 molecule increases expression ISO
EXP		 Lipopolysaccharides results in increased expression of CD68 mRNA
Lipopolysaccharides results in increased expression of CD68 protein		 CTD PMID:27339419, PMID:28693884, PMID:29425760 NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640 		JBrowse link
G Cd69 Cd69 molecule multiple interactions
increases expression		 ISO Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CD69 mRNA]; hydroquinone inhibits the reaction [Lipopolysaccharides results in increased expression of CD69 protein]; Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of CD69 mRNA]; Tetrachlorodibenzodioxin affects the reaction [Lipopolysaccharides results in increased expression of CD69 protein]; tocotrienol, delta inhibits the reaction [Lipopolysaccharides results in increased expression of CD69 mRNA]
Lipopolysaccharides results in increased expression of CD69 mRNA; Lipopolysaccharides results in increased expression of CD69 protein		 CTD PMID:20054000, PMID:20348231, PMID:22185406 NCBI chr 4:163,041,147...163,049,065
Ensembl chr 4:163,041,141...163,049,084 		JBrowse link
G Cd70 Cd70 molecule multiple interactions ISO Triclosan inhibits the reaction [Lipopolysaccharides results in increased expression of CD70 mRNA] CTD PMID:20507366 NCBI chr 9:9,842,585...9,845,728
Ensembl chr 9:9,842,585...9,845,728 		JBrowse link
G Cd80 Cd80 molecule multiple interactions
affects expression
increases expression
decreases expression		 ISO (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]; 2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester affects the reaction [Lipopolysaccharides affects the expression of CD80 protein]; 4-methylhistamine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]; 6-formylindolo(3,2-b)carbazole affects the reaction [Lipopolysaccharides affects the expression of CD80 protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipopolysaccharides] results in increased expression of CD80 protein; [heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine co-treated with Lipopolysaccharides] results in increased expression of CD80 protein; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CD80 protein; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]; CD80 protein affects the reaction [Lipopolysaccharides results in increased expression of TNF protein]; CSF2 protein affects the reaction [Lipopolysaccharides results in increased expression of CD80 protein]; Dimaprit inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]; Famotidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]]; Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]; Ranitidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]]; triptolide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CD80 protein]
Lipopolysaccharides results in increased expression of CD80 mRNA; Lipopolysaccharides results in increased expression of CD80 protein
[Lipopolysaccharides co-treated with CSF2 protein] results in increased expression of CD80 protein; [Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in increased expression of CD80 protein; [Lipopolysaccharides co-treated with indole-3-carbinol] results in increased expression of CD80 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of CD80 protein; daidzein inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]; Estradiol promotes the reaction [Lipopolysaccharides results in increased expression of CD80 protein]; hydroquinone inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]; indirubin-3'-monoxime promotes the reaction [Lipopolysaccharides results in increased expression of CD80 protein]; indole-3-carbinol promotes the reaction [Lipopolysaccharides results in increased expression of CD80 protein]; Niclosamide inhibits the reaction [Lipopolysaccharides affects the expression of CD80 protein]; procyanidin B3 inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 mRNA]; Raloxifene Hydrochloride inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]
Lipopolysaccharides results in decreased expression of CD80 protein		 CTD PMID:11884429, PMID:12538815, PMID:15135313, PMID:15246609, PMID:15663903, PMID:16081843, PMID:16299289, PMID:17512567, PMID:18390722, PMID:19148301, PMID:20348231, PMID:21945492, PMID:21948866, PMID:22169119, PMID:23376802, PMID:24561310, PMID:24749687, PMID:25725100, PMID:26784855, PMID:28811679 NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353 		JBrowse link
G Cd83 CD83 molecule multiple interactions
increases expression		 ISO (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CD83 protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipopolysaccharides] results in increased expression of CD83 protein; [heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine co-treated with Lipopolysaccharides] results in increased expression of CD83 protein; Benzo(a)pyrene inhibits the reaction [Lipopolysaccharides results in increased expression of CD83 protein]; CEP-11004 inhibits the reaction [Lipopolysaccharides results in increased expression of CD83 protein]; CSF2 protein affects the reaction [Lipopolysaccharides results in increased expression of CD83 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CD83 protein] CTD PMID:11884429, PMID:16299289, PMID:17698565, PMID:21362464, PMID:25725100 NCBI chr17:24,416,651...24,435,790
Ensembl chr17:24,416,651...24,435,790 		JBrowse link
G Cd84 CD84 molecule increases expression ISO Lipopolysaccharides results in increased expression of CD84 mRNA CTD PMID:27339419 NCBI chr13:90,241,369...90,283,625
Ensembl chr13:90,244,681...90,277,865 		JBrowse link
G Cd86 CD86 molecule multiple interactions
affects expression
increases expression
decreases expression		 ISO (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; 2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester affects the reaction [Lipopolysaccharides affects the expression of CD86 protein]; 6-formylindolo(3,2-b)carbazole affects the reaction [Lipopolysaccharides affects the expression of CD86 protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with Lipopolysaccharides] results in increased expression of CD86 protein; [heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine co-treated with Lipopolysaccharides] results in increased expression of CD86 protein; [Lipopolysaccharides co-treated with 6-formylindolo(3,2-b)carbazole] results in decreased expression of CD86 protein; [Lipopolysaccharides co-treated with Diethylstilbestrol] results in increased expression of CD86 protein; [Lipopolysaccharides co-treated with Estradiol] results in increased expression of CD86 protein; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CD86 protein; [Lipopolysaccharides co-treated with indole-3-carbinol] results in decreased expression of CD86 protein; [Lipopolysaccharides co-treated with Tetrachlorodibenzodioxin] results in decreased expression of CD86 protein; [Lipopolysaccharides co-treated with Zearalenone] results in increased expression of CD86 protein; [Resveratrol co-treated with Lipopolysaccharides] results in increased expression of CD86 protein; CD86 protein affects the reaction [Lipopolysaccharides results in increased expression of TNF protein]; CEP-11004 inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; CSF2 protein affects the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; NFE2L2 protein affects the reaction [Particulate Matter analog inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]]; NFE2L2 protein affects the reaction [Vehicle Emissions analog inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]]; Particulate Matter analog inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; triptolide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CD86 protein]; Vehicle Emissions analog inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]
Lipopolysaccharides results in increased expression of CD86 mRNA; Lipopolysaccharides results in increased expression of CD86 protein
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; [Lipopolysaccharides binds to and results in increased activity of TLR4 protein] which results in increased expression of CD86 protein; [Lipopolysaccharides co-treated with CSF2 protein] results in increased expression of CD86 protein; [Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of CD86 protein; [Lipopolysaccharides co-treated with indole-3-carbinol] results in increased expression of CD86 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of CD86 protein; [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased expression of CD86 mRNA; Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 mRNA]; daidzein inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; Equol inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; Estradiol promotes the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; Genistein inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; hydroquinone inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; indole-3-carbinol promotes the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; Niclosamide inhibits the reaction [Lipopolysaccharides affects the expression of CD86 protein]; Particulate Matter analog inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; pyrithione inhibits the reaction [Lipopolysaccharides results in increased expression of CD86]; Raloxifene Hydrochloride inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; Tetrachlorodibenzodioxin promotes the reaction [[Lipopolysaccharides binds to and results in increased activity of TLR4 protein] which results in increased expression of CD86 protein]; Vehicle Emissions analog inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]
Lipopolysaccharides results in decreased expression of CD86 mRNA		 CTD PMID:11884429, PMID:12538815, PMID:15135313, PMID:15246609, PMID:15618177, PMID:15663903, PMID:16081843, PMID:16299289, PMID:16890772, PMID:17126599, PMID:17512567, PMID:17698565, PMID:18192897, PMID:19148301, PMID:19172522, PMID:20348231, PMID:20417223, PMID:21097750, PMID:21362464, PMID:21742781, PMID:21945492, PMID:21948866, PMID:22024136, PMID:22916010, PMID:23376802, PMID:24136171, PMID:24561310, PMID:24749687, PMID:25725100, PMID:27783115, PMID:28499610, PMID:28811679, PMID:29689377, PMID:32328699 NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795 		JBrowse link
G Cdc25a cell division cycle 25A increases expression ISO Lipopolysaccharides results in increased expression of CDC25A mRNA CTD PMID:12057914 NCBI chr 8:117,953,223...117,971,552
Ensembl chr 8:117,953,444...117,971,519 		JBrowse link
G Cdc6 cell division cycle 6 multiple interactions
affects expression		 ISO Plant Extracts affects the reaction [Lipopolysaccharides affects the expression of CDC6 mRNA] CTD PMID:28070326 NCBI chr10:86,819,477...86,833,301
Ensembl chr10:86,819,472...86,833,402 		JBrowse link
G Cdh1 cadherin 1 multiple interactions
decreases expression		 ISO resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of CDH1 mRNA]; resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of CDH1 protein]
Lipopolysaccharides results in decreased expression of CDH1 mRNA; Lipopolysaccharides results in decreased expression of CDH1 protein		 CTD PMID:25069516 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395 		JBrowse link
G Cdh12 cadherin 12 increases expression ISO Lipopolysaccharides results in increased expression of CDH12 protein CTD PMID:22344225 NCBI chr 2:71,310,228...72,540,063
Ensembl chr 2:72,006,099...72,540,263 		JBrowse link
G Cdh13 cadherin 13 multiple interactions
decreases expression
increases response to substance		 ISO CDH13 gene mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
Lipopolysaccharides results in decreased expression of CDH13 mRNA
CDH13 results in increased susceptibility to Lipopolysaccharides		 CTD PMID:22156343, PMID:30942577 NCBI chr19:50,848,793...51,971,618
Ensembl chr19:50,848,736...51,972,103 		JBrowse link
G Cdh4 cadherin 4 decreases expression ISO Lipopolysaccharides results in decreased expression of CDH4 mRNA CTD PMID:30942577 NCBI chr 3:175,220,520...175,283,144
Ensembl chr 3:175,144,495...175,279,761 		JBrowse link
G Cdh5 cadherin 5 decreases expression
multiple interactions		 ISO Lipopolysaccharides results in decreased expression of CDH5 mRNA
sodium bisulfide inhibits the reaction [Lipopolysaccharides results in decreased expression of CDH5 mRNA]		 CTD PMID:29128401 NCBI chr19:1,025,122...1,074,333
Ensembl chr19:1,023,683...1,074,365 		JBrowse link
G Cdk1 cyclin-dependent kinase 1 affects expression
multiple interactions		 ISO Lipopolysaccharides affects the expression of CDK1 mRNA
Plant Extracts affects the reaction [Lipopolysaccharides affects the expression of CDK1 mRNA]		 CTD PMID:28070326 NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549 		JBrowse link
G Cdk11b cyclin-dependent kinase 11B increases expression ISO Lipopolysaccharides results in increased expression of CDK11B mRNA CTD PMID:12057914 NCBI chr 5:173,051,900...173,078,049
Ensembl chr 5:173,052,063...173,078,046 		JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions EXP [Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of CDK6 mRNA CTD PMID:16415329 NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398 		JBrowse link
G Cdk9 cyclin-dependent kinase 9 decreases expression
increases expression		 ISO Lipopolysaccharides results in decreased expression of CDK9 mRNA
Lipopolysaccharides results in increased expression of CDK9 mRNA		 CTD PMID:25890327 NCBI chr 3:11,742,269...11,747,117
Ensembl chr 3:11,742,266...11,747,113 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression		 ISO Estradiol promotes the reaction [Lipopolysaccharides results in increased expression of CDKN1A mRNA]; Lipopolysaccharides inhibits the reaction [E804 bisindole results in decreased expression of CDKN1A mRNA] CTD PMID:16977382, PMID:18550754, PMID:23107598, PMID:27339419 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases expression
affects expression
multiple interactions		 ISO Lipopolysaccharides results in increased expression of CDKN1B mRNA; Lipopolysaccharides results in increased expression of CDKN1B protein alternative form
Lipopolysaccharides affects the expression of CDKN1B protein
Tetrachlorodibenzodioxin inhibits the reaction [Lipopolysaccharides affects the expression of CDKN1B protein]; Tetrachlorodibenzodioxin inhibits the reaction [Lipopolysaccharides results in increased expression of CDKN1B mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Lipopolysaccharides results in increased expression of CDKN1B protein alternative form]		 CTD PMID:12883080 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964 		JBrowse link
G Cdkn1c cyclin-dependent kinase inhibitor 1C increases expression
decreases expression		 ISO Lipopolysaccharides results in increased expression of CDKN1C mRNA
Lipopolysaccharides results in decreased expression of CDKN1C mRNA		 CTD PMID:12057914, PMID:18192897 NCBI chr 1:216,661,067...216,663,791
Ensembl chr 1:216,661,080...216,663,721 		JBrowse link
G Cdx2 caudal type homeo box 2 multiple interactions
increases response to substance		 ISO CDX2 protein promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; CDX2 protein promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]
[Lipopolysaccharides co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of CDX2 mRNA; [Lipopolysaccharides co-treated with Tetrachlorodibenzodioxin] results in increased expression of CDX2 mRNA; CDX2 protein affects the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Lipopolysaccharides results in increased expression of IL12A mRNA]]
CDX2 protein results in increased susceptibility to Lipopolysaccharides		 CTD PMID:21131441, PMID:27783115 NCBI chr12:9,464,026...9,470,565
Ensembl chr12:9,464,026...9,470,565 		JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions
decreases expression		 ISO [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein; Indomethacin promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein]; nimesulide promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein]
Lipopolysaccharides results in decreased expression of CEBPA mRNA		 CTD PMID:22107987, PMID:26582142 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta increases expression
increases activity
multiple interactions		 ISO
EXP		 Lipopolysaccharides results in increased expression of CEBPB mRNA
Lipopolysaccharides results in increased expression of CEBPB mRNA; Lipopolysaccharides results in increased expression of CEBPB protein
Lipopolysaccharides results in increased activity of CEBPB protein
3,3',4,5'-tetrahydroxystilbene promotes the reaction [Lipopolysaccharides results in increased expression of CEBPB protein]; [[PTPN6 protein results in increased phosphorylation of MAPK1 protein] which results in increased activity of CEBPB protein] promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; [[PTPN6 protein results in increased phosphorylation of MAPK3 protein] which results in increased activity of CEBPB protein] promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; arachidin-1 promotes the reaction [Lipopolysaccharides results in increased expression of CEBPB protein]; Genistein inhibits the reaction [Lipopolysaccharides results in increased activity of CEBPB protein]; genistin inhibits the reaction [Lipopolysaccharides results in increased activity of CEBPB protein]; resveratrol promotes the reaction [Lipopolysaccharides results in increased expression of CEBPB protein]
trichostatin A inhibits the reaction [Lipopolysaccharides results in increased expression of CEBPB mRNA]		 CTD PMID:11779202, PMID:14670622, PMID:15832817, PMID:17316017, PMID:21068073, PMID:21192080, PMID:21422245, PMID:21911040 NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910 		JBrowse link
G Cebpd CCAAT/enhancer binding protein delta multiple interactions
increases expression		 ISO
EXP		 genipin inhibits the reaction [Lipopolysaccharides results in increased expression of CEBPD mRNA]
APP protein modified form inhibits the reaction [Lipopolysaccharides results in increased activity of CEBPD protein]; APP protein modified form inhibits the reaction [Lipopolysaccharides results in increased expression of CEBPD protein]; Lipopolysaccharides results in increased expression of and results in increased activity of CEBPD protein		 CTD PMID:18405661, PMID:22687549, PMID:25890327, PMID:27339419 NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146 		JBrowse link
G Cebpg CCAAT/enhancer binding protein gamma multiple interactions
increases expression		 ISO 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Lipopolysaccharides results in increased expression of CEBPG mRNA]; 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Lipopolysaccharides results in increased expression of CEBPG protein]; arachidin-1 inhibits the reaction [Lipopolysaccharides results in increased expression of CEBPG mRNA]; arachidin-1 inhibits the reaction [Lipopolysaccharides results in increased expression of CEBPG protein]; resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of CEBPG mRNA]; resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of CEBPG protein]
Lipopolysaccharides results in increased expression of CEBPG mRNA; Lipopolysaccharides results in increased expression of CEBPG protein		 CTD PMID:17316017 NCBI chr 1:91,286,956...91,297,459
Ensembl chr 1:91,287,917...91,296,656 		JBrowse link
G Cenpu centromere protein U multiple interactions
affects expression		 ISO Plant Extracts affects the reaction [Lipopolysaccharides affects the expression of CENPU mRNA] CTD PMID:28070326 NCBI chr16:48,898,032...48,921,248
Ensembl chr16:48,897,982...48,921,242 		JBrowse link
G Cer1 cerberus 1, DAN family BMP antagonist decreases expression ISO Lipopolysaccharides results in decreased expression of CER1 mRNA CTD PMID:12057914 NCBI chr 5:101,003,019...101,006,375
Ensembl chr 5:101,003,023...101,006,375 		JBrowse link
G Ces1d carboxylesterase 1D multiple interactions
decreases expression		 ISO prolinedithiocarbamate inhibits the reaction [Lipopolysaccharides results in decreased expression of CES1 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in decreased expression of CES1 mRNA]
Lipopolysaccharides results in decreased expression of CES1D mRNA
Lipopolysaccharides results in decreased expression of CES1 mRNA; Lipopolysaccharides results in decreased expression of CES1 protein		 CTD PMID:21237253, PMID:27339419 NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821 		JBrowse link
G Ces2c carboxylesterase 2C decreases expression ISO Lipopolysaccharides results in decreased expression of CES2C mRNA CTD PMID:21237253 NCBI chr 1:282,640,752...282,648,319
Ensembl chr 1:282,638,017...282,702,424 		JBrowse link
G Ces2h carboxylesterase 2H decreases expression
multiple interactions		 ISO Lipopolysaccharides results in decreased expression of CES2 mRNA; Lipopolysaccharides results in decreased expression of CES2 protein
prolinedithiocarbamate inhibits the reaction [Lipopolysaccharides results in decreased expression of CES2 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in decreased expression of CES2 mRNA]		 CTD PMID:21237253 NCBI chr19:37,052,555...37,067,176
Ensembl chr19:37,052,556...37,067,156 		JBrowse link
G Ces3a carboxylesterase 3a multiple interactions ISO [Lipopolysaccharides co-treated with resveratrol] results in increased expression of CES3 mRNA CTD PMID:26667767 NCBI chr19:37,070,705...37,079,411 JBrowse link
G Cfb complement factor B increases expression
multiple interactions		 ISO Lipopolysaccharides results in increased expression of CFB mRNA
methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased expression of CFB mRNA]		 CTD PMID:24056979 NCBI chr20:4,536,206...4,542,073
Ensembl chr20:4,536,203...4,561,066
Ensembl chr20:4,536,203...4,561,066 		JBrowse link
G Cfl1 cofilin 1 decreases expression ISO Lipopolysaccharides results in decreased expression of CFL1 mRNA CTD PMID:12057914 NCBI chr 1:220,869,805...220,873,337
Ensembl chr 1:220,869,805...220,873,337 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator multiple interactions
increases expression		 ISO [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein]
Lipopolysaccharides results in increased expression of CFLAR mRNA		 CTD PMID:10975854, PMID:20850421 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251 		JBrowse link
G Cfp complement factor properdin multiple interactions
increases expression		 ISO CFP gene mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of C3 protein]
Lipopolysaccharides results in increased expression of CFP mRNA		 CTD PMID:17916747, PMID:27339419 NCBI chr  X:1,311,121...1,316,683
Ensembl chr  X:1,311,121...1,316,682 		JBrowse link
G Chka choline kinase alpha decreases expression ISO Lipopolysaccharides results in decreased expression of CHKA mRNA CTD PMID:27339419 NCBI chr 1:219,076,618...219,126,221
Ensembl chr 1:219,077,771...219,126,220 		JBrowse link
G Chrna1 cholinergic receptor nicotinic alpha 1 subunit increases expression ISO Lipopolysaccharides results in increased expression of CHRNA1 mRNA CTD PMID:12057914 NCBI chr 3:60,445,657...60,460,724
Ensembl chr 3:60,445,666...60,460,724 		JBrowse link
G Chsy1 chondroitin sulfate synthase 1 increases expression ISO Lipopolysaccharides results in increased expression of CHSY1 mRNA CTD PMID:27339419 NCBI chr 1:127,010,587...127,071,570
Ensembl chr 1:127,010,588...127,071,570 		JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex multiple interactions
increases phosphorylation
increases activity		 ISO
EXP		 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CHUK protein]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CHUK protein]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of CHUK protein]; HNRNPD protein promotes the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CHUK protein]; Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CHUK protein; Melitten inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CHUK protein]; NOX1 protein affects the reaction [Lipopolysaccharides results in increased phosphorylation of CHUK protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Lipopolysaccharides results in increased activity of CHUK protein]
wuzi yanzong analog inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CHUK protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CHUK protein]; 4-hydroxymercuribenzoate inhibits the reaction [Lipopolysaccharides results in increased activity of CHUK protein]; [Lipopolysaccharides results in increased activity of IRAK1 protein] which results in increased phosphorylation of CHUK protein; Auranofin inhibits the reaction [Lipopolysaccharides results in increased activity of CHUK protein]; Aurothioglucose inhibits the reaction [Lipopolysaccharides results in increased activity of CHUK protein]; Bee Venoms inhibits the reaction [Lipopolysaccharides results in increased activity of CHUK protein]; cobaltous chloride inhibits the reaction [Lipopolysaccharides results in increased activity of CHUK protein]; Ethylmaleimide inhibits the reaction [Lipopolysaccharides results in increased activity of CHUK protein]; glutamyl-(2-(((3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl)oxy)carbonyl)-3-((2-(1H-indol-3-yl)ethyl)amino)-3-oxopropyl)-cysteinyl-glycine sodium salt inhibits the reaction [[Lipopolysaccharides results in increased activity of IRAK1 protein] which results in increased phosphorylation of CHUK protein]; gold chloride inhibits the reaction [Lipopolysaccharides results in increased activity of CHUK protein]; Gold Sodium Thiomalate inhibits the reaction [Lipopolysaccharides results in increased activity of CHUK protein]; homoeriodictyol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CHUK protein]; kaempferol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CHUK protein]; Lipopolysaccharides results in increased activity of and results in increased phosphorylation of CHUK protein; Melitten inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CHUK protein]; Mercuric Chloride inhibits the reaction [Lipopolysaccharides results in increased activity of CHUK protein]; Quercetin inhibits the reaction [Lipopolysaccharides results in increased activity of CHUK protein]; Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CHUK protein]; scutellarein tetramethyl ether inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CHUK protein]; sodium bichromate inhibits the reaction [Lipopolysaccharides results in increased activity of CHUK protein]; Zinc Sulfate inhibits the reaction [Lipopolysaccharides results in increased activity of CHUK protein]		 CTD PMID:10820281, PMID:11739238, PMID:15466358, PMID:16171798, PMID:17067557, PMID:17322126, PMID:18789402, PMID:20715105, PMID:21135123, PMID:21276822, PMID:21877189, PMID:21893401, PMID:22118570, PMID:23535395, PMID:30769083, PMID:31850465 NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169 		JBrowse link
G Cidec cell death-inducing DFFA-like effector c multiple interactions ISO [Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of CIDEC mRNA; Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of CIDEC mRNA] CTD PMID:31499194 NCBI chr 4:145,377,482...145,390,497
Ensembl chr 4:145,377,431...145,390,497 		JBrowse link
G Cish cytokine inducible SH2-containing protein increases expression
multiple interactions		 ISO Lipopolysaccharides results in increased expression of CISH mRNA
[Lipopolysaccharides co-treated with Melatonin] results in decreased expression of CISH mRNA; Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of CISH mRNA]		 CTD PMID:21461237 NCBI chr 8:116,054,547...116,059,494
Ensembl chr 8:116,054,465...116,060,723 		JBrowse link
G Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 increases expression ISO Lipopolysaccharides results in increased expression of CITED2 mRNA CTD PMID:12057914 NCBI chr 1:12,823,363...12,825,806
Ensembl chr 1:12,823,363...12,825,786 		JBrowse link
G Ckm creatine kinase, M-type increases expression
multiple interactions		 EXP Lipopolysaccharides results in increased expression of CKM protein
Apigenin inhibits the reaction [Lipopolysaccharides results in increased expression of CKM protein]		 CTD PMID:25557508 NCBI chr 1:80,321,507...80,331,841
Ensembl chr 1:80,321,585...80,331,841 		JBrowse link
G Cks2 CDC28 protein kinase regulatory subunit 2 decreases expression ISO Lipopolysaccharides results in decreased expression of CKS2 mRNA CTD PMID:12057914 NCBI chr17:13,587,664...13,593,423
Ensembl chr17:13,587,665...13,593,423 		JBrowse link
G Clcn7 chloride voltage-gated channel 7 multiple interactions ISO clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CLCN7 mRNA] CTD PMID:19172522 NCBI chr10:14,492,844...14,518,167
Ensembl chr10:14,492,844...14,516,894 		JBrowse link
G Cldn1 claudin 1 decreases expression EXP Lipopolysaccharides results in decreased expression of CLDN1 mRNA; Lipopolysaccharides results in decreased expression of CLDN1 protein CTD PMID:22092031 NCBI chr11:77,815,216...77,830,373
Ensembl chr11:77,815,181...77,830,416 		JBrowse link
G Cldn18 claudin 18 decreases methylation ISO Lipopolysaccharides results in decreased methylation of CLDN18 gene CTD PMID:21212295 NCBI chr 8:107,933,725...107,960,656
Ensembl chr 8:107,934,860...107,952,530 		JBrowse link
G Clec10a C-type lectin domain containing 10A increases expression
multiple interactions
decreases expression		 ISO
EXP		 Lipopolysaccharides results in increased expression of CLEC10A mRNA
pyrrolidine dithiocarbamic acid inhibits the reaction [Lipopolysaccharides results in decreased expression of CLEC10A mRNA]
TLR4 affects the reaction [Lipopolysaccharides results in decreased expression of CLEC10A mRNA]
methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate inhibits the reaction [Lipopolysaccharides results in increased expression of CLEC10A mRNA]		 CTD PMID:17342418, PMID:26918785 NCBI chr10:56,764,927...56,769,447
Ensembl chr10:56,764,927...56,769,457 		JBrowse link
G Clec12a C-type lectin domain family 12, member A increases expression ISO Lipopolysaccharides results in increased expression of CLEC12A mRNA CTD PMID:25890327 NCBI chr 4:163,112,100...163,130,979
Ensembl chr 4:163,112,301...163,126,864 		JBrowse link
G Clec1b C-type lectin domain family 1, member B increases expression ISO Lipopolysaccharides results in increased expression of CLEC1B mRNA CTD PMID:27339419 NCBI chr 4:163,161,941...163,170,470
Ensembl chr 4:163,162,211...163,170,466 		JBrowse link
G Clec2d C-type lectin domain family 2, member D multiple interactions
increases expression		 ISO (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CLEC2D mRNA]; methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased expression of CLEC2D mRNA] CTD PMID:24056979, PMID:25890327 NCBI chr 4:162,278,252...162,302,881
Ensembl chr 4:162,292,305...162,302,156 		JBrowse link
G Clec4d C-type lectin domain family 4, member D multiple interactions
increases expression		 ISO (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CLEC4D mRNA] CTD PMID:18192897, PMID:21461237, PMID:25890327 NCBI chr 4:156,253,084...156,264,766
Ensembl chr 4:156,253,079...156,264,769 		JBrowse link
G Clec4e C-type lectin domain family 4, member E multiple interactions
increases expression
affects response to substance		 ISO [Lipopolysaccharides co-treated with CLEC4E protein] results in increased expression of TNF protein; CLEC4E protein promotes the reaction [[Cholesterol co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]
Lipopolysaccharides results in increased expression of CLEC4E mRNA
CLEC4E protein affects the susceptibility to Lipopolysaccharides		 CTD PMID:21461237, PMID:25890327, PMID:26296894 NCBI chr 4:156,271,087...156,276,243
Ensembl chr 4:156,270,920...156,276,304 		JBrowse link
G Clec7a C-type lectin domain containing 7A multiple interactions
increases expression
decreases expression		 ISO Chitosan inhibits the reaction [Lipopolysaccharides results in decreased expression of CLEC7A mRNA]; curdlan inhibits the reaction [Lipopolysaccharides results in decreased expression of CLEC7A mRNA]; Zymosan inhibits the reaction [Lipopolysaccharides results in decreased expression of CLEC7A mRNA]
Lipopolysaccharides results in increased expression of CLEC7A mRNA
[Lipopolysaccharides co-treated with IL4 protein] results in increased expression of CLEC7A mRNA; methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in decreased expression of CLEC7A mRNA]		 CTD PMID:21329777, PMID:21977998, PMID:24056979, PMID:27339419 NCBI chr 4:163,216,152...163,227,367
Ensembl chr 4:163,216,163...163,227,334 		JBrowse link
G Clic4 chloride intracellular channel 4 increases expression ISO Lipopolysaccharides results in increased expression of CLIC4 mRNA CTD PMID:18192897 NCBI chr 5:153,568,937...153,625,669
Ensembl chr 5:153,568,745...153,625,869 		JBrowse link
G Clic6 chloride intracellular channel 6 decreases methylation
multiple interactions		 ISO Lipopolysaccharides results in decreased methylation of CLIC6 gene
[Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased methylation of CLIC6 gene		 CTD PMID:21212295 NCBI chr11:32,655,653...32,698,004
Ensembl chr11:32,655,616...32,699,382 		JBrowse link
G Clstn2 calsyntenin 2 decreases methylation
multiple interactions		 ISO Lipopolysaccharides results in decreased methylation of CLSTN2 gene
[Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased methylation of CLSTN2 gene		 CTD PMID:21212295 NCBI chr 8:105,322,577...106,036,821
Ensembl chr 8:105,323,837...105,462,168 		JBrowse link
G Cltb clathrin, light chain B multiple interactions ISO [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased methylation of CLTB gene CTD PMID:21212295 NCBI chr17:10,537,348...10,554,999
Ensembl chr17:10,537,365...10,554,989 		JBrowse link
G Clu clusterin decreases expression ISO Lipopolysaccharides results in decreased expression of CLU mRNA CTD PMID:12057914 NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857 		JBrowse link
G Clybl citramalyl-CoA lyase multiple interactions ISO [Lipopolysaccharides co-treated with resveratrol] results in increased expression of CLYBL mRNA CTD PMID:26667767 NCBI chr15:108,608,203...108,838,222
Ensembl chr15:108,608,204...108,838,235 		JBrowse link
G Cmbl carboxymethylenebutenolidase homolog multiple interactions ISO [Lipopolysaccharides co-treated with resveratrol] results in increased expression of CMBL mRNA CTD PMID:26667767 NCBI chr 2:84,645,084...84,666,836
Ensembl chr 2:84,645,084...84,666,835 		JBrowse link
G Cmklr1 chemerin chemokine-like receptor 1 decreases expression ISO Lipopolysaccharides results in decreased expression of CMKLR1 mRNA CTD PMID:12057914 NCBI chr12:48,743,556...48,796,582
Ensembl chr12:48,789,261...48,793,553 		JBrowse link
G Cmpk2 cytidine/uridine monophosphate kinase 2 multiple interactions
increases expression		 ISO (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CMPK2 mRNA] CTD PMID:25890327 NCBI chr 6:45,683,242...45,694,824
Ensembl chr 6:45,683,234...45,694,822 		JBrowse link
G Cmtm3 CKLF-like MARVEL transmembrane domain containing 3 increases expression ISO Lipopolysaccharides results in increased expression of CMTM3 mRNA CTD PMID:27339419 NCBI chr19:830,874...838,528
Ensembl chr19:830,877...838,099 		JBrowse link
G Cnga2 cyclic nucleotide gated channel subunit alpha 2 multiple interactions ISO [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in increased methylation of CNGA2 gene CTD PMID:21212295 NCBI chr16:69,878,513...69,899,075 JBrowse link
G Cnr1 cannabinoid receptor 1 multiple interactions
decreases expression		 ISO
EXP		 [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; [anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]
Lipopolysaccharides results in decreased expression of CNR1 mRNA
[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [IFNG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [IFNG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]]		 CTD PMID:11727767, PMID:11891798, PMID:24448467 NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056 		JBrowse link
G Cnr2 cannabinoid receptor 2 multiple interactions
increases expression
decreases expression		 ISO [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC binds to and results in increased activity of CNR2 protein] promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]; [Lipopolysaccharides co-treated with Benzo(a)pyrene] results in increased expression of CNR2 protein; Docosahexaenoic Acids promotes the reaction [[Lipopolysaccharides co-treated with Benzo(a)pyrene] results in increased expression of CNR2 protein]; Docosahexaenoic Acids promotes the reaction [Lipopolysaccharides results in increased expression of CNR2 protein]
Lipopolysaccharides results in decreased expression of CNR2 mRNA		 CTD PMID:11448490, PMID:15821753, PMID:22442067, PMID:25890327, PMID:27329536 NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126 		JBrowse link
G Cntf ciliary neurotrophic factor increases expression EXP Lipopolysaccharides results in increased expression of CNTF protein CTD PMID:18090921 NCBI chr 1:229,599,009...229,601,032
Ensembl chr 1:229,599,009...229,601,032 		JBrowse link
G Cntnap1 contactin associated protein 1 increases expression ISO Lipopolysaccharides results in increased expression of CNTNAP1 mRNA CTD PMID:22185406 NCBI chr10:89,087,904...89,103,615
Ensembl chr10:89,089,646...89,103,614 		JBrowse link
G Cobl cordon-bleu WH2 repeat protein increases expression ISO Lipopolysaccharides results in increased expression of COBL mRNA CTD PMID:12057914 NCBI chr14:92,341,949...92,497,169
Ensembl chr14:92,342,957...92,577,936 		JBrowse link
G Col10a1 collagen type X alpha 1 chain increases expression ISO Lipopolysaccharides results in increased expression of COL10A1 mRNA CTD PMID:12057914 NCBI chr20:41,180,295...41,190,664
Ensembl chr20:41,184,287...41,189,633 		JBrowse link
G Col12a1 collagen type XII alpha 1 chain multiple interactions ISO [Lipopolysaccharides co-treated with resveratrol] results in decreased expression of COL12A1 mRNA CTD PMID:26667767 NCBI chr 8:87,042,820...87,150,701
Ensembl chr 8:87,040,799...87,158,368 		JBrowse link
G Col1a1 collagen type I alpha 1 chain increases expression
multiple interactions		 ISO
EXP		 Lipopolysaccharides results in increased expression of COL1A1 mRNA
Losartan inhibits the reaction [Lipopolysaccharides results in increased expression of COL1A1 mRNA]
Lipopolysaccharides results in increased expression of COL1A1 mRNA; Lipopolysaccharides results in increased expression of COL1A1 protein		 CTD PMID:17965732, PMID:23585870 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789 		JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions
increases expression		 ISO
EXP		 Losartan inhibits the reaction [Lipopolysaccharides results in increased expression of COL3A1 mRNA]
Lipopolysaccharides inhibits the reaction [Thioacetamide results in increased expression of COL3A1 mRNA]		 CTD PMID:17621560, PMID:23585870, PMID:27339419 NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217 		JBrowse link
G Col4a1 collagen type IV alpha 1 chain increases expression ISO Lipopolysaccharides results in increased expression of COL4A1 mRNA CTD PMID:27339419 NCBI chr16:83,522,162...83,632,153
Ensembl chr16:83,522,162...83,632,153 		JBrowse link
G Col4a2 collagen type IV alpha 2 chain increases expression ISO Lipopolysaccharides results in increased expression of COL4A2 mRNA CTD PMID:27339419 NCBI chr16:83,386,388...83,522,169
Ensembl chr16:83,387,364...83,438,561 		JBrowse link
G Col6a1 collagen type VI alpha 1 chain decreases expression
increases expression
multiple interactions		 ISO Lipopolysaccharides results in decreased expression of COL6A1 mRNA
Lipopolysaccharides results in increased expression of COL6A1 mRNA
Estradiol inhibits the reaction [Lipopolysaccharides results in increased expression of COL6A1 mRNA]		 CTD PMID:12057914, PMID:16977382 NCBI chr20:12,657,913...12,676,370
Ensembl chr20:12,658,065...12,675,561 		JBrowse link
G Col6a2 collagen type VI alpha 2 chain multiple interactions
increases expression		 ISO Estradiol inhibits the reaction [Lipopolysaccharides results in increased expression of COL6A2 mRNA] CTD PMID:16977382 NCBI chr20:12,773,472...12,801,179
Ensembl chr20:12,773,427...12,801,180 		JBrowse link
G Colec12 collectin sub-family member 12 multiple interactions ISO [Lipopolysaccharides co-treated with Melatonin] results in increased expression of COLEC12 mRNA CTD PMID:21461237 NCBI chr18:867,048...1,054,047
Ensembl chr18:867,048...1,052,606 		JBrowse link
G Coro1a coronin 1A increases expression ISO Lipopolysaccharides results in increased expression of CORO1A mRNA CTD PMID:27339419 NCBI chr 1:198,123,883...198,128,890
Ensembl chr 1:198,123,884...198,128,857 		JBrowse link
G Cox16 cytochrome c oxidase assembly factor COX16 multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of COX16 mRNA CTD PMID:31059760 NCBI chr 6:105,195,387...105,214,366
Ensembl chr 6:105,201,395...105,214,329 		JBrowse link
G Cox17 cytochrome c oxidase copper chaperone COX17 increases expression ISO Lipopolysaccharides results in increased expression of COX17 mRNA CTD PMID:22369063 NCBI chr11:64,962,663...64,968,437
Ensembl chr11:64,962,666...64,968,437 		JBrowse link
G Cox4i1 cytochrome c oxidase subunit 4i1 multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of COX4I1 mRNA CTD PMID:31059760 NCBI chr19:54,245,958...54,252,198
Ensembl chr19:54,245,950...54,252,225 		JBrowse link
G Cox6a2 cytochrome c oxidase subunit 6A2 decreases expression ISO Lipopolysaccharides results in decreased expression of COX6A2 mRNA CTD PMID:31059760 NCBI chr 1:199,624,037...199,626,255
Ensembl chr 1:199,624,037...199,624,783 		JBrowse link
G Cox6c cytochrome c oxidase subunit 6C multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of COX6C mRNA CTD PMID:31059760 NCBI chr 7:74,723,177...74,735,650
Ensembl chr 7:74,723,179...74,735,650 		JBrowse link
G Cox7a1 cytochrome c oxidase subunit 7A1 multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of COX7A1 mRNA CTD PMID:31059760 NCBI chr 1:88,619,619...88,650,672
Ensembl chr 1:91,071,493...91,074,294
Ensembl chr 1:91,071,493...91,074,294 		JBrowse link
G Cox7a2 cytochrome c oxidase subunit 7A2 multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of COX7A2 mRNA CTD PMID:31059760 NCBI chr 8:87,209,529...87,213,627
Ensembl chr 8:87,209,530...87,213,627 		JBrowse link
G Cox7a2l cytochrome c oxidase subunit 7A2 like multiple interactions
decreases expression		 ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of COX7A2L mRNA
Lipopolysaccharides results in decreased expression of COX7A2L mRNA		 CTD PMID:31059760 NCBI chr 6:6,695,807...6,709,790
Ensembl chr 6:6,695,827...6,709,783 		JBrowse link
G Cox7b cytochrome c oxidase subunit 7B multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of COX7B mRNA CTD PMID:31059760 NCBI chr  X:77,065,427...77,071,676
Ensembl chr  X:77,065,397...77,071,676 		JBrowse link
G Cox7b2 cytochrome c oxidase subunit 7B2 decreases expression
multiple interactions		 ISO Lipopolysaccharides results in decreased expression of COX7B2 mRNA
Dexamethasone inhibits the reaction [Lipopolysaccharides results in decreased expression of COX7B2 mRNA]; Quercetin inhibits the reaction [Lipopolysaccharides results in decreased expression of COX7B2 mRNA]; tocotrienol, delta inhibits the reaction [Lipopolysaccharides results in decreased expression of COX7B2 mRNA]		 CTD PMID:22185406 NCBI chr14:39,256,685...39,368,886
Ensembl chr14:39,368,530...39,368,769 		JBrowse link
G Cox7c cytochrome c oxidase subunit 7C multiple interactions ISO [Acetaminophen co-treated with Lipopolysaccharides] results in decreased expression of COX7C mRNA CTD PMID:31059760 NCBI chr 2:14,699,878...14,701,903
Ensembl chr 2:14,699,882...14,701,903 		JBrowse link
G Cp ceruloplasmin increases expression
multiple interactions		 ISO Lipopolysaccharides results in increased expression of CP mRNA
Estradiol inhibits the reaction [Lipopolysaccharides results in increased expression of CP mRNA]		 CTD PMID:16977382, PMID:22369063 NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853 		JBrowse link
G Cpb2 carboxypeptidase B2 increases expression ISO Lipopolysaccharides results in increased expression of CPB2 mRNA CTD PMID:27339419 NCBI chr15:57,290,849...57,339,762
Ensembl chr15:57,290,849...57,339,760 		JBrowse link
G Cpeb1 cytoplasmic polyadenylation element binding protein 1 multiple interactions
increases expression		 EXP CPEB1 affects the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Lipopolysaccharides results in increased expression of and results in increased phosphorylation of CPEB1 protein; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased phosphorylation of CPEB1 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of CPEB1 mRNA] CTD PMID:21620800 NCBI chr 1:143,171,457...143,278,485
Ensembl chr 1:143,171,264...143,278,485 		JBrowse link
G Cpne5 copine 5 decreases expression ISO Lipopolysaccharides results in decreased expression of CPNE5 mRNA CTD PMID:30942577 NCBI chr20:6,419,033...6,500,843
Ensembl chr20:6,419,033...6,500,523 		JBrowse link
G Cpne8 copine 8 increases expression ISO Lipopolysaccharides results in increased expression of CPNE8 mRNA CTD PMID:27339419 NCBI chr 7:131,623,180...131,798,236
Ensembl chr 7:131,623,181...131,798,236 		JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A decreases expression
increases expression
multiple interactions		 ISO
EXP		 Lipopolysaccharides results in decreased expression of CPT1A mRNA
Lipopolysaccharides results in increased expression of CPT1A mRNA
dorsomorphin inhibits the reaction [Quercetin inhibits the reaction [Lipopolysaccharides results in decreased expression of CPT1A mRNA]]; Quercetin inhibits the reaction [Lipopolysaccharides results in decreased expression of CPT1A mRNA]		 CTD PMID:11779202, PMID:24465016 NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678 		JBrowse link
G Cpt1b carnitine palmitoyltransferase 1B decreases expression
multiple interactions		 ISO Lipopolysaccharides results in decreased expression of CPT1B mRNA
pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of CPT1B mRNA]		 CTD PMID:18940942, PMID:21873422 NCBI chr 7:130,395,211...130,404,731
Ensembl chr 7:130,395,194...130,405,347 		JBrowse link
G Cpvl carboxypeptidase, vitellogenic-like decreases expression ISO Lipopolysaccharides results in decreased expression of CPVL mRNA CTD PMID:18192897 NCBI chr 4:84,026,851...84,137,172
Ensembl chr 4:84,025,926...84,131,030 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions
increases phosphorylation
increases activity
decreases expression		 ISO [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CREB1 protein]]; Cryptoxanthins inhibits the reaction [Lipopolysaccharides results in decreased expression of CREB1 mRNA]; Lipopolysaccharides results in increased expression of and results in increased activity of CREB1 protein; Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CREB1 protein; oxophenylarsine inhibits the reaction [Lipopolysaccharides results in increased activity of CREB1 protein]; resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CREB1 protein]; resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CREB1 protein]; wortmannin inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CREB1 protein]] CTD PMID:10755711, PMID:20512473, PMID:22363816, PMID:22952890, PMID:26686910 NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435 		JBrowse link
G Crebbp CREB binding protein multiple interactions
decreases expression		 ISO Amino Acids, Peptides, and Proteins inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to CREBBP protein]]; Lipopolysaccharides promotes the reaction [RELA protein binds to CREBBP protein]
Lipopolysaccharides results in decreased expression of CREBBP mRNA		 CTD PMID:15919760, PMID:16847310, PMID:22003094 NCBI chr10:11,590,994...11,721,039
Ensembl chr10:11,595,044...11,721,039 		JBrowse link
G Crem cAMP responsive element modulator multiple interactions
increases expression		 EXP Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CREM mRNA] CTD PMID:16415329 NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888 		JBrowse link
G Crh corticotropin releasing hormone multiple interactions
increases secretion
increases expression
affects expression		 EXP
ISO		 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of CRH mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of CRH protein]; Dipyrone inhibits the reaction [Lipopolysaccharides results in increased secretion of CRH protein]; Indomethacin inhibits the reaction [Lipopolysaccharides results in increased secretion of CRH protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CRH mRNA]
Lipopolysaccharides results in increased expression of CRH mRNA; Lipopolysaccharides results in increased expression of CRH protein
Lipopolysaccharides affects the expression of CRH mRNA		 CTD PMID:11852909, PMID:15667454, PMID:21959975 NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863 		JBrowse link
G Crhbp corticotropin releasing hormone binding protein decreases expression
increases expression		 ISO
EXP		 Lipopolysaccharides results in decreased expression of CRHBP mRNA
Lipopolysaccharides results in increased expression of CRHBP mRNA		 CTD PMID:12057914, PMID:23483921 NCBI chr 2:25,141,471...25,153,334
Ensembl chr 2:25,141,471...25,153,334 		JBrowse link
G Crhr1 corticotropin releasing hormone receptor 1 decreases expression
increases expression		 EXP
ISO		 Lipopolysaccharides results in decreased expression of CRHR1 mRNA
Lipopolysaccharides results in increased expression of CRHR1 protein
Lipopolysaccharides results in increased expression of CRHR1 mRNA		 CTD PMID:12057914, PMID:23483921 NCBI chr10:92,191,473...92,233,662
Ensembl chr10:92,191,718...92,232,645 		JBrowse link
G Crim1 cysteine rich transmembrane BMP regulator 1 multiple interactions ISO [Lipopolysaccharides co-treated with resveratrol] results in decreased expression of CRIM1 mRNA CTD PMID:26667767 NCBI chr 6:788,490...962,663
Ensembl chr 6:788,548...960,703 		JBrowse link
G Crisp3 cysteine-rich secretory protein 3 increases expression ISO Lipopolysaccharides results in increased expression of CRISP3 mRNA CTD PMID:18192897 NCBI chr 9:24,047,405...24,088,066
Ensembl chr 9:24,066,303...24,088,064 		JBrowse link
G Crls1 cardiolipin synthase 1 decreases expression ISO Lipopolysaccharides results in decreased expression of CRLS1 mRNA CTD PMID:20652826 NCBI chr 3:125,503,638...125,522,460
Ensembl chr 3:125,503,638...125,522,441 		JBrowse link
G Crp C-reactive protein multiple interactions
increases expression
decreases expression
increases secretion		 ISO Atorvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CRP mRNA]; Atorvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CRP protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CRP protein]
Lipopolysaccharides results in decreased expression of CRP mRNA
Lipopolysaccharides results in increased secretion of CRP protein
Lipopolysaccharides results in increased expression of CRP mRNA; Lipopolysaccharides results in increased expression of CRP protein		 CTD PMID:12057914, PMID:15824212, PMID:17321000, PMID:19675143, PMID:20699433, PMID:21584495 NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713 		JBrowse link
G Crtam cytotoxic and regulatory T cell molecule decreases expression
multiple interactions		 ISO Lipopolysaccharides results in decreased expression of CRTAM mRNA
methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in decreased expression of CRTAM mRNA]		 CTD PMID:24056979 NCBI chr 8:45,152,584...45,216,082
Ensembl chr 8:45,153,308...45,215,974 		JBrowse link
G Cry1 cryptochrome circadian regulator 1 decreases expression ISO Lipopolysaccharides results in decreased expression of CRY1 mRNA CTD PMID:27339419 NCBI chr 7:24,534,593...24,634,098
Ensembl chr 7:24,534,615...24,634,097 		JBrowse link
G Cryab crystallin, alpha B multiple interactions ISO [usnic acid co-treated with Lipopolysaccharides] results in decreased expression of CRYAB mRNA CTD PMID:22777745 NCBI chr 8:55,178,543...55,182,546
Ensembl chr 8:55,178,289...55,182,545 		JBrowse link
G Crybb3 crystallin, beta B3 increases expression ISO Lipopolysaccharides results in increased expression of CRYBB3 mRNA CTD PMID:27339419 NCBI chr12:49,564,991...49,571,008
Ensembl chr12:49,565,992...49,571,006 		JBrowse link
G Csad cysteine sulfinic acid decarboxylase decreases expression ISO Lipopolysaccharides results in decreased expression of CSAD mRNA CTD PMID:27339419 NCBI chr 7:143,781,520...143,810,880
Ensembl chr 7:143,781,702...143,793,970 		JBrowse link
G Csf1 colony stimulating factor 1 multiple interactions
increases expression
decreases response to substance		 ISO
EXP		 [cobaltiprotoporphyrin results in increased activity of HMOX1 protein] promotes the reaction [[Lipopolysaccharides co-treated with CSF1 protein] results in increased expression of IL10 protein]; [CSF1 protein co-treated with CSF2 protein] promotes the reaction [Lipopolysaccharides results in increased chemical synthesis of Nitric Oxide]; [Lipopolysaccharides co-treated with CSF1 protein] results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides co-treated with CSF1 protein] results in increased expression of CALCR protein; [Lipopolysaccharides co-treated with CSF1 protein] results in increased expression of CTSK protein; [Lipopolysaccharides co-treated with CSF1 protein] results in increased expression of IL10 protein; [Lipopolysaccharides co-treated with CSF1 protein] results in increased expression of OSCAR protein; Benzene promotes the reaction [[[Lipopolysaccharides co-treated with IFNG protein] co-treated with CSF1 protein] results in increased chemical synthesis of Nitric Oxide]; Benzene promotes the reaction [[Lipopolysaccharides co-treated with CSF1 protein] results in increased chemical synthesis of Nitric Oxide]; CSF1 protein promotes the reaction [Lipopolysaccharides results in increased chemical synthesis of Nitric Oxide]; Enzyme Inhibitors inhibits the reaction [CSF1 protein promotes the reaction [Lipopolysaccharides results in increased chemical synthesis of Nitric Oxide]]; Enzyme Inhibitors inhibits the reaction [Lipopolysaccharides results in decreased susceptibility to CSF1 protein]
Lipopolysaccharides results in increased expression of CSF1 mRNA
(+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CSF1 mRNA]; [Benzene promotes the reaction [[CSF1 protein co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]] which results in increased chemical synthesis of Nitric Oxide; [CSF1 protein co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; Benzene promotes the reaction [[CSF1 protein co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; Enzyme Inhibitors inhibits the reaction [Lipopolysaccharides results in decreased susceptibility to CSF1 protein]; NOTCH1 protein affects the reaction [Lipopolysaccharides results in increased expression of CSF1 mRNA]; terameprocol promotes the reaction [Lipopolysaccharides results in increased expression of CSF1 protein]
Lipopolysaccharides results in increased expression of CSF1 mRNA; Lipopolysaccharides results in increased expression of CSF1 protein		 CTD PMID:8193360, PMID:10223745, PMID:18449946, PMID:19133137, PMID:20580464, PMID:21127049, PMID:21846543, PMID:25890327 NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560 		JBrowse link
G Csf1r colony stimulating factor 1 receptor multiple interactions
increases secretion
increases expression		 ISO [CSF1R protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide; Benzene promotes the reaction [[CSF1R protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; hydroquinone promotes the reaction [[CSF1R protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; hydroxyhydroquinone promotes the reaction [[CSF1R protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; quinone promotes the reaction [[CSF1R protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]
Lipopolysaccharides results in increased secretion of CSF1R protein
Lipopolysaccharides results in increased expression of CSF1R mRNA
CSF1R affects the reaction [Lipopolysaccharides results in increased expression of ACP5 mRNA]; CSF1R affects the reaction [Lipopolysaccharides results in increased expression of CTSK mRNA]; CSF1R affects the reaction [Lipopolysaccharides results in increased expression of TNFRSF11A mRNA]; resveratrol inhibits the reaction [Lipopolysaccharides results in increased secretion of CSF1R protein]		 CTD PMID:7884313, PMID:22067001, PMID:22118570 NCBI chr18:56,414,493...56,458,300
Ensembl chr18:56,414,488...56,458,300 		JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions
affects expression
decreases response to substance
increases secretion
increases expression		 ISO
EXP		 (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Lipopolysaccharides results in increased secretion of CSF2 protein]; [CSF1 protein co-treated with CSF2 protein] promotes the reaction [Lipopolysaccharides results in increased chemical synthesis of Nitric Oxide]; [Lipopolysaccharides co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CSF2 protein; [usnic acid co-treated with Lipopolysaccharides] results in decreased expression of CSF2 mRNA; coagulin-L inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 protein]; CSF2 protein affects the reaction [Lipopolysaccharides results in increased expression of CD80 protein]; CSF2 protein affects the reaction [Lipopolysaccharides results in increased expression of CD83 protein]; CSF2 protein affects the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; CSF2 protein affects the reaction [Lipopolysaccharides results in increased phosphorylation of STAT5A protein]; CSF2 protein affects the reaction [Lipopolysaccharides results in increased phosphorylation of STAT5B protein]; CSF2 protein promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL8 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 protein]; Lipopolysaccharides inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD1A protein]; Lipopolysaccharides promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of TFRC protein]; phenethyl isothiocyanate inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Plant Extracts affects the reaction [Lipopolysaccharides affects the expression of CSF2 mRNA]; resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 protein]; Silymarin inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 protein]; Spironolactone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] results in increased expression of CSF2 protein]; Sulfasalazine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] results in increased expression of CSF2 protein]; Triclosan inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]
[Zymosan co-treated with Lipopolysaccharides] results in increased expression of CSF2 protein
Lipopolysaccharides results in decreased susceptibility to CSF2 protein
Lipopolysaccharides results in increased expression of CSF2 mRNA; Lipopolysaccharides results in increased expression of CSF2 protein
1,3-dimethylthiourea inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 protein]; 3,4-dihydroxybenzohydroxamic acid inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; [Benzene co-treated with Enzyme Inhibitors] promotes the reaction [[Lipopolysaccharides co-treated with CSF2 protein] results in increased chemical synthesis of Nitric Oxide]; [CSF2 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with CSF2 protein] results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides co-treated with CSF2 protein] results in increased expression of CD40 protein; [Lipopolysaccharides co-treated with CSF2 protein] results in increased expression of CD80 protein; [Lipopolysaccharides co-treated with CSF2 protein] results in increased expression of CD86 protein; [Lipopolysaccharides co-treated with CSF2 protein] results in increased expression of H2 protein; [Lipopolysaccharides co-treated with CSF2 protein] results in increased expression of ICAM1 protein; [Lipopolysaccharides co-treated with CSF2 protein] results in increased expression of IL10 protein; [Lipopolysaccharides co-treated with CSF2 protein] results in increased expression of IL6 protein; [Lipopolysaccharides co-treated with CSF2 protein] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CSF2 mRNA; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CSF2 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of CD40 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of CD80 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of CD86 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of H2 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of ICAM1 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of IL10 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of IL6 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of TNF protein; [procyanidin B3 co-treated with Eicosapentaenoic Acid] inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Benzene promotes the reaction [[[Lipopolysaccharides co-treated with IFNG protein] co-treated with CSF2 protein] results in increased chemical synthesis of Nitric Oxide]; Benzene promotes the reaction [[CSF2 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; Benzene promotes the reaction [[Lipopolysaccharides co-treated with CSF2 protein] results in increased chemical synthesis of Nitric Oxide]; coagulin-L inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 protein]; cyanoginosin LR inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 protein]; E804 bisindole inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Enzyme Inhibitors results in increased susceptibility to [Lipopolysaccharides co-treated with CSF2 protein]; GLRX protein promotes the reaction [Lipopolysaccharides results in increased expression of CSF2 protein]; hydroquinone promotes the reaction [[CSF2 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; hydroxyhydroquinone promotes the reaction [[CSF2 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; IL6 protein affects the reaction [Lipopolysaccharides results in increased secretion of CSF2 protein]; LCN2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Lipopolysaccharides inhibits the reaction [E804 bisindole results in increased expression of CSF2 mRNA]; Mangifera indica extract inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CSF2 mRNA]; mangiferin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CSF2 protein]; methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased secretion of CSF2 protein]; phenethyl isothiocyanate inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Quercetin inhibits the reaction [Lipopolysaccharides results in increased secretion of CSF2 protein]; quinone promotes the reaction [[CSF2 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; terameprocol inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 protein]; Zinc Oxide promotes the reaction [Lipopolysaccharides results in increased secretion of CSF2 protein]		 CTD PMID:7884313, PMID:8193360, PMID:11752025, PMID:12176910, PMID:12604364, PMID:15135318, PMID:15191912, PMID:15222974, PMID:15712326, PMID:15804595, PMID:16192389, PMID:16880258, PMID:17051331, PMID:17512567, PMID:17618502, PMID:18292240, PMID:18390722, PMID:18684396, PMID:19020770, PMID:19133137, PMID:19211157, PMID:19339665, PMID:20423518, PMID:20507366, PMID:20539014, PMID:21352583, PMID:21540303, PMID:21656334, PMID:22169119, PMID:22777745, PMID:23107598, PMID:23724058, PMID:23735482, PMID:23962744, PMID:24056979, PMID:24707119, PMID:25725100, PMID:25843059, PMID:26790433, PMID:27568862, PMID:28065790, PMID:28070326, PMID:31804693 NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070 		JBrowse link
G Csf2ra colony stimulating factor 2 receptor subunit alpha multiple interactions
increases expression		 ISO (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides promotes the reaction [STAT5A protein binds to CSF2RA promoter]]; (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides promotes the reaction [STAT5B protein binds to CSF2RA promoter]]; (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2RA mRNA]; (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2RA protein]; Lipopolysaccharides promotes the reaction [STAT5A protein binds to CSF2RA promoter]; Lipopolysaccharides promotes the reaction [STAT5B protein binds to CSF2RA promoter]
Lipopolysaccharides results in increased expression of CSF2RA mRNA; Lipopolysaccharides results in increased expression of CSF2RA protein		 CTD PMID:25725100 NCBI chr14:1,462,292...1,467,264
Ensembl chr14:1,462,358...1,467,264 		JBrowse link
G Csf2rb colony stimulating factor 2 receptor subunit beta multiple interactions ISO clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2RB mRNA] CTD PMID:19172522 NCBI chr 7:119,554,383...119,568,248
Ensembl chr 7:119,554,354...119,568,776 		JBrowse link
G Csf3 colony stimulating factor 3 multiple interactions
increases expression
decreases expression		 ISO
EXP		 [Lipopolysaccharides co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CSF3 mRNA; [nickel chloride co-treated with Lipopolysaccharides] results in increased secretion of CSF3 protein; hesperetin inhibits the reaction [Lipopolysaccharides results in increased expression of CSF3 protein]; Phloretin inhibits the reaction [Lipopolysaccharides results in increased expression of CSF3 protein]; resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of CSF3 protein]; Silymarin inhibits the reaction [Lipopolysaccharides results in increased expression of CSF3 protein]
Lipopolysaccharides results in increased expression of CSF3 mRNA
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CSF3 mRNA; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CSF3 mRNA]; Triglycerides promotes the reaction [Lipopolysaccharides results in increased expression of CSF3 mRNA]
Lipopolysaccharides results in increased expression of CSF3 mRNA; Lipopolysaccharides results in increased expression of CSF3 protein
Lipopolysaccharides results in decreased expression of CSF3 mRNA
3,4-dihydroxybenzohydroxamic acid inhibits the reaction [Lipopolysaccharides results in increased expression of CSF3 mRNA]; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CSF3 protein; genipin inhibits the reaction [Lipopolysaccharides results in increased expression of CSF3 mRNA]; IL6 protein affects the reaction [Lipopolysaccharides results in increased secretion of CSF3 protein]; mangiferin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CSF3 protein]; phenethyl isothiocyanate inhibits the reaction [Lipopolysaccharides results in increased expression of CSF3 mRNA]; Polymyxin B inhibits the reaction [Lipopolysaccharides results in increased expression of CSF3 protein]; terameprocol inhibits the reaction [Lipopolysaccharides results in increased expression of CSF3 protein]		 CTD PMID:9122163, PMID:12057914, PMID:15135318, PMID:15804595, PMID:16401727, PMID:18437699, PMID:18710323, PMID:19133137, PMID:20423518, PMID:22687549, PMID:24707119, PMID:25843059, PMID:26790433 NCBI chr10:86,616,785...86,619,160
Ensembl chr10:86,616,785...86,619,157 		JBrowse link
G Cstb cystatin B increases expression ISO Lipopolysaccharides results in increased expression of CSTB mRNA CTD PMID:27339419 NCBI chr20:10,966,357...10,968,399
Ensembl chr20:10,966,331...10,968,432 		JBrowse link
G Ctbs chitobiase increases expression ISO Lipopolysaccharides results in increased expression of CTBS mRNA CTD PMID:27339419 NCBI chr 2:252,305,874...252,320,387
Ensembl chr 2:252,305,874...252,320,387 		JBrowse link
G Ctcf CCCTC-binding factor decreases expression ISO Lipopolysaccharides results in decreased expression of CTCF mRNA CTD PMID:12057914 NCBI chr19:37,600,151...37,649,674
Ensembl chr19:37,600,148...37,649,673 		JBrowse link
G Ctdsp2 CTD small phosphatase 2 decreases expression ISO Lipopolysaccharides results in decreased expression of CTDSP2 mRNA CTD PMID:25890327 NCBI chr 7:70,283,683...70,291,795
Ensembl chr 7:70,283,710...70,288,568 		JBrowse link
G Cth cystathionine gamma-lyase decreases expression
multiple interactions
increases response to substance
increases expression		 EXP
ISO		 Lipopolysaccharides results in decreased expression of CTH protein
[CTH protein mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased expression of IL4 mRNA; [CTH protein mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased expression of IL4 protein; [CTH protein mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased expression of IL6 protein; CTH protein mutant form promotes the reaction [Lipopolysaccharides results in increased expression of IL2 mRNA]; CTH protein mutant form promotes the reaction [Lipopolysaccharides results in increased expression of IL2 protein]; CTH protein mutant form promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; CTH protein mutant form promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; CTH protein mutant form promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Lipopolysaccharides promotes the reaction [CTH protein mutant form results in increased expression of IL2 mRNA]; Lipopolysaccharides promotes the reaction [CTH protein mutant form results in increased expression of IL2 protein]; Lipopolysaccharides promotes the reaction [CTH protein mutant form results in increased expression of IL4 mRNA]; Lipopolysaccharides promotes the reaction [CTH protein mutant form results in increased expression of IL4 protein]; Lipopolysaccharides promotes the reaction [CTH protein mutant form results in increased expression of IL6 mRNA]
Lipopolysaccharides results in decreased expression of CTH mRNA; Lipopolysaccharides results in decreased expression of CTH protein
TLR4 mRNA promotes the reaction [Lipopolysaccharides results in decreased expression of CTH protein]
Lipopolysaccharides results in increased expression of CTH mRNA
[Lipopolysaccharides results in decreased expression of CTH protein] which results in decreased chemical synthesis of Hydrogen Sulfide; Cysteine analog promotes the reaction [[Lipopolysaccharides results in decreased expression of CTH protein] which results in decreased chemical synthesis of Hydrogen Sulfide]; nitroflurbiprofen inhibits the reaction [Lipopolysaccharides results in increased expression of CTH mRNA]		 CTD PMID:16491094, PMID:21308383, PMID:29128401 NCBI chr 2:264,266,959...264,293,040
Ensembl chr 2:264,266,984...264,293,046 		JBrowse link
G Ctnnb1 catenin beta 1 increases expression ISO Lipopolysaccharides results in increased expression of CTNNB1 protein CTD PMID:11739494 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372 		JBrowse link
G Ctnnd1 catenin delta 1 multiple interactions
decreases expression		 ISO CTNND1 protein affects the reaction [Lipopolysaccharides affects the localization of RELA protein]; CTNND1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA]; CTNND1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 protein]
Lipopolysaccharides results in decreased expression of CTNND1 protein		 CTD PMID:20172018 NCBI chr 3:72,001,904...72,053,047
Ensembl chr 3:72,002,152...72,053,049 		JBrowse link
G Ctsb cathepsin B multiple interactions
increases expression		 ISO [Lipopolysaccharides co-treated with Silicon Dioxide] results in increased secretion of CTSB protein; [Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of CTSB protein; methyldithiocarbamate promotes the reaction [Lipopolysaccharides results in increased expression of CTSB mRNA] CTD PMID:18604214, PMID:19339665 NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612 		JBrowse link
G Ctsc cathepsin C increases expression ISO Lipopolysaccharides results in increased expression of CTSC mRNA CTD PMID:27339419 NCBI chr 1:151,918,514...151,949,979
Ensembl chr 1:151,918,571...151,949,983 		JBrowse link
G Ctsd cathepsin D increases expression ISO Lipopolysaccharides results in increased expression of CTSD mRNA CTD PMID:15919760 NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451 		JBrowse link
G Ctsk cathepsin K multiple interactions
increases expression		 ISO [Lipopolysaccharides co-treated with CSF1 protein] results in increased expression of CTSK protein
Lipopolysaccharides results in increased expression of CTSK mRNA; Lipopolysaccharides results in increased expression of CTSK protein
CSF1R affects the reaction [Lipopolysaccharides results in increased expression of CTSK mRNA]; Thymol inhibits the reaction [Lipopolysaccharides results in increased expression of CTSK mRNA]; Thymol inhibits the reaction [Lipopolysaccharides results in increased expression of CTSK protein]		 CTD PMID:21127049, PMID:22067001, PMID:30048646 NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446 		JBrowse link
G Ctsl cathepsin L multiple interactions EXP [Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CTSL mRNA CTD PMID:16415329 NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279 		JBrowse link
G Ctss cathepsin S increases expression ISO Lipopolysaccharides results in increased expression of CTSS mRNA CTD PMID:27339419 NCBI chr 2:197,655,780...197,679,768
Ensembl chr 2:197,655,786...197,679,458 		JBrowse link
G Cux2 cut-like homeobox 2 increases expression ISO Lipopolysaccharides results in increased expression of CUX2 mRNA CTD PMID:12057914 NCBI chr12:40,016,774...40,221,067
Ensembl chr12:40,018,937...40,219,291 		JBrowse link
G Cx3cl1 C-X3-C motif chemokine ligand 1 multiple interactions
increases expression		 ISO (+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CX3CL1 mRNA] CTD PMID:26582142 NCBI chr19:10,644,267...10,654,861
Ensembl chr19:10,644,244...10,653,800 		JBrowse link
G Cx3cr1 C-X3-C motif chemokine receptor 1 increases expression EXP Lipopolysaccharides results in increased expression of CX3CR1 mRNA CTD PMID:21846543 NCBI chr 8:128,740,756...128,754,514
Ensembl chr 8:128,740,756...128,754,514 		JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 multiple interactions
increases secretion
increases expression		 ISO
EXP		 [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CXCL1 protein; [Lipopolysaccharides co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CXCL1 mRNA; Amino Acids, Peptides, and Proteins inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 mRNA]; BIRB 796 inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein]
Lipopolysaccharides results in increased secretion of CXCL1 protein
Lipopolysaccharides results in increased expression of CXCL1 mRNA; Lipopolysaccharides results in increased expression of CXCL1 protein
Acetylcysteine analog inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein]; alpha-Tocopherol inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 mRNA]; Edaravone inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein]; epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein]; MIR34A mRNA promotes the reaction [Sevoflurane inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 mRNA]]; MIR34A mRNA promotes the reaction [Sevoflurane inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein]]; Sevoflurane inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 mRNA]; Sevoflurane inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein]; STAT1 inhibits the reaction [Sevoflurane inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 mRNA]]; STAT1 inhibits the reaction [Sevoflurane inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein]]		 CTD PMID:9122163, PMID:14997032, PMID:15237969, PMID:15629513, PMID:18257742, PMID:19428942, PMID:21504754, PMID:21572044, PMID:21913898, PMID:22003094, PMID:24333275, PMID:28065790, PMID:32147387 NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions
increases expression
increases secretion		 ISO
EXP		 [Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with Imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein; [usnic acid co-treated with Lipopolysaccharides] results in decreased expression of CXCL10 mRNA; coagulin-L inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]; Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]]]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]; Dinoprostone promotes the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]]; Dinoprostone promotes the reaction [roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]]; Ibuprofen inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]; Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]]; Particulate Matter inhibits the reaction [[Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with Imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein]; phenethyl isothiocyanate inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]; roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]; Vehicle Emissions inhibits the reaction [[Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with Imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein]
(+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; 3,4-dihydroxybenzohydroxamic acid inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; 4-hydroxy-2-nonenal inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; 4-hydroxy-2-nonenal inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]; [Lipopolysaccharides binds to and results in increased activity of TLR4 protein] which results in increased expression of CXCL10 mRNA; [Lipopolysaccharides co-treated with Melatonin] results in decreased expression of CXCL10 mRNA; [Lipopolysaccharides results in increased activity of TLR4 protein] which results in increased expression of CXCL10 mRNA; ADIPOQ protein inhibits the reaction [[Lipopolysaccharides results in increased activity of TLR4 protein] which results in increased expression of CXCL10 mRNA]; ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; ADIPOR1 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; ADIPOR2 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; APPL1 protein promotes the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; chrysin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; coagulin-L inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]; cobaltiprotoporphyrin inhibits the reaction [Ethanol promotes the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; cobaltiprotoporphyrin inhibits the reaction [Ethanol promotes the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]]; cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]; E804 bisindole inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; eriodictyol inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; Ethanol promotes the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]; genipin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; HMOX1 protein inhibits the reaction [[Lipopolysaccharides results in increased activity of TLR4 protein] which results in increased expression of CXCL10 mRNA]; HMOX1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; HMOX1 protein promotes the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; Lipopolysaccharides inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; Lipopolysaccharides promotes the reaction [E804 bisindole results in decreased expression of CXCL10 mRNA]; Luteolin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; phenethyl isothiocyanate inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; TLR4 protein affects the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; trametinib promotes the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]
ADIPOQ protein inhibits the reaction [Ethanol promotes the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; Ethanol promotes the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]
Lipopolysaccharides results in increased expression of CXCL10 mRNA; Lipopolysaccharides results in increased expression of CXCL10 protein		 CTD PMID:10027076, PMID:11123339, PMID:15860229, PMID:17529908, PMID:19020770, PMID:19426678, PMID:19428942, PMID:19627980, PMID:20423518, PMID:20737476, PMID:20861358, PMID:21356202, PMID:21461237, PMID:21803157, PMID:21913898, PMID:22687549, PMID:22777745, PMID:23107598, PMID:23445166, PMID:23724058, PMID:23891859, PMID:25171655, PMID:25780039, PMID:25843059, PMID:25890327, PMID:26582142, PMID:27339419, PMID:27568862, PMID:28655636 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930 		JBrowse link
G Cxcl11 C-X-C motif chemokine ligand 11 increases expression ISO Lipopolysaccharides results in increased expression of CXCL11 mRNA CTD PMID:19428942 NCBI chr14:17,195,395...17,198,170
Ensembl chr14:17,195,014...17,198,291 		JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 increases expression
multiple interactions		 EXP Lipopolysaccharides results in increased expression of CXCL12 mRNA
Lipopolysaccharides inhibits the reaction [Rutin results in decreased expression of CXCL12 mRNA]		 CTD PMID:28693884 NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891 		JBrowse link
G Cxcl13 C-X-C motif chemokine ligand 13 increases expression ISO Lipopolysaccharides results in increased expression of CXCL13 mRNA CTD PMID:19136613, PMID:27339419 NCBI chr14:15,253,146...15,258,221
Ensembl chr14:15,253,125...15,258,207 		JBrowse link
G Cxcl14 C-X-C motif chemokine ligand 14 increases expression ISO Lipopolysaccharides results in increased expression of CXCL14 mRNA CTD PMID:19428942 NCBI chr17:9,109,731...9,117,754
Ensembl chr17:9,109,731...9,117,750 		JBrowse link
G Cxcl16 C-X-C motif chemokine ligand 16 multiple interactions
increases expression		 ISO [Lipopolysaccharides co-treated with Monocrotaline] results in increased expression of CXCL16 protein; [Monocrotaline co-treated with Lipopolysaccharides] results in decreased expression of CXCL16 protein
Lipopolysaccharides results in increased expression of CXCL16 mRNA		 CTD PMID:21279329, PMID:21327618, PMID:26582142 NCBI chr10:57,060,005...57,064,600
Ensembl chr10:57,060,007...57,064,600 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions
increases expression
increases secretion		 ISO
EXP		 ANXA1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]
Lipopolysaccharides results in increased expression of CXCL2 mRNA; Lipopolysaccharides results in increased expression of CXCL2 protein
Lipopolysaccharides results in increased secretion of CXCL2 protein
[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CXCL2 mRNA; [Ranitidine co-treated with Lipopolysaccharides] results in increased expression of CXCL2 protein; alpha-Tocopherol inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]; Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of CXCL2 mRNA]; Heparin inhibits the reaction [Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 protein]]; Ibuprofen inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL2 protein]; Lipopolysaccharides promotes the reaction [RELA protein binds to CXCL2 promoter]; oxymatrine inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to CXCL2 promoter]]; oxymatrine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]; Pentoxifylline inhibits the reaction [[Ranitidine co-treated with Lipopolysaccharides] results in increased expression of CXCL2 protein]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]; Ranitidine promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 protein]
[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of CXCL2 protein; [pirinixic acid binds to and results in increased activity of PPARA protein] inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL2 protein]; [Shiga Toxin 2 co-treated with Lipopolysaccharides] results in increased expression of CXCL2 mRNA; CAP18 lipopolysaccharide-binding protein inhibits the reaction [[Shiga Toxin 2 co-treated with Lipopolysaccharides] results in increased expression of CXCL2 mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein]; Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]; dopexamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]; Lipopolysaccharides results in increased expression of and results in increased secretion of CXCL2 protein; methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CXCL2 protein]; Oligopeptides inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]; Oligopeptides inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein]; P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein]]; PARP1 protein affects the reaction [Lipopolysaccharides results in increased expression of CXCL2 protein]; PTGDR protein promotes the reaction [[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of CXCL2 protein]; Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL2 protein]; Tetrachlorodibenzodioxin promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]; Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein]		 CTD PMID:10027076, PMID:10718115, PMID:10975854,